Document:

EX-10.4

 Exhibit 10.4 

AGREEMENT 
 This Agreement
(“Agreement”) is made and entered into as of the 3 day of February 2013 (“Effective Date”), by and between: 
 Tel
Hashomer - Medical Research, Infrastructure and Services Ltd., a private company duly incorporated under the laws of the State of Israel having its registered office at Tel Hashomer, Israel, 52621, represented by its authorized representatives
(“THM”); and 
 Prof. Dror Harats, ID no. 054496641 of Ramat Gan, Israel (“Prof. Harats”); and

 Vascular Biogenics Ltd., Company no. 51-289976-6, a private company duly incorporated under the laws of the State of Israel having its
registered office at 6 Yoni Netanyahu Street, Or Yehuda, Israel, 60376, represented by its authorized representatives (“VBL” or the “Company”). 

 

	WHEREAS:	THM declares that it is a private company, whose purpose is to promote the welfare of the Sheba Medical Center (the “Hospital”); and 

 

	WHEREAS:	THM declares that at the request of the Hospital and the Fund, as defined below, THM undertook to act as the operational body of the Hospital and Fund, with respect to promotion, development and commercialization
of intellectual property deriving from inventions of Hospital’s and/or Fund’s employees; and 

  

	WHEREAS:	Prof. Harats has been an employee of the Hospital and/or the Fund since 1995; and 

  

	WHEREAS:	VBL was established in 1999; and 

  

	WHEREAS:	The Hospital and the Fund have claims regarding the ownership of certain inventions and patent rights of the Company, developed in part by Prof. Harats, and certain other inventors defined herein as Inventors and VBL
disagrees, denies and refutes all such claims in their entirety; and 

  

	WHEREAS:	THM, on behalf of the Hospital, and the Fund reached an agreement resolving the above dispute as stipulated and set forth hereunder; 

NOW, THEREFORE, in consideration of the mutual covenants and undertakings herein contained, the parties hereby agree and stipulate as follows: 

 

	1.	PREAMBLE AND DEFINITIONS 

  

	 	1.1	The Preamble to this Agreement as well as all the Agreement’s appendices constitutes an integral part thereof. 

  

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	1.2	The descriptive headings of this Agreement are inserted for convenience only and shall not be considered a part or affect the interpretation of this Agreement. 

 

	 	1.3	In addition to terms defined elsewhere in this Agreement or its appendices, the following terms shall have the meaning ascribed to them hereinafter: 

 

	 	1.3.1	“Affiliate” shall mean, with respect to a Party, any person, organization or entity controlling, controlled by or under common control with, such party. For purposes of this definition only,
“control” of another person, organization or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether
through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, “control” shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or
more of the outstanding share capital or other ownership interest of the other organization or entity, or (ii) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing
body of the organization or other entity. 

  

	 	1.3.2	The “Fund” shall mean Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA). 

 

	 	1.3.3	“Intellectual Property” shall mean any or all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including without limitation: (i) all United States,
Israeli, international and foreign patents and applications therefor (including PCT), including any and all reissues, divisionals, patent of division applications, renewals, extensions, continuations, and continuity applications thereof, whether or
not related to such divisionals, patent of division application, renewals, extensions, continuations or continuity applications through one or more intervening applications, and any patent or application acquired as a result of prevailing in any
interference proceeding (the “Patent Rights”); (ii) all inventions (whether patentable or not), invention disclosures, trade secrets, proprietary information, know-how, technology, technical data and customer lists, and all
documentation in any form or media relating to any of the foregoing; (iii) all copyrights, copyrights registrations and applications therefor, and all other rights corresponding thereto throughout the world; (iv) all databases and data
collections and all rights therein throughout the world; (v) all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefore throughout the world; and (vi) all domain
names, uniform resource locators, and other names and locators associated with the internet. 

  

	 	1.3.4	The “Inventors” – As specifically detailed in Appendix A attached hereto and constituting an integral part thereof. Such Inventors are inventors who have been employed by Sheba.

  
 2 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	1.3.5	The “Company’s IP”: shall mean (i) the Intellectual Property owned, registered or controlled by the Company which is specified in Appendix B attached hereto; (ii) any
continuations in part of the Company’s IP listed in Appendix B; and (iii) any Intellectual Property to the extent that it is dated prior to the date hereof and incorporates and /or based upon the patents specified in Appendix
B and/or any Intellectual Property to the extent that it is dated prior to the date hereof and that the patents listed in Appendix B are based thereon. 

  

	 	1.3.6	The “Products” shall mean any product, agent, process, or service device which is covered by or is produced or manufactured or rendered (as the case may be) using a process or method covered by the
Company’s IP. 

  

	 	1.3.7	“Net Sales” shall mean the total amount invoiced by or on behalf of VBL or any of its Affiliates or Licensees, in connection with the sale of a Product after deduction of: (i) value added taxes,
excise and sales taxes, or other similar taxes imposed on such sales (excluding income or franchise taxes of any kind) (ii) amounts credited by a credit note; and (iii) reasonable quantities for promotional purposes, and compassionate
uses; provided however that the Company doesn’t receive any consideration relating thereto; 

  

	 	  	For the purpose hereof: (a) with respect to sales which are not at arm’s length and/or are not according to the current market conditions for such a sale, the term “Net Sales” shall mean the total
amount that would have been paid in an arm’s length sale made according to the current market conditions for such sale or according to market conditions for sale of products similar to the Products; (b) with respect to sales by VBL and/or
a Licensee, as applicable, to any Affiliate, the term, “Net Sales” shall mean the higher of: (i) “Net Sales”, as defined above in paragraph (a) and (ii) the total amount invoiced by such affiliated entity on resale
to an independent third party purchaser and (c) with respect to sales for non-monetary consideration for any Products, “Net Sales” shall be calculated based on the higher of: (i) “Net Sales”, as defined in paragraph
(a) above; and (ii) the total amount invoiced by the party acquiring the Products in such transaction in each case, after deducting the amounts permitted above, to the extent applicable. 

 

	 	1.3.8	“License” shall mean the grant of any right or license and any agreement executed, by VBL to or with any entity, permitting any use of Company’s IP (or any part thereof) including for the
development and/or manufacture and/or marketing and/or distribution and/or sale of Company’s IP, and/or the Products and the term “Licensee” shall be construed accordingly. 

 

	 	1.3.9	 “License Fee” shall mean the consideration of any type or nature, received (for the removal of doubt, whether received before or
after the First Commercial Sale in any country) by the Company in return for or in connection with the grant of Licences or the grant of an 

  
 3 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	
option for a Licence, and excluding amounts received by the Company which are included under the definition of “Net Sales” based on sales of the Products by Licensees, in respect of
which the Company has paid royalties to THM according to this Agreement or otherwise constitute payment upon Exit Event according to this Agreement; License Fee shall include any lump sums, revenues from License Fees, milestone payments, etc. but
shall specifically exclude reimbursement for research and development and patent related expenses/reimbursement for payments specifically committed to cover costs reasonably and actually incurred by Company under, and in accordance with detailed
budgets and workplans included in, license agreements with Licensees. Any consideration other than cash payment shall be calculated based on the fair market value of such consideration assuming an arm’s length transaction made in the ordinary
course of business. Upon request, the Company shall provide THM with all documents and figures reasonably necessary in order to verify Company’s compliance with this clause. 

 

	 	1.3.10	“First Commercial Sale” shall mean with respect to any Product in any country, the first commercial sale of the Product in such country after FDA Approval for marketing or equivalent approval in such
country has been obtained if such approval is required. 

  

	2.	PARTIES’ DECLARATIONS AND UNDERTAKINGS 

  

	 	2.1	THM undertakes and covenants as follows: 

  

	 	2.1.1	Subject to the performance of the Company’s obligations hereunder, THM hereby irrevocably confirms on behalf of the Hospital and the Fund that such entities, or anyone on their behalf do not have any further right
to receive any payment, compensation, funds or securities from Prof. Dror Harats and/or from the Company (including its officers, directors, shareholders, employees, affiliates, successors and assigns, whether current, past or in the future) and/or
the Inventors (the “Released Parties”) deriving from any claim of ownership in the Company’s IP, and hereby irrevocably waives and releases acquits and forever discharges each of the Released Parties from any and all rights,
claims, demands, commitments, actions, charges, complaints, promises, agreements, controversies, debts, counterclaims, suits, causes of action, damages, liabilities, obligations, costs and expenses of every kind and nature whatsoever, known or
unknown, past, present or future, at law or in equity, contingent or otherwise (collectively, a “Claim”), such parties, including their successors and/or assigns, may have, as a result of a claim of ownership in the Company’s
IP now or in the future, (“Released Matters”). 

  

	 	2.1.2	 Notwithstanding anything to the contrary in this Agreement, it is hereby clarified that the above waiver specified in this clause 2.1.1, applies and
relates only to any part of the Company’s IP which is created, conceived and/or developed by the Inventors and not to Company’s IP or any part thereof or any other Intellectual Property

  
 4 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	
owned by the Company which is created, conceived and/or developed by any other inventors, employees, agents and/or contractors on behalf of the Company to the extent they are not listed in
Appendix A. 

  

	 	2.1.3	Prof Harats shall be entitled to serve as Chief Executive Officer and member of the Board of Directors of the Company to develop intellectual property that constitutes continuations in part of the Company IP and subject
to duly filing the required reports to THM and to the Ministry of Health, to receive compensation in shares and in cash, without any further claim by the Releasing Parties. 

 

	 	2.2	Each party hereby represents and warrants that: (a) it has the power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and that the execution, delivery and performance
by it of this Agreement and its compliance with the terms and provisions hereof do not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) any loan agreement, guaranty,
financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) any other right or obligation provided under any other agreement or obligation that it has with any third party;
or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; (b) the Agreement is a binding enforceable obligation of such Party; and (c) no
consent, approval, authorization order, filing, registration, or qualification of or with any court, governmental authority, or third person is required to be made or obtained by a party in connection with the execution and delivery of this
Agreement or the consummation by a party of the transactions contemplated hereby, which has not been received. 

  

	3.	LICENSE BY THE COMPANY 

 VBL undertakes that any License granted by it shall be subject to the
following terms: 

  
 5 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	3.1	The License is granted according to a written appropriate and binding agreement. The material terms of each License will be disclosed orally by the legal counsel of VBL to the head of THM prior to the execution of any
License agreement. Following execution of any such agreement, the Company will either (i) provide a copy of such agreement to THM; or (ii) if the provision of a copy of such agreement is not allowed under the terms thereof, disclose to
THM’s attorney and its accounting firm the material terms of such agreement, including without limitation, any terms that have bearing upon the consideration payable to THM hereunder. Such disclosure to THM’s attorney or CPA shall be
subject to their execution of a non disclosure agreement. The Company shall verify that the License includes terms that will allow the disclosure of the material terms thereof to THM or to a third party to be designated by THM, and shall comply with
such terms. 

  

	 	3.2	The License is being granted in a bona fide arms-length commercial transaction. 

  

	 	3.3	Non monetary consideration, if any, shall be valued as set forth in this Agreement. 

  

	4.	CONSIDERATION TO THM 

  

	 	4.1	VBL undertakes to pay THM the following amounts on a Product-by-Product and country-by-country basis until the later to occur of: (i) the last to expire or terminate of any of the Patent Rights covering such
Product in such country; or (ii) fifteen (15) years from the date of the First Commercial Sale of such Product in such country: 

  

	 	4.1.1	Royalties. VBL shall pay THM 1% (one percent) of Net Sales by or on behalf of VBL or any Affiliate or any Licensee (the “Royalties”). 

 

	 	4.1.2	Licensing Consideration. VBL shall pay THM 2% (two percent) of any License Fee received by VBL (the “Licensing Consideration”). 

 

	 	4.2	The amounts payable to THM under clause 4.1 shall be paid as follows: 

  

	 	4.2.1	Royalties, as specified in sub-clause 4.1.1 in connection with Net Sales by VBL and its Affiliate, shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which the respective sale
took place, commencing on the first quarter where the First Commercial Sale took place. Royalties in connection with Net Sales by a Licensee shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which VBL
receives payment on account of Net Sales. 

  

	 	4.2.2	Licensing Consideration, as specified in sub-clause 4.1.2 shall be paid within 30 (thirty) business days from receipt of any License Fee by the VBL. 

  
 6 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	4.3	Consideration from Exit. Upon the closing of each Exit Event, as defined bellow, THM shall be entitled to receive from the Company 1% (one percent) of any and all consideration received by the Company and/or its
shareholders as a result of or in connection with such Exit Event (“Consideration From Exit”). 

 Consideration from Exit
Event under clause 4.3 shall be paid in cash within 15 (fifteen) days from the closing of the Exit Events defined above. To the extent that the applicable Exit Event is an IPO or the consideration is in kind and not cash payment then the Company may
pay the Consideration From Exit within 12 months following the closing of the respective Exit Event. 
 “Exit Event” means any of the
following events: (i) the closing of the merger or consolidation of VBL into or with other corporation or the acquisition of the Company thereby, excluding a transaction following which VBL is the surviving corporation and the shareholders of
VBL prior to the transaction constitute the majority of the shareholders following such transaction; or (ii) the closing of the sale of all or substantially all of the assets of VBL or all or substantially all of its issued and outstanding
share capital or (iii) the closing of an Initial Public Offering (“IPO”). Notwithstanding the above, in all cases, a transaction with a wholly owned subsidiary or a transaction effected for the purpose of changing the domicile
or structure of VBL shall not be deemed an Exit Event. 
  

	 	4.4.	Payment obligations under clause 4 shall expire if the payment to THM upon or prior to such Exit Event (but not by way of payment of Royalties under clause 4.1.1) is or exceeds NIS100 million. In addition, at any time
following the execution hereof the Company, its assignees or successors shall be entitled to terminate the payment obligations under clause 4 by payment to THM of the amount of NIS100 million after deduction of any amount previously received by THM,
provided that such amounts were not received by THM as Royalties under clause 4.1.1. 

  

	 	4.5	All amounts set forth herein are inclusive of any and all taxes. The Company (or the escrow agent, if applicable) shall be entitled to deduct at source or withhold from any amount payable hereunder any tax amount
applicable to THM in connection with each payment. 

  

	 	4.6	The Company shall report in writing to THM immediately upon execution of an agreement relating to the First Commercial Sale and upon the occurrence of such first Commercial Sale. The Company shall specify in such report
the date of execution of such agreement and the date of the First Commercial Sale according to the agreement. 

  

	 	4.7	In calculating Net Sales and License Fee, all amounts shall be expressed in US Dollars and any amount received or invoiced in a currency other than US Dollars shall be translated into US Dollars, for the
purposes of calculation, in accordance with the exchange rate between the US Dollar and such currency on the date of such receipt or invoice, as the case may be. 

 

	 	4.8	 The Company shall provide THM with the following written reports: (a) a detailed quarterly report, commencing with the first calendar quarter in
which any Net Sales are made, or License Fee received, in a form reasonably acceptable to THM, signed by the chief financial officer of VBL, 

  
 7 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	
specifying all amounts payable to THM under this clause 4 in respect of the previous quarter to which the report refers. Such report shall include: (i) the sales made by the Company,
Affiliates and Licensees with a breakdown of Net Sales according to country, identity of seller, currency of sales, dates of invoices, number and type of Products sold and; (ii) License Fee with a breakdown according to identity of Licensees,
countries, the currency of the payment and date of receipt thereof; and (iii) deductions applicable, as provided in the definition of “Net Sales”; (b) a detailed report within twenty one (21) days of an Exit Event specifying
the nature of the Exit Event, the consideration to be received by the Company or its shareholders in connection with such Exit Event and all other substantial terms and details of such Exit Event and enclose to the report any agreement executed in
connection with such Exit Event immediately following the execution thereof; and (iv) any other matter, data and documents reasonably required by THM and existing with VBL in order to calculate and/or verify the amounts payable hereunder; and
(c) Within four months after the end of each fiscal year, the Company will provide THM with a detailed report, certified by VBL’s Chairman of the Board and by its independent auditor, stating all amounts due to THM pursuant to this clause 4 in
the reported year including relevant invoices issued and all invoices and all payments received by the Company with respect to details specified in the above reports; 21 days prior to an Exit Event he material terms of such Exit will be disclosed
orally by the legal counsel of VBL to the head of THM. 

  

	 	4.9	The Company shall keep and shall cause Licensees to keep complete, accurate and correct books of account and records consistent with sound business and accounting principles and practices. 

 

	 	4.10	Following the First Commercial Sale, THM shall be entitled to appoint an independent auditor selected by it to inspect, after coordination with VBL and during VBL’s regular business hours, all records, and
documents of VBL as may contain information bearing upon the amounts payable to THM under this clause 4. The Company shall take all steps necessary so that all such books of account, records and other documentation of VBL and its Licensees and
Affiliates are available for inspection as aforesaid for each of the Company and its Licensees and Affiliates. The cost of such auditing shall be borne by VBL if the audit uncovers an underreporting of the corresponding amounts owed to THM by more
than ten percent (10%). Otherwise, such costs and expenses shall be borne by THM. VBL shall remedy such discrepancy and pay (i) the shortfall within thirty (30) days of the date of discovery; and (ii) interest thereon at the rate of
4% above the London Interbank Offered Rate (LIBOR) applicable to a 12 month USD deposit, as such rate shall be in effect on each Disbursement Date. The Interest shall be compounded annually and computed on the basis of a 360 day year.

  

	 	4.11	 Upon THM’s request but not more than once every six months, the Company shall provide THM with a progress report specifying the following
details, as updated from the last report: (i) the activities the 

  
 8 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	
Company conducted for the development of Products; and (ii) sales and marketing efforts. 

  

	5.	INDEMNITY 

  

	 	5.1	VBL undertakes to indemnify and hold harmless THM, the Fund, the Hospital, the State of Israel, and their employees, representatives, agents and contractors (the “THM Beneficiaries”) against and from
any loss, liability, claims, damages or expenses of whatever kind or nature incurred by or imposed upon the THM Beneficiaries, to the extent arising out of or resulting from (i) the use and/or exploitation of the Company’s IP or any use of
any products incorporating the Company’s IP or any part thereof and/or manufactured or developed based upon the Company’s IP; and (ii) to the extent that it is based on a claim that the Company’s IP, the Products or other
material produced or developed or marketed by or on behalf of VBL or any of its Affiliates or Licensee infringes any third party’s intellectual property rights including copyright, trade secret, patent, trademark (a “THM
Claim”). 

  

	 	5.2	     

  

	 	5.3	The following mechanism shall apply to any THM Claim pursuant to clause 5.1. If any THM Beneficiary receives notice of any THM Claim, such THM Beneficiary shall, as promptly as is reasonably
possible, give VBL notice of such THM Claim. The failure to give such notice promptly shall relieve VBL of any indemnification obligation it may have hereunder to the extent such failure diminishes its ability to respond to or to defend the
Beneficiary against such THM Claim. VBL shall exclusively assume the defence or represent the interests of the THM Beneficiary in respect of such THM Claim, that shall include the right to select and direct legal counsel and other
consultants to appear in proceedings on behalf of the THM Beneficiary and to propose, accept or reject offers of settlement, all at its sole cost and discretion. 

  

	 	5.4	VBL, at its own expense, shall maintain insurance in an amount consistent with industry standards which provides VBL adequate coverage for (i) performing clinical studies of the Product in humans, (ii) product
liability and (iii) commercial sales of applicable and relevant Products. 

  

	6.	PATENT RIGHTS 

 In the event that the Company decides to abandon its patents in all
applicable jurisdictions in connection with its intent to stop its entire business activities of either of its two business units, then with respect to such Patent Rights that are included in the Company’s IP, the Company will inform THM
(“VBL Notice”) of its intention prior to the abandonment of any such Patent Rights. 
 THM shall have the right to continue to
support and maintain any such Patent Rights provided that it notifies VBL of its intention within 30 days following the receipt of VBL Notice, and provided further that within 60 days following the notice by THM, the parties reach an agreement for
the assignment or license of such Patent Rights to THM. The parties shall negotiate such agreement in good faith. The parties further agree that such agreement shall provide VBL with payments similar to those set forth in clause 4

  
 9 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 
and that any such agreement shall be subject to any limitations and restrictions imposed by applicable third parties, including without limitation, the Office of the Chief Scientist and shall be
subject to the assumption by THM of any repayment obligations thereto. THM right hereunder shall lapse and be of no further force and effect, in the event that THM fails to timely respond to VBL Notice, indicates that it is not interested in the
Patent Rights or otherwise the parties fail to reach an agreement as aforesaid during the 90 day period. 
  

	7.	MISCELLANEOUS  

  

	 	7.1	Law and Venue. All disputes arising in connection with this Agreement shall be settled amicably in the first instance. If amicable settlement cannot be reached by the Parties within 15 (fifteen) days from the day
either Party approached the other Parties specifying the essence of the dispute, the dispute shall be settled by 1 (one) arbitrator. If the Parties fail to reach an agreement on the nomination of the arbitrator within 30 (thirty) days of the date
when the claimant’s request for arbitration was communicated by the other Parties, the appointment shall be made by the Head of the Israel Bar. The arbitration will be conducted in Tel Aviv, Israel. The Parties shall be entitled to seek interim
measures of protection in the form of pre-award attachment of assets or injunctive relief. The tribunal shall issue a reasoned award. Such award may grant any relief appropriate under applicable law including without limitation declaratory relief
and/or specific performance. As part of its award the tribunal may award attorneys fees and costs to the prevailing party. The award of the arbitrator shall be final and binding upon the Parties, but subject to appeal, with respect to the disputes
so submitted and the costs of such arbitration. The law that shall apply shall be the statutes and laws of the State of Israel. 

  

	 	7.2	Use of Names. The Company shall not use the names of the State Of Israel, Hospital, the Fund and/or THM and/or their employees, representatives, agents and contractors in any manner or in any publication
including commercial publicity, without the prior written consent of THM. 

  

	 	7.3	Assignment. This Agreement shall be personal to the parties and therefore the Parties may not assign any of their rights or obligations hereunder without the prior written consent of the other party.
Notwithstanding the aforementioned, THM shall be entitled to assign the right to receive payments under this Agreement to any association and/or organization and or company that was established in connection with or for the benefit of the Hospital.
In addition, VBL may, without the consent of THM, assign this Agreement and the rights, obligations and interests of VBL, in whole, to any purchaser of all or substantially all of its assets, or to any successor corporation resulting from any merger
or consolidation of VBL with or into such corporation, provided that any such assignee agrees in writing to be bound by all the terms of this Agreement. 

  

	 	7.4	 Notices. Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing and shall be
deemed to have been duly served (i) upon personal delivery (ii) upon facsimile transmission (receipt of which has been orally confirmed by the recipient) or (iii) Seven (7) business days after deposit, postage prepaid,

  
 10 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	 	
return receipt requested, if sent by Registered Mail and addressed to the address of the parties first above stated or in accordance with such other address information as the party to receive
notice may provide in writing to the other party in accordance with the above notice provisions. Any notice given by any other method will be deemed to have been duly served upon receipt thereof. 

 

	 	7.5	Waivers. No course of dealing in respect of, nor any omission or delay in the exercise of, any right, power, or privilege by either Party shall operate as a waiver thereof, nor shall any single or partial
exercise thereof preclude any further or other exercise thereof or of any other, as each such right, power, or privilege may be exercised either independently or concurrently with others and as often and in such order as each party may deem
expedient. 

  

	 	7.6	Entire Agreement; Amendments. This Agreement, including, without limitation, its schedules, contains the entire agreement of the parties with respect to its subject matter. No oral or prior written statements or
representations not incorporated herein shall have any force or effect, nor shall any part of this Agreement be amended, supplemented, waived or otherwise modified except in a writing signed by both parties. 

 

	 	7.7	Confidentiality. Each party undertakes to the other party that all confidential information disclosed by a party to the other party hereunder or as a result of this Agreement, including the terms and conditions
set forth herein, will be kept in the strictest confidence and will not, without the prior written consent of the disclosing party, be used by the receiving party or be disclosed to, or discussed with, any third party whatsoever. The above
undertaking of confidentiality will not apply to information which: (i) is in the public domain at the time of disclosure; or (ii) subsequently becomes part of the public domain, except by breach by the receiving party of its obligations,
or (iii) is received from a third party who is not under an obligation of confidentiality to the disclosing party. VBL may disclose, on a confidential basis, the terms of this Agreement to its Board of Directors, shareholders, potential
investors, acquirers or licensees in the process of due diligence reviews of its contracted obligations, assets and undertakings. 

  

	 	7.8	THM hereby declares that Sheba’s management reached an understanding with the management of Tel Aviv University (“TAU”), that as between the Hospital and TAU, inventions of TAU professors who work
as medical doctors for Sheba such as Prof. Dror Charats, Prof. Shoenfeld and Prof. Gerge Jacob, shall belong to Sheba. 

[Remainder of the Page was left intentionally blank] 

  
 11 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and each of the
undersigned hereby warrants and represents that it has been and is, on the date of this Agreement, duly authorized by all necessary and appropriate action to execute this Agreement. 

 

											
	Tel Hashomer - Medical Research,	 		 		 	Vascular Biogenics Ltd.
	Infrastructure and Services Ltd.	 		 		 	
						
	By:	 	 /s/ [Illegible]
	 		 		 	By:	 	 /s/ Dror Harats

					
	 /s/ Dror Harats

Prof. Dror Harats
	 		 		 		 	
					
	Approved and Acknowledged	 		 		 		 	
					
	 /s/ [Illegible]

The Government of Israel
 By the Ministry of Health
	 		 		 		 	

  
 12 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 Appendix A 

INVENTORS 
 1. Prof. Dror Harats

 2. Shoenfeld Yehuda 
 3. George Jacob 

4. Halperin Gideon – up to 2003 
 5. Bloom Nira 

6. Greenberger Shoshana 
 7. Tal Reshef 

8. Peled Michael 
  

	*	detailed list of inventions is provided under Appendix B. 

  
 13 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

 Appendix B’ up to 3 Feb 2013 

 

																											
	METHODS AND COMPOSITIONS FOR ENHANCING TARGETING OF VIRAL VECTORS	  
									
	 Our Ref
	  	Country	 	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	  	Issue Date
Patent No.	  	SKGF Ref	 	  	Status	 	  	Inventor	 
	 [***]
	  	 	[***]	  	  		  		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  

  

																													
	ISOLATED POLYNUCLEOTIDES AND NUCLEIC ACID CONSTRUCTS FOR DIRECTING EXPRESSION OF A GENE-OF-INTEREST IN CELLS	   
									
	 Our Ref
	  	Country	 	  	Earliest Priority	 	  	Entry Date	  	Filing Date
Application No.	 	  	Issue Date
Patent No.	  	SKGF Ref	 	  	Status	 	  	Inventor	 
	 [***]
	  	 	[***]	  	  				  		  	 	[***]	  	  		  				  	 	[***]	  	  	 	[***]	  
	 52423
	  	 	PCT	  	  	 	19-Oct-2010	  	  		  	 	12/10/2011	  	  		  	 	3182.041PC01	  	  	 	Pending	  	  			

  

																									
	TREATMENT WITH VB-201	  
									
	 Our Ref
	  	Country	 	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	 	  	Inventor	 
	 [***]
	  	 	[***]	  	  		  		  	 	[***]	  	  		  		  	 	[***]	  	  	 	[***]	  

  
 14 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 [***]
	  	[***]	 	[***]	 		  	[***]	 		 		  	[***]	 	[***]
	 50378
	  	PCT	 	05-Jan-2010
 61/292,226
	 		  	05-Jan-2011
 IL2011/000012
	 	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083469
	 	3182.018PC05	  	Expired	 	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak; FEIGE
Erez; COHEN Yael

  

																	
	PAF-LIKE HOMOLOGS AND USES THEREOF
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	Inventor
	 [***]
	  	[***]	 		  		  	[***]	 		 		  	[***]	 	[***]
	 44504
	  	PCT	 	16-Oct-2007
 60/960,846
	  		  	05-Oct-2008
 IL2008/001315
	 	Publ. Date: 23-Apr-2009

Publ. #: WO2009/050692
	 		  	Expired	 	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48215
	  	Israel
 NP
	 	16-Oct-2007
 60/960,846
	  	15-Apr-2010	  	05-Oct-2008
 205144
	 		 	3182.019IL01	  	Aban	 	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48216
	  	USA
 NP
	 	16-Oct-2007
 60/960,846
	  	15-Apr-2010	  	05-Oct-2008
 12/738,097
	 		 	3182.0190001	  	Aban	 	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48217
	  	Europe
 NP
	 	16-Oct-2007
 60/960,846
	  	14-May-2010	  	05-Oct-2008
 08808113.8
	 		 	3182.019EP01	  	Aban	 	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak

  
 15 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	IMPROVED SYNTHESIS OF OXIDIZED PHOSPHOLIPIDS
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	Inventor
	 [***]
	  	[***]	 		  		  	[***]	 		 		  	[***]	 	[***]
	
	IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	Inventor
	 28367
	  	PCT	 	09-Jul-2004
 60/586,219
	  		  	10-Jul-2005
 IL2005/000735
	 	Publ. Date: 19-Jan-2006

Publ. #: WO2006/006161
	 		  	Expired	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33799
	  	Israel
 NP
	 	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005	 	1-Mar-2012
 180628
	 	3182.020IL00	  	GRANTED	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50430
	  	Israel
 DIV
	 	09-Jul-2004
 60/586,219
	  	17-Mar-2011	  	10-Jul-2005
 211795
	 		 		  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50431
	  	Israel
 DIV
	 	09-Jul-2004
 60/586,219
	  	17-Mar-2011	  	10-Jul-2005
 211796
	 		 		  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33793
	  	Europe
 NP
	 	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 05758938.4
	 		 		  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33793 Div
	  	Europe
 Div
	 	09-Jul-2004
 60/586,219
	  	Oct 2012	  	10-Jul-2005	 		 	3182.020EP10	  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  
 16 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 33793 Div
	  	Europe
 Div
	 	09-Jul-2004
 60/586,219
	 	Oct 2012	 	10-Jul-2005
 12179533.0
	 		  	3182.020EP20	  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 39643
	  	Hong Kong
 NP
	 	09-Jul-2004
 60/586,219
	 	31-May-2007	 	10-Jul-2005
 07105789.7
	 		  		  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33795
	  	Canada
 NP
	 	09-Jul-2004
 60/586,219
	 	09-Jan-2007	 	10-Jul-2005
 2,573,396
	 		  		  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33796
	  	Japan
 NP
	 	09-Jul-2004
 60/586,219
	 	09-Jan-2007	 	10-Jul-2005
 2007-519983
	 	24-Jun-2011
 4,767,948
	  		  	Granted	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48896
	  	Japan
 DIV
	 	09-Jul-2004
 60/586,219
	 	21-May-2010	 	10-Jul-2005
 2010-116964
	 		  		  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33797
	  	Republic of Korea
 NP
	 	09-Jul-2004
 60/586,219
	 	09-Feb-2007	 	10-Jul-2005
 2007-7003288
	 	9-Nov-2012
 10-1201935
	  		  	Granted	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33798
	  	China
 NP
	 	09-Jul-2004
 60/586,219
	 	28-Feb-2007	 	10-Jul-2005
 200580029218.9
	 	3-Aug-2011
 200580029218.9
	  		  	Granted	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48018
	  	China
 DIV
	 	09-Jul-2004
 60/586,219
	 	11-Feb-2010	 	10-Jul-2005
 201010128184.1
	 		  		  	Pending	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]
	 33801
	  	Russian Federation
 NP
	 	09-Jul-2004
 60/586,219
	 	09-Feb-2007	 	10-Jul-2005
 2007105097
	 	20-Sep-2010
 2399626
	  		  	Granted	 	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  
 17 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 33802
	  	Mexico
 NP
	  	09-Jul-2004
 60/586,219
	  	08-Jan-2007	  	10-Jul-2005
 MX/a/
2007/000361
	  	17-Mar-2011
 284830
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33803
	  	Australia
 DIV
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005
 2007200090
	  	2007200090
 5 Jan 2012
	  	3182.020AU00	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50536
	  	Mexico
 DIV
	  	09-Jul-2004
 60/586,219
	  	14-Jan-2011	  	10-Jul-2005
 MX/a/
2011/000630
	  	3 Sep 2012
 303011
	  		  	Granetd	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33804
	  	New Zealand
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 553147
	  	06-Nov-2010
 553147
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48999
	  	New Zealand
 DIV
	  	09-Jul-2004
 60/586,219
	  	29-Jun-2010	  	10-Jul-2005
 586503
	  	10 Oct 2011
 586503
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33805
	  	South Africa
 NP
	  	09-Jul-2004
 60/586,219
	  		  	10-Jul-2005
 2007/01178
	  	25-Sep-2008
 2007/01178
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  

																	
	PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME
									
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	 SKGF Ref
	  	Status	  	Inventor
	 02/23345
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	01-May-2002
 10/135,447
	  	27-Jun-2006
 7,067,649
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 28786
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	29-Oct-2004	  	01-May-2002
 10/975,619
	  	25-Aug-2009
 7,579,327
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira

  
 18 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																			
	 45023
	  	USA
 DIV
	 	17-Nov-2000
 60/248,582
	 	03-Jun-2009	 	01-May-2002
 12/457,200
	 		 		  	 	Pending	  	  	HARATS Dror; BREITBART
 Eyal; BLOOM Nira

	 50926
	  	USA
 DIV
	 	17-Nov-2000
 60/248,582
	 	27-Apr-2011	 	01-May-2002
 13/094,900
	 		 		  	 	Pending	  	  	HARATS Dror; BREITBART
 Eyal; BLOOM Nira

	 53777
	  	USA
 DIV
	 	17-Nov-2000
 60/248,582
	 	24-April 2012	 	01-May-2002
 13/454,171
	 		 	3182.0350004	  	 	Pending	  	  	HARATS Dror; BREITBART
 Eyal; BLOOM Nira

	 25974
	  	PCT	 	01-May-2002
 10/135,447
	 		 	30-Apr-2003
 IL03/00347
	 	Publ. Date: 13-
 Nov-2003Publ. #: WO03/093409
	 		  	 	Expired	  	  	HARATS Dror
	 28650
	  	Singapore
 NP
	 	01-May-2002
 10/135,447
	 	01-Nov-2004	 	30-Apr-2003
 200406381-4
	 	30-May-2008
 107841 [WO 03/093409]
	 		  	 	Granted	  	  	HARATS Dror; BREITBART
 Eyal; BLOOM Nira

	 28655
	  	South Africa
 NP
	 	01-May-2002
 10/135,447
	 	05-Nov-2004	 	30-Apr-2003
 2004/8989
	 	26-Jul-2006
 2004/8989
	 		  	 	Granted	  	  	HARATS Dror; BREITBART
 Eyal; BLOOM Nira

	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		  	 	[***]	  	  	[***]
	 28646
	  	Japan
 NP
	 	01-May-2002
 10/135,447
	 	01-Nov-2004	 	30-Apr-2003
 2004-501545
	 		 		  	 	Abandoned	  	  	HARATS Dror
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		  	 	[***]	  	  	[***]

  
 19 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]
	 28651
	  	Canada
 NP
	 	01-May-2002
 10/135,447
	 	01-Nov-2004	 	30-Apr-2003
 2,483,996
	 		  		  	Abandoned	 	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 28652
	  	Mexico
 NP
	 	01-May-2002
 10/135,447
	 	28-Oct-2004	 	30-Apr-2003
 PA/a/2004/010711
	 		  		  	Abandoned	 	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]

  

																	
	COMBINED TREATMENT UTILIZING VB-201
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	Inventor
	 [***]
	  	[***]	 		  		  	[***]	 		 		  	[***]	 	[***]
	 50379
	  	PCT	 	05-Jan-2010
 61/292,226
	  		  	05-Jan-2011
 IL2011/000010
	 	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083467
	 		  	Expired	 	YACOV Niva; BREITBART
Eyal; COHEN Yael
		  	US NP	 	05-Jan-2010
 61/292,226
	  	5-July 2012	  	05-Jan-2011
 13/520,713
	 		 	3182.0160005	  	Pending	 	YACOV Niva; BREITBART
Eyal; COHEN Yael
		  	EP NP	 	05-Jan-2010
 61/292,226
	  	1-Aug 2012	  		 		 	3182.016EP05	  	Pending	 	YACOV Niva; BREITBART
Eyal; COHEN Yael

  
 20 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
		  	JP NP	  	05-Jan-2010
 61/292,226
	  	4-July 2012	  		  		  	3182.016JP05	  	Pending	  	YACOV Niva; BREITBART
Eyal; COHEN Yael

  

																	
	POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	Inventor
	 [***]
	  	[***]	 		  		  	[***]	 		 		  	[***]	 	[***]
	 41795
	  	PCT	 	31-Jul-2006
 60/834,157
	  		  	31-Jul-2007
 IL2007/000959
	 	Publ. Date: 07-Feb-2008

Publ. #: WO/2008/015675
	 		  	Expired	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45501
	  	China
 NP
	 	31-Jul-2006
 60/834,157
	  	26-Mar-2009	  	31-Jul-2007
 200780035863.0
	 	8-Aug 2012
 ZL20078003 5863.0
	 	3182.040CN01	  	Granted	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 54283
	  	China
 Div
	 	31-Jul-2006
 60/834,157
	  	26-June-2012	  	31-Jul-2007
 201210210646.3
	 		 	3182.040CN11	  	Pending	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45495
	  	USA
 NP
	 	31-Jul-2006
 60/834,157
	  	02-Feb-2009	  	31-Jul-2007
 12/309,856
	 		 		  	Abandoned	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 51521
	  	USA
 DIV
	 	31-Jul-2006
 60/834,157
	  	20-Jun-2011	  	31-Jul-2007
 13/163,776
	 		 		  	Pending	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45496
	  	Israel
 NP
	 	31-Jul-2006
 60/834,157
	  	29-Jan-2009	  	31-Jul-2007
 196792
	 		 		  	Pending	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat

  
 21 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]
	 45499
	  	Australia
 NP
	 	31-Jul-2006
 60/834,157
	 	02-Feb-2009	 	31-Jul-2007
 2007280017
	 	26-July 2012
 2007280017
	  	3182.040AU01	  	Granted	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 54370
	  	Australia
 Div
	 	31-Jul-2006
 60/834,157
	 	12-July 2012	 	31-Jul-2007
 2012204128
	 		  	3182.040AU11	  	Pending	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45500
	  	Japan
 NP
	 	31-Jul-2006
 60/834,157
	 	02-Feb-2009	 	31-Jul-2007
 2009-522416
	 		  		  	Pending	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45502
	  	Republic of Korea
 NP
	 	31-Jul-2006
 60/834,157
	 	27-Feb-2009	 	31-Jul-2007
 2009-7004288
	 		  		  	Abandoned	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45503
	  	Mexico
 NP
	 	31-Jul-2006
 60/834,157
	 	29-Jan-2009	 	31-Jul-2007
 MX/a/
2009/001157
	 		  		  	Pending	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45504
	  	New Zealand
 NP
	 	31-Jul-2006
 60/834,157
	 	26-Jan-2009	 	31-Jul-2007
 574410
	 	9 July 2012
 574410
	  	3182.040NZ01	  	Granted	 	TAL Reshef; BREITBART
Eyal; BANGIO Livnat

  
 22 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 45505
	  	South Africa
 NP
	  	31-Jul-2006
 60/834,157
	  	26-Jan-2009	  	31-Jul-2007
 2009/00581
	  	31-Mar-2010
 2009/00581
	 		  	Granted	  	 TAL Reshef; BREITBART
 Eyal; BANGIO
Livnat

	 45506
	  	Singapore
 NP
	  	31-Jul-2006
 60/834,157
	  	30-Jan-2009	  	31-Jul-2007
 200900642-0
	  	30-Jun-2011
 149616[WO2008/015675]
	 		  	Granted	  	 TAL Reshef; BREITBART
 Eyal; BANGIO
Livnat

  

																	
	TREATMENT WITH VB-201
									
	 Our Ref
	  	Country	 	Earliest Priority	 	Entry Date	 	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	 	Status	 	Inventor
	 [***]
	  	[***]	 	[***]	 		 	[***]	 		 		 	[***]	 	[***]
	 50377
	  	PCT	 	05-Jan-2010
 61/292,226
	 		 	05-Jan-2011
 IL2011/000008
	 	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083465
	 		 	Expired	 	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak;
SHER Naamit; COHEN Yael
		  	US NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		 	3182.0170005	 	Pending	 	
		  	AU NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		 	3182.017AU05	 	Pending	 	
		  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]	 	
		  	CANADA NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		 	3182.017CA05	 	Pending	 	

  
 23 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
		  	China NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		  	3182.017CN05	 	Pending	 	
		  	HK NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		  	3182.017HK05	 	Pending	 	
		  	EP NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		  	3182.017EP05	 	Pending	 	
		  	[***]	 	[***]	 	[***]	 	[***]	 		  	[***]	 	[***]	 	
		  	Japan NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		  	3182.017JP05	 	Pending	 	
		  	South Korea NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		  	3182.017KR05	 	Pending	 	
		  	MX NP	 	05-Jan-2010
 61/292,226
	 	June 2012	 	05-Jan-2011	 		  	3182.017MX05	 	Pending	 	
		  	[***]	 	[***]	 	[***]	 	[***]	 		  	[***]	 	[***]	 	

  
 24 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	ANTI-ANGIOGENIC ADENOVIRUS VECTOR SUITABLE FOR CLINICAL APPLICATIONS AND METHODS FOR PRODUCTION THEREOF
									
	 Our Ref
	  	Country	 	Earliest Priority	 	Entry Date	 	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	 	Status	 	Inventor
	 [***]
	  	[***]	 		 		 	[***]	 		 		 	[***]	 	[***]
	
	METHODS OF PRODUCING ADENOVIRUS VECTORS AND VIRAL PREPARATIONS GENERATED THEREBY
									
	 Our Ref
	  	Country	 	Earliest Priority	 	Entry Date	 	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	 	Status	 	Inventor
	 49684
	  	PCT	 	12-Jan-2010
 61/294,158
	 		 	12-Jan-2011
 IB2011/050137
	 	Publ. Date: 21-Jul-2011

Publ. #: WO2011/086509
	 		 	Expired	 	BREITBART Eyal; BANGIO
Livnat; SHER Naamit
		  	US NP	 	12-Jan-2010
 61/294,158
	 	June 2012	 	12-Jan-2011	 		 	3182.0330001	 	Pending	 	BREITBART Eyal; BANGIO
Livnat; SHER Naamit
		  	EP NP	 	12-Jan-2010
 61/294,158
	 	June 2012	 	12-Jan-2011	 		 	3182.033EP01	 	Pending	 	BREITBART Eyal; BANGIO
Livnat; SHER Naamit
		  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]
		  	JP NP	 	12-Jan-2010
 61/294,158
	 	June 2012	 	12-Jan-2011	 		 	3182.033JP01	 	Pending	 	BREITBART Eyal; BANGIO
Livnat; SHER Naamit
		  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]	 	[***]

  
 25 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	IMMUNOMODULATION (IMMUNIZATION AND TOLERANCE) OF APO-E DEFICIENT MICE WITH 1 HEXADECINYL 2-5’ OXOPENTYL PHOSPHATIDYCHLOLINE (2-5 ALLE-ALDEHYDE LECITIN ETHER) SUPPRESSES EARLY ATHEROGENESIS
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	 Inventor

	 [***]
	  	[***]	 		  		  	[***]	 		 		  	[***]	 	[***]
	
	METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	 Inventor

	 01/22753
	  	PCT	 	24-Nov-2000
 60/252,574
	  		  	22-Nov-2001
 IL01/01080
	 	Publ. Date: 30-May-2002
 Publ. #:
WO02/41827
	 		  	Expired	 	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 26035
	  	Europe
 NP
	 	22-Nov-2000
 60/252,574
	  	15-May-2003	  	22-Nov-2001
 01997274.4
	 		 		  	Pending	 	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 52529
	  	EP Div	 	22-Nov-2000
 60/252,574
	  	17-Nov 2011	  	22-Nov-2001
 11189562.9
	 		 	3182.021EP11	  	Pending	 	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 27265
	  	Hong Kong
 NP
	 	24-Nov-2000
 60/252,574
	  	12-Dec-2003	  	22-Nov-2001
 03109096.1
	 		 		  	Pending	 	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 26036
	  	Israel
 NP
	 	22-Nov-2000
 60/252,574
	  	20-May-2003	  	22-Nov-2001
 156015
	 	10-May-2008
 156015
	 		  	Granted	 	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 32434
	  	Israel
 DIV
	 	24-Nov-2000
 60/252,574
	  	20-Jul-2006	  	22-Nov-2001
 176976
	 	1-Dec 2012
 176976
	 	3182.021IL11	  	Granted	 	HARATS Dror; GEORGE Jacob; HALPERIN Gideon

  
 26 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 26037
	  	India
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 796/CHENP/2003
	  	19-Sep-2008
 223638
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 26039
	  	Canada
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 2,429,817
	  		  	3182.021CA01	  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 26040
	  	Australia
 NP
	  	22-Nov-2000
 60/252,574
	  	23-May-2003	  	22-Nov-2001
 2002218461
	  	21-Dec-2006
 2002218461
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 26041
	  	Japan
 NP
	  	22-Nov-2000
 60/252,574
	  	23-May-2003	  	22-Nov-2001
 2002-544008
	  	01-Aug-2008
 4,162,486
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 44299
	  	Japan
 DIV
	  	24-Nov-2000
 60/252,574
	  	10-Jun-2008	  	22-Nov-2001
 2008-151301
	  	25 May 2012
 5001906
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 26042
	  	China
 NP
	  	22-Nov-2000
 60/252,574
	  	22-Jul-2003	  	22-Nov-2001
 01822215.3
	  	06-Jan-2010
 ZL01822215.3
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 26043
	  	Republic of Korea
 NP
	  	22-Nov-2000
 60/252,574
	  	24-May-2003	  	22-Nov-2001
 2003-7006991
	  	17-Oct-2008
 865142
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 26044
	  	Mexico
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 PA/a/2003/004517
	  	02-Sep-2009
 269738
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 46494
	  	Mexico
 DIV
	  	24-Nov-2000
 60/252,574
	  	12-Jun-2009	  	22-Nov-2001
 MX/a/2009/006365
	  	2 December 2011
 293020
	  	3182.021MX11	  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon

  

	
	PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

  
 27 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	 Inventor

	 36194
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	30-Apr-2007
 11/790,992
	  		 		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 43177
	  	PCT	  	30-Apr-2007
 11/790,992
	  		  	27-Apr-2008
 IL2008/000543
	  	Publ. Date: 06-Nov-2008

Publ. #: WO2008/132729
	 		  	Expired	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47030
	  	Europe
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Nov-2009	  	27-Apr-2008
 08738245.3
	  		 		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 48882
	  	Hong Kong
 NP
	  	30-Apr-2007
 11/790,992
	  	11-Jun-2010	  	27-Apr-2008
 10105838.3
	  		 		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47031
	  	Japan
 NP
	  	30-Apr-2007
 11/790,992
	  	30-Oct-2009	  	27-Apr-2008
 2010-505002
	  		 		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47032
	  	Canada
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Oct-2009	  	27-Apr-2008
 2,685,394
	  		 		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47033
	  	China
 NP
	  	30-Apr-2007
 11/790,992
	  	30-Dec-2009	  	27-Apr-2008
 200880022935.2
	  		 	3182.039CN01	  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

  
 28 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 47034
	  	 Australia
 NP
	  	30-Apr-2007
 11/790,992
	 	27-Nov-2009	 	27-Apr-2008
 2008243817
	 		  		  	Pending	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47035
	  	 Republic of Korea
 NP
	  	30-Apr-2007
 11/790,992
	 	18-Nov-2009	 	27-Apr-2008
 2009-7024041
	 		  		  	Pending	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 [***]
	  	[***]	  	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]
	 47037
	  	 Israel
 NP
	  	30-Apr-2007
 11/790,992
	 	26-Oct-2009	 	27-Apr-2008
 201760
	 		  		  	Pending	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47038
	  	 Mexico
 NP
	  	30-Apr-2007
 11/790,992
	 	29-Oct-2009	 	27-Apr-2008
 MX/a/2009/011750
	 		  		  	Pending	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47039
	  	 New Zealand
 NP
	  	30-Apr-2007
 11/790,992
	 	27-Nov-2009	 	27-Apr-2008
 581511
	 	5 June 2012
 581511
	  	3182.039NZ01	  	Granetd	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47040
	  	 South Africa
 NP
	  	30-Apr-2007
 11/790,992
	 	25-Nov-2009	 	27-Apr-2008
 2009/08331
	 	29-Dec-2010
 2009/08331
	  		  	Granted	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47041
	  	 Singapore
 NP
	  	30-Apr-2007
 11/790,992
	 	30-Oct-2009	 	27-Apr-2008
 200907209-1
	 	15 May 2012
 156740
	  	3182.039SG01	  	Granted	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

  
 29 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	THE EFFECT OF MUCOSAL TOLERANCE WITH LIPID IPOPROTEIN AND PROTEIN ANTIGENS ON ATHEROSCLEROSIS IN LDL-RECEPTOR DEFICIENT MICE
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	 Inventor

	 [***]
	  	[***]	 		  		  	[***]	 		 		  	[***]	 	[***]
	
	METHODS EMPLOYING AND COMPOSITIONS CONTAINING PLAQUE ASSOCIATED MOLECULES FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
									
	 Our Ref
	  	Country	 	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	 	SKGF Ref	  	Status	 	 Inventor

	 01/23033
	  	PCT	 	04-Jan-2001
 60/259,512
	  		  	03-Jan-2002
 IL02/00005
	 	Publ. Date: 11-Jul-2002

Publ. #: WO02/053092
	 		  	Expired	 	HARATS Dror; GEORGE Jacob
	 26046
	  	Israel
 NP
	 	04-Jan-2001
 60/259,512
	  	03-Jul-2003	  	03-Jan-2002
 156770
	 		 		  	Allowed	 	HARATS Dror; GEORGE Jacob
	 26047
	  	India
 NP
	 	04-Jan-2001
 60/259,512
	  	04-Jul-2003	  	03-Jan-2002
 1044/CHENP/
2003
	 	19-Sep-2008
 223640
	 		  	Granted	 	HARATS Dror; GEORGE Jacob
	 26048
	  	USA
 NP
	 	04-Jan-2001
 60/259,512
	  	02-Jul-2003	  	03-Jan-2002
 10/451,370
	 	09-Oct-2007
 7,279,459
	 		  	Granted	 	HARATS Dror; GEORGE Jacob
	 26050
	  	Australia
 NP
	 	04-Jan-2001
 60/259,512
	  	11-Jul-2003	  	03-Jan-2002
 2002225301
	 	03-Mar-2006
 2002225301
	 		  	Granted	 	HARATS Dror; GEORGE Jacob

  
 30 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 26051
	  	Japan
 NP
	 	04-Jan-2001
 60/259,512
	 	03-Jul-2003	 	03-Jan-2002
 2002-554043
	 	26-Sep-2008
 4,191,997
	  		  	Granted	 	HARATS Dror; GEORGE Jacob
	 26052
	  	China
 NP
	 	04-Jan-2001
 60/259,512
	 	04-Sep-2003	 	03-Jan-2002
 02805950.6
	 		  		  	Pending	 	HARATS Dror; GEORGE Jacob
	 26054
	  	Mexico
 NP
	 	04-Jan-2001
 60/259,512
	 	01-Jun-2003	 	03-Jan-2002
 PA/a/2003/006043
	 	17-Mar-2009
 265173
	  		  	Granted	 	HARATS Dror; GEORGE Jacob
	 26045
	  	Europe
 NP
	 	04-Jan-2001
 60/259,512
	 	18-Jul-2003	 	03-Jan-2002
 02715682.7
	 		  		  	Abandoned	 	HARATS Dror; GEORGE Jacob
	 27463
	  	Hong Kong
 NP
	 	04-Jan-2001
 60/259,512
	 	28-Jan-2004	 	03-Jan-2002
 04100565.1
	 		  		  	Abandoned	 	HARATS Dror; GEORGE Jacob
	 26049
	  	Canada
 NP
	 	04-Jan-2001
 60/259,512
	 	03-Jul-2003	 	03-Jan-2002
 2,433,781
	 		  		  	Abandoned	 	HARATS Dror; GEORGE Jacob
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]
	
	FORMULATIONS AND DOSAGE FORMS OF CI-201 AND RELATED COMPOUNDS
									
	 Our Ref
	  	Country	 	Earliest Priority	 	Entry Date	 	Filing Date
Application No.	 	Issue Date
Patent No.	  	SKGF Ref	  	Status	 	 Inventor

	 [***]
	  	[***]	 		 		 	[***]	 		  		  	[***]	 	[***]

  
 31 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
		  	PCT	  	Sept. 1, 2011
 61/529,989
	  		  	Aug. 31, 2012
 PCT/US2012/053533
	  		 	3182.013PC01	  	Pending	  	SHER Naamit; YOUNG Victor M.; McNAUGHTON Alyn; WILDING Ian; BAKHSHAEE Massoud
	
	PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS
									
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	  
	  	Status	  	 Inventor

	 31577
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	23-Feb-2006
 11/359,513
	  	18 October 2011
 8,039,261
	 	3182.0380000	  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 37180
	  	PCT	  	23-Feb-2006
 11/359,513
	  		  	22-Feb-2007
 IL2007/000242
	  	Publ. Date: 30-Aug-2007
 Publ. #: WO2007/096882
	 		  	Expired	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat
	 44720
	  	USA
 NP
	  	17-Nov-2000
 60/248,582
	  	20-Aug-2008	  	22-Feb-2007
 12/224,178
	  		 		  	Abandoned	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 44708
	  	Europe
 NP
	  	23-Feb-2006
 11/359,513
	  	28-Aug-2008	  	22-Feb-2007
 07713267.8
	  		 		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

  
 32 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]
	 44709
	  	Israel
 NP
	 	23-Feb-2006
 11/359,513
	 	19-Aug-2008	 	22-Feb-2007
 193554
	 		  		  	Abandoned	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]
	 44711
	  	Canada
 NP
	 	23-Feb-2006
 11/359,513
	 	20-Aug-2008	 	22-Feb-2007
 2,638,829
	 		  		  	Abandoned	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat
	 44712
	  	Australia
 NP
	 	23-Feb-2006
 11/359,513
	 	23-Sep-2008	 	22-Feb-2007
 2007219088
	 		  		  	Abandoned	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat
	 44713
	  	Japan
 NP
	 	23-Feb-2006
 11/359,513
	 	25-Aug-2008	 	22-Feb-2007
 2008-555946
	 		  		  	Abandoned	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat
	 44714
	  	China
 NP
	 	23-Feb-2006
 11/359,513
	 	21-Oct-2008	 	22-Feb-2007
 200780014285.2
	 		  		  	Abandoned	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat
	 44715
	  	Republic of Korea
 NP
	 	23-Feb-2006
 11/359,513
	 	22-Sep-2008	 	22-Feb-2007
 2008-7023144
	 		  		  	Abandoned	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat
	 44716
	  	Mexico
 NP
	 	23-Feb-2006
 11/359,513
	 	22-Aug-2008	 	22-Feb-2007
 MX/a/2008/010859
	 		  		  	Abandoned	 	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		  		  	[***]	 	[***]

  
 33 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	
	PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS
									
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	Status	  	 Inventor

	 33794
	  	USA
 CIP
	  	09-Jul-2004
 60/586,219
	  		  	09-Jan-2007
 11/650,973
	  	 05-Oct-2010
 7,807,847
	  	3182.0200001	  	Granted	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 49396
	  	USA
 DIV
	  	09-Jul-2004
 60/586,219
	  	24-Aug-2010	  	09-Jan-2007
 12/861,921
	  	 28- Feb 2012
 8,124,800
	  	3182.0200002	  	Granted	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 52800
	  	USA DIV	  	09-Jul-2004
 60/586,219
	  	May 24, 2012	  	January 26, 2012
 13/358,573
	  		  	3182.0200003	  	Pending	  	HALPERIN Gideon; KOVALEVSKI
		  	USA CIP	  	09-Jul-2004
 60/586,219
	  		  	Nov. 9, 2012
 13/672,811
	  		  	3182.0200004	  	Pending	  	HALPERIN Gideon; KOVALEVSKI
		  	US CON	  	09-Jul-2004
 60/586,219
	  		  	Dec. 10, 2012
 13/709,198
	  		  	3182.0200005	  	Pending	  	HALPERIN Gideon; KOVALEVSKI

  

	
	IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

  
 34 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 43029
	  	PCT	  	 09-Jan-2007
 11/650,973
	  		  	 02-Jan-2008
 IL2008/000013
	  	 Publ. Date: 17-Jul-2008

Publ. #: WO2008/084472
	  		  	Expired	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 46756
	  	 South Africa
 NP
	  	 09-Jan-2007
 11/650,973
	  		  	 02-Jan-2008
 2009/05601
	  	 26-May-2010
 2009/05601
	  		  	Granted	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 46755
	  	 New Zealand
 NP
	  	 09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	 02-Jan-2008
 578947
	  	 4-Dec 2011
 578947
	  	3182.020NZ01	  	Granted	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 51026
	  	 New Zealand
 DIV
	  	 09-Jan-2007
 11/650,973
	  	15-Jun-2011	  	 02-Jan-2008
 593529
	  		  	3182.020NZ11	  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
		  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
	 46754
	  	 Australia
 NP
	  	 09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	 02-Jan-2008
 2008204238
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 46753
	  	 Mexico
 NP
	  	 09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	 02-Jan-2008
 MX/a/2009/007422
	  	 9-Jan 2012
 294470
	  		  	Granted	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
		  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]	  	[***]
	 46751
	  	 Israel
 NP
	  	 09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	 02-Jan-2008
 199792
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 46750
	  	 China
 NP
	  	 09-Jan-2007
 11/650,973
	  	31-Aug-2009	  	 02-Jan-2008
 200880006707.6
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

  
 35 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 46749
	  	 Republic of Korea
 NP
	  	 09-Jan-2007
 11/650,973
	  	27-Jul-2009	  	 02-Jan-2008
 2009-7015780
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 46748
	  	 Japan
 NP
	  	 09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	 02-Jan-2008
 2009-545295
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 46747
	  	 Canada
 NP
	  	 09-Jan-2007
 11/650,973
	  	06-Jul-2009	  	 02-Jan-2008
 2,674,902
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 46746
	  	 Europe
 NP
	  	 09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	 02-Jan-2008
 08700247.3
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
		  	 Europe
 Div
	  	 09-Jan-2007
 11/650,973
	  	July 27, 2012	  	 02-Jan-2008
 EP 12178298.1
	  		  	3182.020EP11	  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	 48328
	  	 Hong Kong
 NP
	  		  	16-Mar-2010	  	 02-Jan-2008
 10102729.2
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
	
	COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  		  		  	[***]	  		  		  	[***]	  	[***]
	
	METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT

  
 36 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  		  	[***]	  	[***]
	 50375
	  	PCT	  	 05-Jan-2010
 61/282,228
	  		  	 05-Jan-2011
 IL2011/000007
	  	 Publ. Date: 14-Jul-2011

Publ. #: WO2011/083464
	  		  	Expired	  	BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
		  	US NP	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.0310002	  	Pending	  	BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
		  	EP	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031EP02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
		  	IL	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031IL02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
		  	[***]	  		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	JP	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031JP02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
		  	[***]	  		  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	MX	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031MX02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael

  
 37 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
		  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
		  	 Canada
	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031CA02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
		  	 Au
	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031AU02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
	
	COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  		  	[***]	  	[***]
	 50376
	  	PCT	  	 05-Jan-2010
 61/282,228
	  		  	 05-Jan-2011
 IL2011/000009
	  	 Publ. Date: 14-Jul-2011
 Publ. #:
WO2011/083466
	  	3182.032PC02	  	Expired	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.

  
 38 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
		  	 US NP
	  	 05-Jan-2010

61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.0320002	  	Pending	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
		  	 EU NP
	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032EP02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
		  	 IL NP
	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032IL02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]
	  	 [***]
	  	 [***]

		  	 JP NP
	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032JP02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
		  	 KR NP
	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032KR02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
		  	 MX NP
	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032MX02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
		  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]
	  	 [***]
	  	 [***]

  
 39 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
		  	CA NP	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032CA02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
		  	AU NP	  	 05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032AU02	  	Pending	  	BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
	
	OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry
Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 	  	 Status
	  	 Inventor

	 32516
	  	 USA
 CIP
	  	 27-May-2003
 10/445,347
	  		  	 28-Sep-2006
 11/528,657
	  	 01-Dec-2009
 7,625,882
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; MENDEL Itzhak
	 46643
	  	 USA
 DIV
	  	 27-May-2003
 10/445,347
	  	14-Oct-2009	  	 28-Sep-2006
 12/588,371
	  	 05-Jul-2011
 7,973,023
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; MENDEL Itzhak
	 50968
	  	 USA
 CON
	  	 27-May-2003
 10/445,347
	  	13-Apr-2011	  	 28-Sep-2006
 13/085,542
	  		  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; MENDEL Itzhak

  

	
	AN IMMUNOLOGICAL AND ORAL TOLERANCE-INDUCING COMPOSITION AND USE THEREOF FOR THE PREVENTION AND/OR FOR THE TREATMENT OF ATHEROSCLEROSIS

  
 40 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	 Inventor

	 00/21414
	  	Israel
 Basic
	  		  		  	04-Oct-1998
 126447
	  	30-Dec-2004
 126447
	 		  	Granted	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	
	A COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS
									
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	 Inventor

	 01/21558
	  	PCT	  	04-Oct-1998
 126447
	  	01-Apr-2001	  	30-Sep-1999
 IL99/00519
	  	Publ. Date: 13-Apr-2000
 Publ. #:
WO00/20019
	 		  	Expired	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 01/21884
	  	Europe
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 99970026.3
	  	14-May-2003
 1126867
	 		  	Granted	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 01/21886
	  	Canada
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 2,345,445
	  	24-Aug-2010
 2,345,445
	 		  	Granted	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 01/21887
	  	Australia
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 59966/99
	  	28-Aug-2003
 760582
	 		  	Granted	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 01/21888
	  	China
 NP
	  	04-Oct-1998
 126447
	  	04-Apr-2001	  	30-Sep-1999
 99814030.9
	  	24-Nov-2004
 ZL99814030.9
	 		  	Granted	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 02/23904
	  	Hong Kong
 NP
	  	04-Oct-1998
 126447
	  	19-Jul-2002	  	30-Sep-1999
 02105365.4
	  	18-Nov-2005
 HK1043743
	 		  	Granted	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 28590
	  	China
 DIV
	  	04-Oct-1998
 126447
	  	23-Sep-2004	  	30-Sep-1999
 200410011940.7
	  	05-Nov-2008
 ZL200410011940.7
	 		  	Granted	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 30562
	  	Hong Kong
 DIV
	  	04-Oct-1998
 126447
	  	28-Sep-2005	  	30-Sep-1999
 05108561.7
	  	21-Aug-2009
 HK1076600
	 		  	Granted	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

  
 41 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 01/21889
	  	Singapore
 NP
	 	04-Oct-1998
 126447
	 		  	30-Sep-1999
 200101998-3
	 	30-Apr-2003
 80182
	  		  	Granted	 	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 01/21890
	  	Japan
 NP
	 	04-Oct-1998
 126447
	 		  	30-Sep-1999
 2000-573378
	 		  		  	Pending	 	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 01/21891
	  	Hungary
 NP
	 	04-Oct-1998
 126447
	 	30-Sep-1999	  	30-Sep-1999
 P0104410
	 		  		  	Pending	 	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 [***]
	  	[***]	 	[***]	 		  	[***]	 		  		  	[***]	 	[***]
	 01/21893
	  	Republic of Korea
 NP
	 	04-Oct-1998
 126447
	 		  	30-Sep-1999
 2001-7004285
	 	02-Feb-2007
 680707
	  		  	Granted	 	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 01/21885
	  	USA
 NP
	 	04-Oct-1998
 126447
	 	30-Mar-2001	  	30-Sep-1999
 09/806,400
	 		  		  	Abandoned	 	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	 01/22498
	  	USA
 CON
	 	04-Oct-1998
 126447
	 	04-Sep-2001	  	30-Sep-1999
 09/944,592
	 		  		  	Abandoned	 	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
	
	COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE
									
	 Our Ref
	  	Country	 	Earliest Priority	 	Entry Date	  	Filing Date
Application No.	 	Issue Date
Patent No.	  	SKGF Ref	  	Status	 	 Inventor

	 28919
	  	USA
 CIP
	 	04-Oct-1998
 126447
	 		  	15-Apr-2005
 11/106,665
	 		  		  	Abandoned	 	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

  
 42 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	
	METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 26038
	  	 USA
 CIP
	  	 22-Nov-2000
 60/252,574
	  		  	 27-May-2003
 10/445,347
	  	 04-Jan-2005
 6,838,452
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 27041
	  	 USA
 DIV
	  	 24-Nov-2000
 60/252,574
	  	24-Nov-2003	  	 27-May-2003
 10/718,596
	  	 06-Mar-2007
 7,186,704
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 29890
	  	 USA
 DIV
	  	 24-Nov-2000
 60/252,574
	  	19-Jul-2005	  	 27-May-2003
 11/183,884
	  	 17-Mar-2009
 7,504,388
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 45347
	  	 USA
 DIV
	  	 24-Nov-2000
 60/252,574
	  	17-Feb-2009	  	 27-May-2003
 12/371,930
	  	 22-Feb-2011
 7,893,291
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 50439
	  	 USA
 CON
	  	 24-Nov-2000
 60/252,574
	  	06-Jan-2011	  	 27-May-2003
 12/985,365
	  	 17 April 2012
 8,158,611
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 53355
	  	 USA
 CON
	  	 24-Nov-2000
 60/252,574
	  	March 27, 2012	  	 27-May-2003
 13/431,262
	  		  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	
	OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS

  
 43 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 27909
	  	PCT	  	 27-May-2003
 10/445,347
	  		  	 27-May-2004
 IL2004/000453
	  	 Publ. Date: 09-Dec-2004

Publ. #: WO2004/106486
	  		  	Expired	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 31532
	  	 USA
 NP
	  	 27-May-2003
 10/445,347
	  	25-Apr-2008	  	 27-May-2004
 10/567,543
	  	 08-Mar-2011
 7,902,176
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 30958
	  	 Mexico
 NP
	  	 27-May-2003
 10/445,347
	  	25-Nov-2005	  	 27-May-2004
 pa/A/2005/012784
	  	 14-Oct-2008
 261341
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]	  	[***]
	 30947
	  	 Europe
 NP
	  	 27-May-2003
 10/445,347
	  	07-Dec-2005	  	 27-May-2004
 04735088.9
	  		  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 32340
	  	 Hong Kong
 NP
	  	 27-May-2003
 10/445,347
	  	03-Aug-2006	  	 27-May-2004
 06108608.1
	  		  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 30948
	  	 Japan
 NP
	  	 27-May-2003
 10/445,347
	  	30-Nov-2005	  	 27-May-2004
 2006-531006
	  		  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
		  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]

  
 44 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 30949
	  	 Canada
 NP
	  	 27-May-2003
 10/445,347
	  	28-Nov-2005	  	 27-May-2004
 2,527,483
	  		  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 30950
	  	 China
 NP
	  	 27-May-2003
 10/445,347
	  	01-Nov-2005	  	 27-May-2004
 200480021217.5
	  	 22-Dec-2010
 ZL200480021217.5
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 49865
	  	 China
 DIV
	  	 27-May-2003
 10/445,347
	  	25-Oct-2010	  	 27-May-2004
 201010537971.1
	  		  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 30951
	  	 Australia
 NP
	  	 27-May-2003
 10/445,347
	  	13-Dec-2005	  	 27-May-2004
 2004243695
	  	 17-Mar-2011
 2004243695
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 30952
	  	 Republic of Korea
 NP
	  	 27-May-2003
 10/445,347
	  	28-Nov-2005	  	 27-May-2004
 2005-7022741
	  	 3-Nov 2011
 1081977
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 50809
	  	 Republic of Korea
 DIV
	  	 27-May-2003
 10/445,347
	  	18-Feb-2011	  	 27-May-2004
 2011-7003840
	  	 23 Feb 2012
 10-1122160
	  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 30953
	  	 New Zealand
 NP
	  	 27-May-2003
 10/445,347
	  	01-Dec-2005	  	 27-May-2004
 544285
	  	 12-Mar-2009
 544285
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

  
 45 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 30954
	  	 South Africa
 NP
	  	 27-May-2003
 10/445,347
	  	01-Dec-2005	  	 27-May-2004
 2005/09929
	  	 27-Dec-2006
 2005/9929
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 30955
	  	 India
 NP
	  	 27-May-2003
 10/445,347
	  	27-Dec-2005	  	 27-May-2004
 3555/CHENP/2005
	  	 26-Mar-2009
 232654
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]	  	[***]
	 30957
	  	 Russian Federation
 NP
	  	 27-May-2003
 10/445,347
	  	01-Dec-2005	  	 27-May-2004
 2005140666
	  	 27-Jul-2009
 2362567
	  		  	Granted	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
	 46052
	  	 Russian Federation
 DIV
	  	 27-May-2003
 10/445,347
	  	06-Apr-2009	  	 27-May-2004
 2009112686
	  		  		  	Pending	  	HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

  

																	
	OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	[***]	  	[***]	  		  		  	[***]	  		  		  	[***]	  	[***]

  
 46 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 46530
	  	PCT	  	 08-Oct-2008
 61/103,571
	  		  	 01-Oct-2009
 IL2009/000949
	  	 Publ. Date: 15-Apr-2010

Publ. #: WO2010/041242
	  		  	Expired	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez
	 50053
	  	 USA
 NP
	  	 08-Oct-2008
 61/103,571
	  	06-Apr-2011	  	 01-Oct-2009
 13/122,766
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez
	 50054
	  	 Europe
 NP
	  	 08-Oct-2008
 61/103,571
	  	20-Apr-2011	  	 01-Oct-2009
 09818874.1
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez
	 50055
	  	 Israel
 NP
	  	 08-Oct-2008
 61/103,571
	  	05-Apr-2011	  	 01-Oct-2009
 212153
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

  

																	
	COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I-DERIVED PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  		  		  	[***]	  		  		  	[***]	  	[***]

  
 47 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 31865
	  	PCT	  	 15-Apr-2005
 60/671,500
	  		  	 11-Apr-2006
 IL2006/000467
	  	 Publ. Date: 19-Oct-2006

Publ. #: WO2006/109312
	  		  	Expired	  	YACOV Niva; BREITBART Eyal
	 41853
	  	 Europe
 NP
	  	 15-Apr-2005
 60/671,500
	  	24-Oct-2007	  	 11-Apr-2006
 06728268.1
	  		  		  	Abandoned	  	YACOV Niva; BREITBART Eyal
	 41854
	  	 USA
 NP
	  	 15-Apr-2005
 60/671,500
	  	10-Oct-2007	  	 11-Apr-2006
 11/918,141
	  		  		  	Abandoned	  	YACOV Niva; BREITBART Eyal
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]	  	[***]

  

																	
	NOVEL DERIVATIVES OF OXIDIZED PHOSPHOLIPIDS
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  		  		  	[***]	  		  		  	[***]	  	[***]
	
	OXIDIZED LIPID COMPOUNDS AND USES THEREOF

  
 48 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 45018
	  	PCT	  	 06-Nov-2008
 61/193,220
	  		  	 05-Nov-2009
 IL2009/001049
	  	 Publ. Date: 14-May-2010

Publ. #: WO2010/052718
	  		  	Expired	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;
 YACOV Niva; BREITBART Eyal;

MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

	 50603
	  	 USA
 NP
	  	 06-Nov-2008
 61/193,220
	  	05-May-2011	  	 05-Nov-2009
 13/127,717
	  		  		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;
 MENDEL Itzhak; ZINIUK Zeev; FEIGE
Erez

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]	  	[***]
	 50605
	  	 Europe
 NP
	  	 06-Nov-2008
 61/193,220
	  	16-May-2011	  	 05-Nov-2009
 09824498.1
	  		  		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;
 MENDEL Itzhak; ZINIUK Zeev; FEIGE
Erez

	 51983
	  	 Hong Kong
 NP
	  		  		  	05-Nov-2009	  		  		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;
 MENDEL Itzhak; ZINIUK Zeev; FEIGE
Erez

	 50606
	  	 Canada
 NP
	  	 06-Nov-2008
 61/193,220
	  	13-Apr-2011	  	 05-Nov-2009
 2,740,726
	  		  		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;
 MENDEL Itzhak; ZINIUK Zeev; FEIGE
Erez

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]	  	[***]

  
 49 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 50608
	  	 Australia
 NP
	  	 06-Nov-2008
 61/193,220
	  	15-Apr-2011	  	 05-Nov-2009
 2009312355
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez
	 50609
	  	 New Zealand
 NP
	  	 06-Nov-2008
 61/193,220
	  	19-Apr-2011	  	 05-Nov-2009
 592357
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]	  	[***]
	 50611
	  	 Japan
 NP
	  	 06-Nov-2008
 61/193,220
	  	06-May-2011	  	05-Nov-2009	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez
	 50612
	  	 Republic of Korea
 NP
	  	 06-Nov-2008
 61/193,220
	  	02-Jun-2011	  	 05-Nov-2009

2011-7012700
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez
	 50613
	  	 Mexico
 NP
	  	 06-Nov-2008
 61/193,220
	  	04-May-2011	  	 05-Nov-2009
 MX/a/2011/004773
	  		  		  	Pending	  	HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal;
MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

  
 50 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 50614
	  	 Russian Federation
 NP
	  	 06-Nov-2008
 61/193,220
	  	06-Jun-2011	  	 05-Nov-2009
 2011122729
	  		  		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;
 MENDEL Itzhak; ZINIUK Zeev; FEIGE
Erez

	 50615
	  	 China
 NP
	  	 06-Nov-2008
 61/193,220
	  	30-Jun-2011	  	 05-Nov-2009
 200980153378.2
	  		  		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;
 MENDEL Itzhak; ZINIUK Zeev; FEIGE
Erez

  

																	
	ENDOTHELIAL-SPECIFIC APOPTOSIS INDUCED BY AN ADENOVIRAL VECTOR CONTAINING A CHIMERIC RECEPTOR DRIVEN BY A TISSUE SPECIFIC PROMOTER
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  		  		  	[***]	  		  		  	[***]	  	[***]
	
	POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATION OF ANGIOGENESIS AND ANTICANCER THERAPY
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 02/23346
	  	PCT	  	 19-Oct-2001
 60/330,118
	  		  	 01-May-2002
 IL02/00339
	  	 Publ. Date: 24-Apr-2003

Publ. #: WO03/033514
	  		  	Expired	  	HARATS Dror; GREENBERGER Shoshana
	 27526
	  	 USA
 NP
	  	 19-Oct-2001
 60/330,118
	  	12-Apr-2004	  	 01-May-2002
 10/490,746
	  	 08-Sep-2009
 7,585,666
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

  
 51 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 44506
	  	 USA
 DIV
	  	 19-Oct-2001
 60/330,118
	  	08-Aug-2008	  	 01-May-2002
 12/222,439
	  	 02-Aug-2011
 7,989,427
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 51506
	  	 USA
 DIV
	  	 19-Oct-2001
 60/330,118
	  	20-Jun-2011	  	 01-May-2002
 13/163,767
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 27527
	  	 Europe
 NP
	  	 19-Oct-2001
 60/330,118
	  	21-Apr-2004	  	 01-May-2002
 02801473.6
	  	 22-Sep-2010
 1436313
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 29028
	  	 Hong Kong
 NP
	  	 19-Oct-2001
 60/330,118
	  	06-Jan-2005	  	 01-May-2002
 05100081.5
	  	 01-Apr-2011
 HK1067641
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 49785
	  	 Europe
 DIV
	  	 19-Oct-2001
 60/330,118
	  	17-Sep-2010	  	 01-May-2002
 EP10177257.2
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 47553
	  	 Europe
 DIV
	  	 19-Oct-2001
 60/330,118
	  	18-Nov-2009	  	 01-May-2002
 09176343.3
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 49931
	  	 Hong Kong
 DIV
	  	 19-Oct-2001
 60/330,118
	  	10-Dec-2010	  	 01-May-2002
 10111522.2
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 51004
	  	 Hong Kong
 DIV
	  	 19-Oct-2001
 60/330,118
	  	27-Apr-2011	  	 01-May-2002
 11104228.3
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 27528
	  	 Japan
 NP
	  	 19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	 01-May-2002
 2003-536253
	  	 22-Aug-2008
 4,173,446
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 27529
	  	 Republic of Korea
 NP
	  	 19-Oct-2001
 60/330,118
	  	17-Apr-2004	  	 01-May-2002
 2004-7005720
	  	 24-Oct-2008
 866117
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

  
 52 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 27530
	  	 India
 NP
	  	 19-Oct-2001
 60/330,118
	  	19-Apr-2004	  	 01-May-2002
 801/CHENP/2004
	  	 26-Dec-2008
 226357
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 27531
	  	 China
 NP
	  	 19-Oct-2001
 60/330,118
	  	09-Jun-2004	  	 01-May-2002
 02824547.4
	  	 01-Jul-2009
 ZL02824547.4
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 46077
	  	 China
 DIV
	  	 19-Oct-2001
 60/330,118
	  	27-Apr-2009	  	 01-May-2002
 200910137707.6
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 27532
	  	 Singapore
 NP
	  	 19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	 01-May-2002
 200402237-2
	  	 31-May-2006
 103725
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 27533
	  	 Canada
 NP
	  	 19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	 01-May-2002
 2,463,816
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 27534
	  	 Mexico
 NP
	  	 19-Oct-2001
 60/330,118
	  	19-Apr-2004	  	 01-May-2002
 PA/a/2004/003514
	  	 12-Nov-2010
 280956
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 [***]
	  	[***]	  	[***]	  		  		  		  		  	[***]	  	[***]
	 27535
	  	 Australia
 NP
	  	 19-Oct-2001
 60/330,118
	  	20-Apr-2004	  	 01-May-2002
 2002307793
	  	 17-May-2007
 2002307793
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal
	 27536
	  	 New Zealand
 NP
	  	 19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	 01-May-2002
 532348
	  	 12-Oct-2006
 532348
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

  
 53 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 27537
	  	 South Africa
 NP
	  	 19-Oct-2001
 60/330,118
	  	08-Apr-2004	  	 01-May-2002
 2004/2756
	  	 31-May-2006
 2004/02756
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

  

																	
	USING A MINI-GENE CONSTRUCT (3X-PPR-1) FOR ENDOTHELIAL CELLS SPECIFIC GENE THERAPY. IMPLICATIONS IN CARDIOVASCULAR, CANCER AND WOUND HEALING
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  		  		  	[***]	  		  		  	[***]	  	[***]
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 01/22752
	  	PCT	  	 17-Nov-2000
 60/248,582
	  		  	 15-Nov-2001
 IL01/01059
	  	 Publ. Date: 23-May-2002

Publ. #: WO02/40629
	  		  	Expired	  	HARATS Dror
	 26025
	  	 Europe
 NP
	  	 17-Nov-2000
 60/248,582
	  	15-May-2003	  	 15-Nov-2001
 01996590.4
	  	 20-Jan-2010
 1443970
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 29027
	  	 Hong Kong
 NP
	  	 17-Nov-2000
 60/248,582
	  	12-Jan-2005	  	 15-Nov-2001
 05100240.3
	  	 20-Aug-2010
 HK1068057
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 47088
	  	 Europe
 DIV
	  	 17-Nov-2000
 60/248,582
	  	04-Nov-2009	  	 15-Nov-2001
 09174998.6
	  		  		  	Pending	  	HARATS Dror; BLOOM Nira
	 49806
	  	 Europe
 DIV
	  	 17-Nov-2000
 60/248,582
	  	01-Oct-2010	  	 15-Nov-2001
 EP10185193.9
	  		  		  	Pending	  	HARATS Dror; BLOOM Nira

  
 54 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 49498
	  	 Hong Kong
 DIV
	  	 17-Nov-2000
 60/248,582
	  	13-Oct-2010	  	 15-Nov-2001
 10109698.4
	  		  		  	Pending	  	HARATS Dror; BLOOM Nira
	 52630
	  	 Hong Kong
 DIV
	  	 17-Nov-2000
 60/248,582
	  	2-Dec-2011	  	 15-Nov-2001
 11113094.5
	  		  	3182.034HK21	  	Pending	  	HARATS Dror; BLOOM Nira
	 26026
	  	 Israel
 NP
	  	 17-Nov-2000
 60/248,582
	  	15-May-2003	  	 15-Nov-2001
 155940
	  	 30-Mar-2009
 155940
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26027
	  	 India
 NP
	  	 17-Nov-2000
 60/248,582
	  	14-May-2003	  	 15-Nov-2001
 743/CHENP/2003
	  	 20-Nov-2007
 211599
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26028
	  	 USA
 NP
	  	 17-Nov-2000
 60/248,582
	  	16-May-2003	  	 15-Nov-2001
 10/416,917
	  		  		  	Abandoned	  	HARATS Dror
	 26029
	  	 Canada
 NP
	  	 17-Nov-2000
 60/248,582
	  	15-May-2003	  	 15-Nov-2001
 2,429,342
	  		  		  	Pending	  	HARATS Dror; BLOOM Nira
	 26030
	  	 Australia
 NP
	  	 17-Nov-2000
 60/248,582
	  	15-May-2003	  	 15-Nov-2001
 2002224002
	  	 26-Jul-2007
 2002224002
	  		  	Abandoned	  	HARATS Dror
	 28653
	  	 Australia
 DIV
	  	 17-Nov-2000
 60/248,582
	  	01-Dec-2004	  	 15-Nov-2001
 2003222427
	  	 09-Sep-2010
 2003222427
	  		  	Granted	  	HARATS Dror; BREITBART Eyal; BLOOM Nira
	 49098
	  	 Australia
 DIV
	  	 15-Nov-2001
 2002224002
	  	25-Jun-2010	  	 15-Nov-2001
 2010202660
	  	 1-Dec 2011
 2010202660
	  		  	Granted	  	HARATS Dror; BREITBART Eyal; BLOOM Nira
	 26031
	  	 Japan
 NP
	  	 17-Nov-2000
 60/248,582
	  	16-May-2003	  	 15-Nov-2001
 2002-543626
	  	 16-Jan-2009
 4,243,653
	  		  	Granted	  	HARATS Dror; BLOOM Nira

  
 55 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 26032
	  	 China
 NP
	  	 17-Nov-2000
 60/248,582
	  	16-Jul-2003	  	 15-Nov-2001
 01822075.4
	  	 04-Feb-2009
 ZL0182275.4
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26033
	  	 Republic of Korea
 NP
	  	 17-Nov-2000
 60/248,582
	  	17-May-2003	  	 15-Nov-2001
 2003-7006728
	  	 14-Nov-2008
 869814
	  		  	Granted	  	HARATS Dror
	 44105
	  	 Republic of Korea
 DIV
	  	 17-Nov-2000
 60/248,582
	  	28-Jul-2008	  	 15-Nov-2001
 2008-7018598
	  	 10-Sep-2009
 917854
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26034
	  	 Mexico
 NP
	  	 17-Nov-2000
 60/248,582
	  	16-May-2003	  	 15-Nov-2001
 PA/a/2003/004325
	  	 15-Aug-2008
 259670
	  		  	Granted	  	HARATS Dror

  

																	
	COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 28918
	  	 USA
 CIP
	  	 04-Oct-1998
 126447
	  		  	 17-Nov-2004
 10/989,724
	  		  		  	Abandoned	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva
	
	COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 30236
	  	PCT	  	 17-Nov-2004
 10/989,724
	  		  	 25-Sep-2005
 IL2005/001022
	  	 Publ. Date: 26-May-2006

Publ. #: |WO2006/054281
	  		  	Expired	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva
	 39233
	  	 Europe
 NP
	  	 17-Nov-2004
 10/989,724
	  	13-Jun-2007	  	 25-Sep-2005
 05788473.6
	  		  		  	Abandoned	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

  
 56 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 42004
	  	 Hong Kong
 NP
	  	 17-Nov-2004
 10/989,724
	  		  	 12-Sep-2007
 07109873.6
	  		  		  	Abandoned	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

  

																	
	PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 28376
	  	 USA
 CIP
	  	 17-Nov-2000
 60/248,582
	  		  	 14-Nov-2004
 10/988,487
	  	 6-Dec 2011
 8,071,740
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 50225
	  	 USA
 DIV
	  	 17-Nov-2000
 60/248,582
	  	01-Feb-2011	  	 14-Nov-2004
 13/018,447
	  	 26-June 2012
 8,206,743
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 50927
	  	 USA
 DIV
	  	 17-Nov-2000
 60/248,582
	  	02-May-2011	  	 14-Nov-2004
 13/098,512
	  		  		  	Aban	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47407
	  	 USA
 DIV
	  	 17-Nov-2000
 60/248,582
	  	13-Nov-2009	  	 14-Nov-2004
 12/591,252
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 60001
	  	 USA
 Con
	  	 17-Nov-2000
 60/248,582
	  	13-July 2012	  	 14-Nov-2004
 13/549,355
	  		  	3182.0370004	  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

  
 57 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 30269
	  	PCT	  	 14-Nov-2004
 10/988,487
	  		  	 14-Nov-2005
 IL2005/001195
	  	 Publ. Date: 18-May-2006

Publ. #: WO2006/051545
	  		  	Expired	  	HARATS Dror; GREENBERGER Shoshana
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]	  	[***]
	 47087
	  	 Europe
 DIV
	  	 14-Nov-2004
 10/988,487
	  	28-Aug-2009	  	 14-Nov-2005
 09168899.4
	  	 2 Nov 2011
 2174668
	  		  	Grnated	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 49224
	  	 Hong Kong
 DIV
	  		  	12-Oct-2010	  	 14-Nov-2005
 10109638.7
	  	 15 June 2012
 HK1143078
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 49804
	  	 Europe
 DIV
	  	 14-Nov-2004
 10/988,487
	  	01-Oct-2010	  	 14-Nov-2005
 EP10185195.4
	  	 26 Sep 2012
 2301586
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 49805
	  	 Europe
 DIV
	  	 14-Nov-2004
 10/988,487
	  	30-Sep-2010	  	 14-Nov-2005
 EP10184033.8
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 39318
	  	 Australia
 NP
	  	 14-Nov-2004
 10/988,487
	  	08-Jun-2007	  	 14-Nov-2005
 2005303385
	  		  		  	Allowed	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

  
 58 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 51825
	  	 Australia
 DIV
	  	 14-Nov-2004
 10/988,487
	  		  	14-Nov-2005	  	 28 June 2012
 2011205076
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 53691
	  	 Australia
 DIV
	  	 14-Nov-2004
 10/988,487
	  	15 June 2012	  	 14-Nov-2005
 2012203578
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 39323
	  	 New Zealand
 NP
	  	 14-Nov-2004
 10/988,487
	  	05-Jun-2007	  	 14-Nov-2005
 555612
	  	 08-Apr-2010
 555612
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 47297
	  	 New Zealand
 DIV
	  	 14-Nov-2004
 10/988,487
	  	09-Oct-2009	  	 14-Nov-2005
 580289
	  	 05-Apr-2011
 580289
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 39324
	  	 South Africa
 NP
	  	 14-Nov-2004
 10/988,487
	  	05-Jun-2007	  	 14-Nov-2005
 2007/04687
	  	 31-Dec-2008
 2007/04687
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]
	  	 [***]

	 50629
	  	 Singapore
 DIV
	  	 14-Nov-2004
 10/988,487
	  	11-Apr-2011	  	 14-Nov-2005
 201102612-7
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat
	 39315
	  	 Israel
 NP
	  	 14-Nov-2004
 10/988,487
	  	14-May-2007	  	 14-Nov-2005
 183187
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

  
 59 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 50104
	  	 Israel
 DIV
	  	 14-Nov-2004
 10/988,487
	  	31-Oct-2010	  	 14-Nov-2005
 209034
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]
	  	 [***]

	 39317
	  	 Canada
 NP
	  	 14-Nov-2004
 10/988,487
	  	17-May-2007	  	 14-Nov-2005
 2,587,469
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 39319
	  	 Japan
 NP
	  	 14-Nov-2004
 10/988,487
	  	14-May-2007	  	 14-Nov-2005
 2007-540833
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 52137
	  	 Japan
 Div
	  	 14-Nov-2004
 10/988,487
	  	Sep 2011	  	 14-Nov-2005
 2011-191492
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 39320
	  	 China
 NP
	  	 14-Nov-2004
 10/988,487
	  	13-Aug-2007	  	 14-Nov-2005
 200580046412.8
	  		  		  	Aban	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael
	 39321
	  	 Republic of Korea
 NP
	  	 14-Nov-2004
 10/988,487
	  	14-Jun-2007	  	 14-Nov-2005

2007-7013464
	  		  		  	Pending	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

  
 60 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 39322
	  	 Mexico
 NP
	  	 14-Nov-2004
 10/988,487
	  	11-May-2007	  	 14-Nov-2005
 MX/a/2007/005783
	  	 8 May 2012
 299008
	  		  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat
	 52598
	  	 Mexico
 Div
	  	 14-Nov-2004
 10/988,487
	  		  	14-Nov-2005	  	 4 Sep 2012
 303042
	  	3182.037MX11	  	Granted	  	HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]

  

																	
	Method for treating vascular inflammation and psoriasis
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

		  	[***]	  	[***]	  		  	[***]	  		  	[***]	  	[***]	  	[***]

  
 61 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	Treatment Of Inflammation
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  	[***]	  	[***]
	 53305
	  	PCT	  	 12 Dec 2011
 61/569,545 and

12 Dec 2011
 61/569,481
	  		  	 11 Dec 2012
 PCT/US2012/068995
	  		  	3182.014PC01	  	Pending	  	 MENDEL, Itzhak;
 FEIGE, Erez;

YACOV, Niva;
 PROPHETE-MEIRAN, Oshrat; BREITBART, Eyal;

SALEM, Yaniv

  
 62 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	Treatment Methods Using Adenovirus
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  	[***]	  	[***]

  

																	
	TARGETED GENE EXPRESSION USING PREPROENDOTHELIN-1 PROMOTERS
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 N/A
	  	USA CIP	  	 03-Mar-1994
 08/254,015
	  		  	 28-Feb-1995
 08395742
	  	 05-May-1998
 5747340
	  	Originally assinged to Syntex USA. Licensed to VBL	  	Granted	  	 HARATS Dror;
 KURIHARA Hiroki;

NANETTE BELLONI Paula; SIGAL Charles Elliott

  

	
	METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS

  
 63 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
									
	 Our Ref
	  	 Country
	  	 Earliest Priority
	  	 Entry Date
	  	 Filing Date

Application No.
	  	 Issue Date

Patent No.
	  	 SKGF Ref
	  	 Status
	  	 Inventor

	 N/A
	  	PCT	  	 08-Dec-2009
 61/283,696
	  		  	 07-Dec-2010
 US2010/059204
	  	 Publ. Date: 16-Jun-2011

Publ. #: WO/2011/071859
	  	As of June 2012, the applicant is also VBL	  	Pending	  	 KOLESNICK, Richard, N.
 STANCEVIC, Branka;

SADELAIN, Michel;
 FUKS, Zvi;

VARDA-BLOOM, Nira;
 HARATS, Dror;

		
	Trademark: VBL therapeutics & logo	  	
									
	 Our Ref

Client Ref
	  	 Country
	  	 Class
	  	 Earliest

Priority
	  	 Filing Date

Application No.
	  	 Registration Date

Registration No.
	  	 SKGF Ref
	  	 Status
	  	 
	 47638
	  	Europe	  	5, 42 & 44	  		  	 03-Dec-2009
 008730541
	  	 02-Jun-2010
 008730541
	  		  	Registered	  	
		
	Trademark: VASCULAR BIOGENICS	  	
									
	 Our Ref

Client Ref
	  	 Country
	  	 Class
	  	 Earliest Priority
	  	 Filing Date

Application No.
	  	 Registration Date

Registration No.
	  	 SKGF Ref
	  	 Status
	  	 
	 42092
	  	Israel	  	42	  		  	 23-Aug-2007
 203346
	  	 06-May-2009
 203346
	  		  	Registered	  	
	 43074
	  	 USA
 (Paris)
	  	42	  	 23-Aug-2007
 203346
	  	 14-Feb-2008
 77/397,305
	  	 22-Jun-2010
 3,805,239
	  		  	Registered	  	

  
 64 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 43075
	  	 Europe
 (Paris)
	  	5, 42 & 44	  	 23-Aug-2007
 203346
	  	 18-Feb-2008
 006675599
	  	 20-Feb-2009
 006675599
	  		  	Registered	  	
		
	Trademark: VBL VASCULAR BIOGENICS LTD. & Device	  	
									
	 Our Ref

Client Ref
	  	 Country
	  	 Class
	  	 Earliest

Priority
	  	 Filing Date

Application No.
	  	 Registration Date

Registration No.
	  	 SKGF Ref
	  	 Status
	  	 
	 42199
	  	Israel	  	42	  		  	 09-Sep-2007
 203748
	  	 10-May-2009
 203748
	  		  	Registered	  	
	 43602
	  	 USA
 (Paris)
	  	42	  	 09-Sep-2007
 203748
	  	 03-Mar-2008
 77/411,204
	  	 22-Jun-2010
 3,805,245
	  		  	Registered	  	
	 43603
	  	 Europe
 (Paris)
	  	42	  	 09-Sep-2007
 203748
	  	 04-Mar-2008
 006721823
	  	 04-Sep-2009
 006721823
	  		  	Registered	  	
		
	Trademark: VTS	  	
									
	 Our Ref

Client Ref
	  	 Country
	  	 Class
	  	 Earliest

Priority
	  	 Filing Date

Application No.
	  	 Registration Date

Registration No.
	  	 SKGF Ref
	  	 Status
	  	 
	 42198
	  	Israel	  	5	  		  	 09-Sep-2007
 203747
	  	 06-May-2009
 203747
	  		  	Registered	  	
	 43600
	  	 USA
 (Paris)
	  	5	  	 09-Sep-2007
 203747
	  	 03-Mar-2008
 77/411,151
	  	 20-Oct-2009
 3,697,519
	  		  	Registered	  	

  
 65 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	 43601
	  	 Europe
 (Paris)
	  	5	  	 09-Sep-2007
 203747
	  	 04-Mar-2008
 006721484
	  	 20-Feb-2009
 006721484
	  		  	Registered	  	
		
	Trademark: VASCULAR TARGETING SYSTEM VTS	  	
									
	 Our Ref

Client Ref
	  	 Country
	  	 Class
	  	 Earliest Priority
	  	 Filing Date

Application No.
	  	 Registration Date

Registration No.
	  	 SKGF Ref
	  	 Status
	  	 
	 41864
	  	Israel	  	5	  		  	 23-Aug-2007
 203345
	  	 08-Sep-2009
 203345
	  		  	Registered	  	
	 43072
	  	 USA
 (Paris)
	  	5	  	 23-Aug-2007
 203345
	  	 14-Feb-2008
 77/397,328
	  	 18-May-2010
 3,789,108
	  		  	Registered	  	
	 43073
	  	 Europe
 (Paris)
	  	5, 42 & 44	  	 23-Aug-2007
 203345
	  	 18-Feb-2008
 006675896
	  	 29-Jan-2009
 006675896
	  		  	Registered	  	

  
 66 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

																	
	  
 Trademark: VBL
	  	
									
	 Our Ref

Client Ref
	  	 Country
	  	 Class
	  	 Earliest

Priority
	  	 Filing Date

Application No.
	  	 Registration Date

Registration No.
	  	 SKGF Ref
	  	 Status
	  	 
	 42093
	  	Israel	  	42	  		  	 23-Aug-2007
 203347
	  	 22-Jan-2009
 203347
	  		  	Registered	  	
	 43076
	  	 USA
 (Paris)
	  	42	  	 23-Aug-2007
 203347
	  	 14-Feb-2008
 77/397,293
	  	 14-Jul-2009
 3,653,176
	  		  	Registered	  	
	 43077
	  	 Europe
 (Paris)
	  	5, 42 & 44	  	 23-Aug-2007
 203347
	  	 18-Feb-2008
 006673263
	  	 22-Jan-2009
 006673263
	  		  	Registered	  	
		
	Trademark: VBL therapeutics & logo	  	
									
	 Our Ref

Client Ref
	  	 Country
	  	 Class
	  	 Earliest Priority
	  	 Filing Date

Application No.
	  	 Registration Date

Registration No.
	  	 SKGF Ref
	  	 Status
	  	 
	 47612
	  	Israel	  	42	  		  	 30-Nov-2009
 225329
	  	 07-Feb-2011
 225329
	  		  	Registered	  	
	 47639
	  	 USA
 (Paris)
	  	42	  	 30-Nov-2009
 225329
	  	 26-Apr-2010
 85/023,397
	  	 24-May-2011
 3,964,829
	  		  	Registered	  	

  

	
	Domains: VBL

  
 67 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

	
	vascularbiogenics.com
	  
 vascularbiogenicsltd.com

 
 vbl-therapeutics.com

 
 vbltherapeutics.com

 
 vbltx.com
  

vascularbiogenics.net
  

vbl.co.il
  

vblrx.com
  

vascular-biogenics.com

  
 68 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].EX-10.5

 Exhibit 10.5 

EXECUTION COPY 
 MANUFACTURING
SERVICES AGREEMENT 
 This Manufacturing Services Agreement (the “Agreement”) is made as of January 5, 2012, (the
“Effective Date”) between Lonza Houston, Inc., a Delaware corporation having its principal place of business at 8066 El Rio St., Houston, TX 77054 (“LHI”), and Vascular Biologics, Ltd., an Israeli
corporation, having an office at 6 Jonathan Netanyahu St., Or Yehuda, Israel 60376 (“CLIENT”) (each of LHI and CLIENT, a “Party” and, collectively, the “Parties”). 

RECITALS 
 A. LHI operates
multi-client research, testing and production facilities located at 8030, 8032 and 8066 El Rio, Houston, Texas 77054 (the “Facility”). 

B. CLIENT desires to have LHI produce a product containing human cells and/or viruses intended for therapeutic use in humans, and LHI desires
to produce such product. 
 C. CLIENT desires to have LHI conduct work according to individual Statement of Work, as further defined in
Section 1.30 below. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants hereinafter set forth,
LHI and CLIENT, intending to be legally bound, hereby agree as follows: 
 AGREEMENT 

 

	1.	DEFINITIONS 

 When used in this Agreement, capitalized terms will have the
meanings as defined below and throughout the Agreement. Unless the context indicates otherwise, the singular will include the plural and the plural will include the singular. 

1.1. “Acceptance Period” shall have the meaning set forth in Section 5.2.2. 

1.2. “Affiliate” means, with respect to either Party, any other corporation or business entity that directly, or indirectly
through one or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, the term “control” and, with correlative meanings, the terms “controlled by” and
“under common control with” means direct or indirect ownership of more than fifty percent (50%) of the securities or other ownership interests representing the equity voting stock or general partnership or membership interest of such
entity or the power to direct or cause the direction of the management or policies of such entity, whether through the ownership of voting securities, by contract, or otherwise. 

1.3. “Batch” means a quantity of Product derived from a process which is the subject of an SOW that is intended to have
uniform character and quality, within specified 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
limits, and is produced according to a single manufacturing order during the same cycle of manufacture 
  

	 	1.4.	“Batch Record” means the production record pertaining to a Batch. 

  

	 	1.5.	“cGMP” means the regulatory requirements for current good manufacturing practices promulgated by the FDA under 21 CFR Parts 210 and 211, as amended from time to time. 

 

	 	1.6.	“Change Order” has the meaning set forth in Section 2.2. 

  

	 	1.7.	“CLIENT Development Materials” has the meaning set forth in Section 2.3. 

  

	 	1.8.	“CLIENT Inventions” means any know-how or inventions, whether or not patentable, conceived, developed or reduced to practice by CLIENT on or before the Effective Date. 

 

	 	1.9.	“CLIENT Materials” means the CLIENT Development Materials and the CLIENT Production Materials. 

  

	 	1.10.	“CLIENT Personnel” has the meaning set forth in Section 4.7.1. 

  

	 	1.11.	“CLIENT Production Materials” has the meaning set forth in Section 4.1. 

  

	 	1.12.	“Commencement Date” means the date set forth in the Statement of Work for the commencement of the production of the Product. 

 

	 	1.13.	“Confidential Information” has the meaning set forth in Section 10.1. 

  

	 	1.14.	“Disapproval Notice” shall have the meaning set forth in Section 5.2.2. 

  

	 	1.15.	“FDA” means the U.S. Food and Drug Administration, and any successor agency thereof. 

  

	 	1.16.	“First Statement of Work” has the meaning set forth in the definition of Statement of Work. 

  

	 	1.17.	“Intellectual Property” means all worldwide patents, copyrights, trade secrets, know-how and all other intellectual property rights, including all applications and registrations with respect thereto,
but excluding all trademarks, trade names, service marks, logos and other corporate identifiers. 

  

	 	1.18.	“LHI Inventions” means any know-how, media, assays, methods or other inventions, whether or not patentable, conceived, developed or reduced to practice by LHI on or before the Effective Date.

  

	 	1.19.	 “LHI Operating Documents” means the standard operating procedures, standard manufacturing procedures, raw material specifications,
protocols, validation documentation, and supporting documentation used by LHI, such as environmental 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
monitoring, for operation and maintenance of the Facility and LHI equipment used in the process of producing the Product, excluding any of the foregoing that are unique to the manufacture of
Product. 
  

	 	1.20.	“LHI Parties” has the meaning set forth in Section 15.2. 

  

	 	1.21.	“Materials” means all raw materials and supplies to be used in the production of a Product. 

  

	 	1.22.	“Process” means the manufacturing process for a Product provided to LHI by CLIENT and further developed by LHI pursuant to the terms of this Agreement. 

 

	 	1.23.	“Product” has the meaning set forth in a Statement of Work. 

  

	 	1.24.	“Product Warranties” means those warranties as specifically stated in Section 5.2.2. 

  

	 	1.25.	“Production Term” shall have the meaning set forth in Section 4.3. 

  

	 	1.26.	“Regulatory Approval” means the approval by the FDA to market and sell the Product in the United States. 

  

	 	1.27.	“SOP” means a standard operating procedure. 

  

	 	1.28.	“SOW Documentation” means the compilation of documentation generated by LHI in preparation of and during the performance of a given SOW, including, without limitation, executed batch records, component
records, test records and test record forms, certificates of analysis, study protocols, study summary reports, deviation reports, laboratory investigations, environment excursions, formulation records, and other related documents.

  

	 	1.29.	“Specifications” means the Product specifications set forth in the Statement of Work or as modified by the Parties in connection with the production of a particular Batch of Product hereunder.

  

	 	1.30.	“Statement of Work” or “SOW” means a plan to develop a Process or Product that is attached hereto as Appendix A or later becomes attached through an amendment by the Parties. The
first Statement of Work, which is attached hereto, is numbered Appendix A-1 and is hereby incorporated and made a part of this Agreement (the “First Statement of Work”). It is contemplated that each separate project shall
have its own Statement of Work. As each subsequent Statement of Work is agreed to by the Parties, each shall state that it is to be incorporated and made a part of this Agreement and shall be consecutively numbered as A-2, A-3, etc.

  

	 	1.31.	“Technology Transfer” means the transfer of documentation, specifications, and production process by CLIENT to LHI for the development of the SOW Documentation for the manufacture of the Product
specifically for the CLIENT. 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

	 	1.32.	“Third Party” means any party other than LHI, CLIENT or their respective Affiliates. 

  

	2.	STATEMENTS OF WORK - PROCESS AND PRODUCT DEVELOPMENT; TECHNOLOGY TRANSFER;
PROCESS OR PRODUCT MANUFACTURE 

 2.1 Statement of Work.
Prior to performing any Process or Product development, Technology Transfer, or Process or Product manufacture, the Parties will collaborate to develop a Statement of Work, describing the activities to be performed by the Parties, or to be
subcontracted by LHI to Third Parties. Once agreed to by the Parties, the Statement of Work shall be executed by each of the Parties and appended hereto as part of Appendix A. In the event of a conflict between the terms and conditions of
this Agreement and any Statement of Work, the terms and conditions of this Agreement shall control. 
 2.2 Modification of Statement of
Work. Should CLIENT want to change a Statement of Work, to reduce services not yet performed or to include additional services to be provided by LHI, CLIENT may propose to LHI an amendment to the Statement of Work with the desired changes or
additional services (“Change Order”). If LHI determines that it has the resources and capabilities to accommodate such Change Order, LHI will prepare a modified version of the Statement of Work reflecting such Change Order
(including, without limitation, any changes to the estimated timing, estimated charges or scope of a project) and will submit such modified version of the Statement of Work to CLIENT for review and comment. The modified Statement of Work shall be
binding on the Parties only if it refers to this Agreement, states that it is to be made a part thereof, and is signed by both Parties. Thereafter such modified version of the Statement of Work will be deemed to have replaced the prior version of
the Statement of Work. Notwithstanding the foregoing, if a modified version of the Statement of Work is not agreed to by both Parties, the existing Statement of Work shall remain in effect. 

2.3 CLIENT Deliverables. Within the time period specified in a Statement of Work, CLIENT will provide LHI with (a) the materials
listed in the Statement of Work for which CLIENT is responsible for delivering to LHI, and any handling instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for the performance of the Statement
of Work, and (b) any protocols, SOPs and other information and documentation in possession or control of CLIENT and necessary for the performance of the Statement of Work, and for the preparation of the SOW Documentation in conformance with
cGMP, including, without limitation, process information, SOPs, development data and reports, quality control assays, raw material specifications (including vendor, grade and sampling/testing requirements), product and sample packing and shipping
instructions, and product specific cleaning and decontamination information, (collectively, the “CLIENT Development Materials”). It is hereby agreed that CLIENT Development Materials are the proprietary and confidential
information of the CLIENT and shall be used by LHI solely for the purpose of this Agreement. 
 2.4 Performance by LHI. Subject to the
provision by CLIENT of the CLIENT Development Materials pursuant to Section 2.3, LHI will use commercially reasonable efforts to perform, directly or, subject to the terms of the Statement of Work or approval by CLIENT (such approval not to be
unreasonably withheld), through a Third Party contractor, the work described 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
in a Statement of Work in a professional and workmanlike manner in accordance with the terms of this Agreement. LHI shall ensure, and at all times remain responsible and liable for the compliance
of such Third Party contractor with the terms of this Agreement. LHI will use commercially reasonable efforts promptly to notify CLIENT of any material delays that arise during the performance of the Statement of Work. Subject to the exceptions in
Section 17.2, delay of commencement of the Statement of Work due to delay by a Third Party contractor by more than 45 days shall be considered a breach of the Agreement. 
  

	3.	TECHNOLOGY TRANSFER 

 3.1 Based on the information
provided by CLIENT and including process changes developed by LHI pursuant to any applicable Statement of Work, LHI will prepare the SOW Documentation for the Process in accordance with the schedule set forth in the Statement of Work. CLIENT will
inform LHI of any specific requirements CLIENT may have relating to the SOW Documentation, including, without limitation, any information or procedures CLIENT wishes to have incorporated therein. If LHI intends to include in the SOW Documentation
the use of any assay, medium, or other technology that is not commercially available, LHI will inform CLIENT of such intention and the Parties will meet to discuss and attempt to agree in good faith on the terms of use of such non-commercially
available materials or technology in the Process. The SOW Documentation shall be completed and delivered by LHI at completion of a Batch. 

3.2 CLIENT will cooperate with LHI to assist LHI to develop the SOW Documentation and Process, including, without limitation, by
providing LHI with additional information and procedures as may be required to create the SOW Documentation, Process, and/or any of the following: (i) manufacturing process information, SOPs, development reports, (ii) quality control
assays, (iii) raw material specifications (including vendor, grade and sampling/testing requirements), (iv) Product and sample packing and shipping instructions, (v) Product specific cleaning and decontamination information. 

3.3 LHI will deliver a draft version of the SOW Documentation to CLIENT for its review and approval in accordance with the schedule set
forth in the Statement of Work. CLIENT will notify LHI in writing of any objections it has to the draft Master Production Record, and upon such notification, representatives of LHI and CLIENT will meet promptly to resolve such objections. Upon
CLIENT’s written acceptance of the draft SOW Documentation, or in the event that CLIENT does not submit a written notice setting forth CLIENT’s objections to the draft SOW Documentation within fifteen (15) working days following
receipt of such draft by CLIENT, such draft will be deemed approved by CLIENT. 
 3.4 The Process, SOW Documentation, Specifications,
and any improvements or modifications thereto developed during the term of this Agreement, but excluding any LHI Operating Documents, LHI Inventions or LHI Confidential Information included in any of the foregoing, will be deemed CLIENT Confidential
Information and subject to the provisions set forth in Article 10. Without derogating from Section 11.2.2, CLIENT shall be permitted to use the Process and/or the SOW Documentation for any research or commercial purpose solely related to the
Product or Process and to manufacture and sell Product, either alone or by a Third Party on its behalf; provided, however, that if the Process and/or the SOW Documentation 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
incorporates or contains any LHI Intellectual Property or LHI Confidential Information that does not solely relate to Product or Process, then prior to any disclosure of such LHI Intellectual
Property or LHI Confidential Information to, or use by, a Third Party manufacturer, Client shall obtain LHI prior approval, which shall not be unreasonably withheld. 
  

	4.	MANUFACTURE OF PRODUCT; ORDER PROCESS; DELIVERIES 

4.1 CLIENT Deliverables. Within any time period agreed to in any applicable Statement of Work, CLIENT will provide LHI with the
materials listed in the Statement of Work required to be supplied by CLIENT for the production of the Product, and any handling instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for the
performance of the Statement of Work (collectively, the “CLIENT Production Materials”). 
 4.2 Commencement Date. The
Statement of Work will include a Commencement Date agreed upon by the Parties. 
 4.3 Manufacture by LHI. During the time period
specified in any Statement of Work during which Product will be manufactured (the “Production Term”), LHI will use commercially reasonable efforts to manufacture, package, ship, handle quality assurance and quality control for the
Product, all as set forth in the Statement of Work, and to deliver to CLIENT the quantities of Product requested by CLIENT in the Statement of Work, all in accordance with the terms set forth in Section 4.4 below. Notwithstanding the foregoing,
LHI shall have the right to revise the production schedule with respect to a Statement of Work provided that such schedule does not advance or delay commencement of the production of Batches under a Statement of Work by more than forty five
(45) days. 
 4.4 Packaging and Shipping. LHI will package and label the Product for shipment in accordance with the SOW
Documentation and LHI’s standard practices in effect at the time of performance by LHI. LHI will ship the Product FOB Shipping Point delivered at the Facility to a common carrier designated by CLIENT to LHI in writing not less than ten days
prior to the applicable delivery date unless otherwise agreed to in a Statement of Work. CLIENT will provide to LHI its account number with the selected carrier and will pay for all shipping costs in connection with each shipment of Product. Each
shipment will be accompanied by the documentation listed in the Statement of Work. LHI will use commercially reasonable efforts to deliver each shipment of Product to CLIENT or to any CLIENT-designated Third Party on its behalf on the requested
delivery date for such shipment. CLIENT may ask to ship Batches in different shipments and to different locations. LHI will promptly notify CLIENT if LHI reasonably believes that it will be unable to meet a delivery date. CLIENT shall be required to
take delivery of a Batch of Product within thirty (30) days after acceptance of such Batch in accordance with Section 5.2 (the “Delivery Period”), unless CLIENT requests in writing, and LHI consents in writing, to store the
material on CLIENT’s behalf and at CLIENT’s expense. 
 4.5 Genetic Alterations. LHI is not responsible for any genetic
alterations that occur during production of any product, except for those genetic alterations that result from a grossly negligent or intentionally wrongful act or omission of LHI and not as a result of the predisposition of any material provided by
CLIENT. Unless they arise from a grossly negligent 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
or intentionally wrongful act or omission of LHI, genetic alterations shall not be the basis for a breach of warranty claim by CLIENT. If LHI fails to deliver materials in accordance with the
terms of this Agreement or a Statement of Work, or if materials produced pursuant to the Statement of Work fail to meet any technical specification required by the Statement of Work, and such failure is due to genetic alterations which do not arise
from a grossly negligent or intentionally wrongful act or omission of LHI, LHI will re-perform the specific project at issue at the earliest practicable time, for an additional fee equal to the original fee for that part of the project. 

4.6 Records. LHI will maintain accurate records for the production of the Product, as required by applicable laws and regulations. LHI
will retain possession of the SOW Documentation, all Batch Records and LHI Operating Documents, and will make copies thereof available to CLIENT upon CLIENT’s request and at CLIENT’s expense. LHI Operating Documents will remain LHI
Confidential Information provided that it shall not limit in any way the CLIENT rights to use the Product. CLIENT will have the right to use and reference any of the foregoing in connection with a filing for Regulatory Approval of the Product or as
otherwise authorized by the Agreement. 
 4.7 CLIENT Access.  

4.7.1 CLIENT’s employees and agents (including its independent contractors) (collectively, “CLIENT Personnel”)
shall be entitled to participate in the production of the Product only in order to review the production process in such capacities as shall be agreed in writing in advance by the Parties, subject to mutually agreed scheduling. CLIENT Personnel
working at the Facility are required to comply with LHI’s Operating Documents and any other applicable LHI facility and/or safety policies. For the avoidance of doubt, CLIENT Personnel may not physically participate in the production or
manufacture of any Product that may be used in or on humans. 
 4.7.2 CLIENT Personnel working at the Facility will be and remain
employees of CLIENT, and CLIENT will be solely responsible for the payment of compensation for such CLIENT Personnel (including applicable Federal, state and local withholding, FICA and other payroll taxes, workers’ compensation insurance,
health insurance, and other similar statutory and fringe benefits). CLIENT covenants and agrees to maintain workers’ compensation benefits and employers’ liability insurance as required by applicable laws with respect to all CLIENT
Personnel working at the Facility. 
 4.7.3 CLIENT will pay for the actual cost of repairing or replacing to its previous status (to
the extent that LHI determines, in its reasonable judgment, that repairs cannot be adequately effected) any property of LHI damaged or destroyed by CLIENT Personnel, provided CLIENT shall not be liable for repair or replacement costs resulting from
ordinary wear and tear. 
 4.7.4 CLIENT Personnel visiting or having access to the Facility will abide by LHI standard policies,
operating procedures and the security procedures established by LHI. CLIENT will be liable for any breaches of security by CLIENT Personnel. In addition, CLIENT will reimburse LHI for the cost of any lost security cards issued to CLIENT Personnel,
at the rate 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
of $50 per security card. All CLIENT Personnel will agree to abide by LHI policies and SOPs established by LHI, and will sign an appropriate confidentiality agreement. 

4.7.5 CLIENT will indemnify and hold harmless LHI from and against any and all losses, damages, liabilities, costs and expenses
(including reasonable attorneys’ fees and expenses) arising out of any injuries suffered by CLIENT Personnel while at the Facility or elsewhere, except to the extent caused by the gross negligence or willful misconduct on the part of any LHI
Party. 
 4.8 Disclaimers. CLIENT acknowledges and agrees that LHI Parties will not engage in any Product refinement or
development of the Product, other than as expressly set forth in this Agreement and the Statement of Work. CLIENT acknowledges and agrees that LHI Parties have not participated in the invention or testing of any Product, and have not evaluated its
safety or suitability for use in humans or otherwise. 
  

	5.	PRODUCT WARRANTIES; ACCEPTANCE AND REJECTION OF PRODUCTS 

5.1 Product Warranties. LHI warrants that any Product manufactured by LHI pursuant to this Agreement, at the time of delivery pursuant
to Section 4.4: (a) conforms to the Specifications; (b) was manufactured in accordance with the SOW Documentation; and (c) where applicable was manufactured in accordance with cGMP. 

5.2 Approval of Completed Product.  

5.2.1 When a Statement of Work has been completed, LHI will notify CLIENT and supply CLIENT with the required documentation set forth in
the Statement of Work. 
 5.2.2 Within twenty one (21) calendar days after CLIENT’s receipt of substantially complete
documentation and Batch Records regarding such Product (the “Acceptance Period”), Client shall determine by review of such documentation whether or not the given Batch conforms to the product warranties set forth in Section 5.1
above (“Product Warranties”). If CLIENT asserts that the Product does not comply with the Product Warranties set forth in Section 5.1 above, CLIENT will deliver to LHI, in accordance with the notice provisions set forth in
Section 17.4 hereof, written notice of disapproval (the “Disapproval Notice”) of such Product, stating in reasonable detail the basis for such assertion of non-compliance with the Product Warranties. If a valid Disapproval
Notice is received by LHI during the Acceptance Period, then LHI and CLIENT will provide one another with all related paperwork and records (including, but not limited to, quality control tests) relating to both the production of the Product and the
Disapproval Notice. If a valid Disapproval Notice is not received during the Acceptance Period, the Product will be deemed accepted and ready for shipment to CLIENT, or storage for CLIENT, as applicable. If Product is to be shipped to CLIENT, then
upon acceptance, the Product shall be delivered to CLIENT, and CLIENT shall accept delivery thereof, within 10-days after such acceptance. Title and risk of loss to such Product shall pass to CLIENT at the time of delivery to the common carrier
pursuant to Section 4.4. If the Product is to be stored by LHI for CLIENT, LHI shall do so in accordance with agreed upon terms of a Statement of Work which covers all relevant details of a Product storage engagement. 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 5.3 Dispute Resolution. LHI and CLIENT will attempt to resolve any dispute regarding
the conformity of a Batch of Product with the Product Warranties. If such dispute cannot be settled within 30 days of the submission by each Party of such related paperwork and records to the other Party, and if the Product is alleged not to conform
with the Product Warranties set forth in Section 5.1(a), then CLIENT will submit a sample of the Batch of the disputed Product to an independent testing laboratory of recognized repute selected by CLIENT and approved by LHI (such approval not
to be unreasonably withheld) for analysis, under quality assurance approved procedures, of the conformity of such Batch of Product with the Specifications. The costs associated with such analysis by such independent testing laboratory will be paid
by the Party whose assessment of the conformity of the Batch of Product with the Specifications was mistaken. 
 5.4 Remedies for
Non-Conforming, Damaged, or Destroyed Product.  
 5.4.1 In the event that the Parties agree, or an independent testing
laboratory determines, pursuant to Section 5.3, that a Batch of Product materially fails to conform to the Product Warranties, or Product and/or Materials are destroyed or damaged by LHI Personnel, due to the failure of: (a) LHI personnel
properly to execute the SOW Documentation, (b) LHI personnel to comply with cGMP, or (c) the Facility utilities, then, at CLIENT’s written request, LHI will commence, as soon as it is commercially practicable to do so and not later
than 30 days after such written request, unless the Facility is not available due to prior obligations which cannot be postponed, produce one time for CLIENT sufficient quantities of Product to replace the non-conforming, damaged or destroyed
portion of such Batch of Product (the “Production Rerun”), in accordance with the provisions of this Agreement and at no additional cost to CLIENT. 

5.4.2 In the event that the Parties agree, or an independent testing laboratory determines, pursuant to Section 5.3, that a Batch
of Product materially fails to conform to the Product Warranties, or Product and/or Materials are destroyed or damaged by LHI Personnel, for any reason other than as set forth in Section 5.4.1, then LHI shall have no liability to CLIENT with
respect to such Batch, Product or Material and LHI will, at CLIENT’s request, produce for CLIENT a Production Rerun at CLIENT’s expense. Notwithstanding anything to the contrary set forth in Section 5.4, if during the manufacture of
Product pursuant to this Agreement, Product or Materials are destroyed or damaged by LHI Personnel while LHI Personnel were acting at the written direction of CLIENT Personnel, then LHI will have no liability to CLIENT as the result of such
destruction or damage. 
 5.4.3 CLIENT acknowledges and agrees that its sole remedy with respect to (i) the failure of Product
to conform with any of the Product Warranties and (ii) damaged or destroyed Materials and/or Product, is as set forth in this Section 5.4, and in furtherance thereof, Client hereby waives all other remedies at law or in equity regarding
the foregoing claims. 
  

	6.	RESERVED 

  

	7.	STORAGE OF MATERIALS 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 7.1 Pre-Production. LHI will store at the expense of CLIENT any CLIENT Materials,
equipment or other property delivered pursuant to the Statement of Work to the Facility by CLIENT more than 30 days prior to the Commencement Date. The storage rates will be set forth in the Statement of Work and may be amended from time to time by
LHI. No storage fees will be charged during the period starting 30 days prior to the Commencement Date and ending upon the expiration or termination of the Production Term. 

7.2 Post-Production. LHI will store at the Facility free of charge any in–process materials, CLIENT Materials, equipment and other
CLIENT property (other than Product manufactured hereunder) that remains at the Facility on the date of expiration or termination of the Production Term (collectively “Remaining CLIENT Property”), for up to 30 calendar days. If
CLIENT has not provided any instructions as to the shipment or other disposition of Remaining CLIENT Property prior to the expiration of such thirty (30)-day period, LHI may, continue to store such Remaining CLIENT Property at the Facility or
elsewhere. In the event that LHI continues to store such Remaining CLIENT Property, CLIENT will enter into a storage agreement with LHI and agree to pay to LHI a storage charge at LHI’s then-standard monthly storage rates for the period
beginning on the thirty-first (31st) day after the expiration or termination of the Production Term through the date that the storage terminates. 

7.3 Product. Notwithstanding the foregoing, if CLIENT fails to take delivery of a Product within the applicable Delivery Period as
required by Section 4.4 and fail to enter into a storage agreement with LHI, CLIENT will pay to LHI a storage charge at one and a half times LHI’s then-standard monthly storage rate, which shall begin accruing on the first day following
the expiration of the applicable Delivery Period. 
  

	8.	REGULATORY MATTERS 

 8.1 Permits and Approvals. Upon
the Commencement Date and during the Production Term, LHI will maintain any licenses, permits and approvals necessary for the manufacture of the Product in the Facility. LHI will promptly notify CLIENT if LHI receives notice that any such license,
permit, or approval is or may be revoked or suspended. 
 8.2 Inspections/Quality Audit by CLIENT. Up to two times during the
Production Term and upon not less than 15 days’ prior written notice, LHI will permit CLIENT to inspect and audit the parts of the Facility where the manufacture of the Product is carried out in order to assess LHI’s compliance with cGMP,
and to discuss any related issues with LHI’s management personnel. CLIENT Personnel engaged in such inspection will abide by the terms and conditions set forth in Sections 4.7.4 and 10. 

8.3 Inspections by Regulatory Agencies. LHI will allow representatives of any regulatory agency to inspect the relevant parts of the
Facility where the manufacture of the Product is carried out and to inspect the SOW Documentation and Batch Records to verify compliance with cGMP and other practices or regulations and will promptly notify CLIENT of the scheduling of any such
inspection relating to the manufacture of Product. LHI will promptly send to CLIENT a copy of any reports, citations, or warning letters received by CLIENT in connection with an inspection of a regulatory agency to the extent such documents relate
to or affect the manufacture of the Product. 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

	9.	FINANCIAL TERMS 

 9.1 Payments. CLIENT will make
payments to LHI in the amounts and on the dates set forth in the Statement of Work. In the event that CLIENT has not paid an invoice within thirty (30) business days of the applicable due date (as established by Section 9.2), CLIENT’s
failure shall be considered a material breach under Section 14.2, subject to the cure provisions set forth therein. Further, in addition to all other remedies available to LHI, in the event that CLIENT has not paid an invoice within sixty
(60) business days of the applicable due date (as established by Section 9.2), LHI may elect to suspend the provision of all or a portion of the services under this Agreement, provided that CLIENT shall remain liable for all fees owed
pursuant to the Statement of Work during any such suspension. LHI will submit to the CLIENT a valid certificate of Tax Residency (Form 6166) at least 45 days prior to first payment under this Agreement, and thereafter shall provide such certificate
annually upon the CLIENT’s written request. 
 9.2 Invoices. LHI will charge for the services in accordance with the price
schedule in each individual Statement of Work. LHI will invoice CLIENT according to the schedule set forth in a Statement of Work. LHI will deliver invoices electronically by email, which shall be considered to be an original invoice. Invoices
should be e-mailed to Dr. Eyal Breitbart (eyal@vblrx.com), and/or to such other e-mail address(es) as CLIENT may stipulate from time to time. LHI will not deliver a paper invoice. Payment of invoices is due as provided in the Statement of Work.
.. 
 9.3 Taxes. CLIENT agrees that it is responsible for and will pay any sales, use or other taxes (the “Taxes”)
resulting from LHI’s production of Product under this Agreement (except for income or personal property taxes payable by LHI). To the extent not paid by CLIENT, CLIENT will indemnify and hold harmless the LHI Parties from and against any and
all penalties, fees, expenses and costs whatsoever in connection with the failure by CLIENT to pay the Taxes. LHI will not collect any sales and use taxes from CLIENT in connection with the production of any Product hereunder if CLIENT provides to
LHI the appropriate valid exemption certificates. 
 9.4 Interest. Any fee, charge or other payment due to LHI by CLIENT under
this Agreement that is not paid within 30 days after it is due will accrue interest on a daily basis at a rate of 1.0% per month (or the maximum legal interest rate allowed by applicable law, if less) from and after such date. 

9.5 Method of Payment. All payments to LHI hereunder by CLIENT will be in United States currency and will be by check, wire transfer,
money order, or other method of payment approved by LHI. Bank information for wire transfers is as follows: 
 Mailing address for wire
transfer payments: 
  

			
	 To:
 Branch:
	  	 [***]
 [***]

	 Wire ABA Routing:
 Check-ACH ABA:
	  	 [***]

[***]

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

			
	 Account:
 Remarks:
	  	 [***]
 [***]

 9.6 Cost Adjustments. After the first anniversary of the Effective Date, LHI may annually adjust the
various costs and rates set forth in the Statement of Work attached hereto to reflect changes in the cost of materials and/or labor rate paid by LHI in connection with the production of Product under this Agreement; provided, however, that any
increase in labor rates shall not exceed any percentage increase in the US Consumer Price Index for the most recently published percentage change for the 12-month period preceding the applicable contract anniversary date. LHI agrees to provide
CLIENT with written notice of any such cost adjustment. 
  

	10.	CONFIDENTIAL INFORMATION 

 10.1 Definition.
“Confidential Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures,
specifications, data, results and other material, pre-clinical and clinical trial results, manufacturing procedures, test procedures and purification and isolation techniques, and any tangible embodiments of any of the foregoing, and any scientific,
manufacturing, marketing and business plans, any financial and personnel matters relating to a Party or its present or future products, sales, suppliers, customers, employees, investors or business, that has been disclosed by or on behalf of such
Party to the other Party either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement. Without limiting the foregoing, the terms of this Agreement will be deemed
“Confidential Information” and will be subject to the terms and conditions set forth in this Article 10. 
 10.2 Exclusions.
Notwithstanding the foregoing Section 10.1, any information disclosed by a Party to the other Party will not be deemed “Confidential Information” to the extent that such information: 

(a) at the time of disclosure is in the public domain; 

(b) becomes part of the public domain, by publication or otherwise, through no fault of the Party receiving such information; 

(c) at the time of disclosure is already in possession of the Party who received such information, as established by contemporaneous
written records; 
 (d) is lawfully provided to a Party, without restriction as to confidentiality or use, by a Third Party lawfully
entitled to possession of such Confidential Information; or 
 (e) is independently developed by a Party without use of or reference
to the other Party’s Confidential Information, as established by contemporaneous written records. 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 10.3 Disclosure and Use Restriction. Except as expressly provided herein, the Parties
agree that for the term of the Agreement and the five-year period following any termination of the Agreement, each Party and its Affiliates will keep completely confidential and will not publish or otherwise disclose any Confidential Information of
the other Party, its Affiliates or sublicensees, except in accordance with Section 10.4. Neither Party will use Confidential Information of the other Party except as necessary to perform its obligations or to exercise its rights under this
Agreement. 
 10.4 Permitted Disclosures. Each receiving Party agrees to (i) institute and maintain security procedures to
identify and account for all copies of Confidential Information of the disclosing Party and (ii) limit disclosure of the disclosing Party’s Confidential Information to its U.S. and European Affiliates and each of its and their respective
officers, directors, employees, agents, consultants and independent contractors having a need to know such Confidential Information for purposes of this Agreement; provided that such U.S. and European Affiliates and each of its and their respective
officers, directors, employees, agents, consultants and independent contractors are informed of the terms of this Agreement and are subject to obligations of confidentiality, non-disclosure and non-use similar to those set forth herein. Each Party
may disclose this Agreement during a due diligence process in connection with the proposed transfer of its assets or capital stock, whether through purchase, merger, consolidation or otherwise. Such disclosure will be subject to obligations of
confidentiality, non-disclosure and non-use similar to those set forth herein.  
 10.5 Government-Required Disclosure. If a
duly constituted government authority, court or regulatory agency orders that a Party hereto disclose information subject to an obligation of confidentiality under this Agreement, such Party shall comply with the order, but shall notify the other
Party as soon as possible, so as to provide the said Party an opportunity to apply to a court of record for relief from the order.  

10.6 Publicity. Neither Party will refer to, display or use the other’s name, trademarks or trade names confusingly similar
thereto, alone or in conjunction with any other words or names, in any manner or connection whatsoever, including any publication, article, or any form of advertising or publicity, except with the prior written consent of the other Party or as
otherwise set forth in Section 10.7. 
 10.7 Publications. The confidentiality provisions of this Section 10 are applicable
to all publications, abstracts, and papers authored by either Party , or its respective employees, consultants or contractors (the “Submitting Party”) relating to services performed by LHI hereunder or to data created pursuant to or
related to the Statement of Work. Manuscripts of all such publications shall be submitted to the other Party (the “Reviewing Party”) at least sixty (60) days prior to submission in final form to any publisher. The Reviewing Party
shall promptly inform the Submitting Party of any alterations or deletions necessary to protect its rights under Section 10 and the Submitting Party shall be obligated to make such changes prior to submitting any manuscripts in final form. The
Reviewing Party may further withhold its approval for such publication if necessary to protect its rights under Section 10. For general business development purposes, each Party may announce on its website or in press releases the general
nature of work performed for CLIENT under any given Statement of Work upon receiving permission from the other Party, such permission not being unreasonably withheld or delayed. 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

	11.	INTELLECTUAL PROPERTY 

 11.1 Ownership.  

11.1.1 Neither party will acquire any right, title, or interest in any Intellectual Property that the other party owns or controls as of
the Effective Date of this Agreement, or that the other party obtains separate and apart from this Agreement. 
 11.1.2 As between the
Parties, CLIENT shall own any and all inventions or discoveries that are (i) made, conceived or reduced to practice in the course of or resulting from this Agreement by either Party alone or the Parties jointly and (ii) applicable to the
Product or the Process (“CLIENT New IP”). LHI hereby assigns to CLIENT all of LHI’s right, title and interest in and to such CLIENT New IP. 

11.1.3 As between the Parties, LHI shall own any and all inventions or discoveries that are (i) made, conceived or reduced to
practice in the course of or resulting from this Agreement by LHI and (ii) capable of being applied to products or processes other than the Product or the Process, and (iii) relates generally to LHI’s business of producing biological
materials and (iv) are not a part of CLIENT New IP and (v) do not make use of or any reference of CLIENT’s Confidential Information (“LHI New IP”). CLIENT hereby assigns to LHI all of CLIENT’s right, title and
interest in and to such LHI New IP. 
 11.1.4 LHI shall own any know-how, media, assays, methods or other inventions, whether or not
patentable that are conceived, acquired from a third party, developed or reduced to practice by LHI after the Effective Date that is not LHI New IP (“LHI Independent IP”). LHI may offer to CLIENT to include said LHI Independent IP into the
Product or Process. If CLIENT elects to include such LHI Independent IP in the Product or Process, such use of LHI Independent IP shall be subject to a license to be negotiated in good faith by the Parties. For the avoidance of doubt, LHI
Independent IP is Intellectual Property developed by or for LHI independently and outside the scope of this Agreement by persons (i) without using actual knowledge of or not having access to CLIENT Confidential Information, but excluding LHI
New IP, or (ii) not performing Process or Product development activities under a Statement of Work pursuant to this Agreement. 

11.2 License Grants.  

11.2.1 During the term of this Agreement, CLIENT hereby grants to LHI a fully paid, non-exclusive license under any and all CLIENT
Intellectual Property that is necessary for LHI to perform its obligations under this Agreement for the sole and limited purpose of LHI’s performance of its obligations under this Agreement, including, without limitation, the development of the
Process and the manufacture of Product for CLIENT. 
 11.2.2 LHI hereby grants to CLIENT an irrevocable, fully paid, non-exclusive
license, with the right to grant and authorize sublicenses, under any and all (i) LHI Intellectual Property (including LHI Inventions and LHI New IP but excluding LHI Independent IP) that LHI incorporates into the Process, to make, have made,
use, sell, offer for sale, have sold and import the Product, or for any other commercial or research purpose related solely to the Product or Process, either by the CLIENT or a Third Party on its behalf and (ii) know-how included in

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
the LHI New IP and not claimed in a patent or patent application, to use for any purpose related solely to the Product or Process. 

11.3 Further Assurances. Each Party agrees to take all necessary and proper acts, and will cause its employees, Affiliates, contractors,
and consultants to take such necessary and proper acts, to effectuate the ownership provisions set forth in this Article 11. 
 11.4
Prosecution of Patents.  
 11.4.1 LHI will have the sole right and discretion to file, prosecute and maintain patent
applications and patents claiming LHI Inventions at LHI’s expense. CLIENT will cooperate with LHI to file, prosecute and maintain patent applications and patents claiming LHI Inventions, and will have the right to review and provide comments to
LHI relating to such patent applications and patents. 
 11.4.2 CLIENT will have the sole right and discretion to file, prosecute and
maintain patent applications and patents claiming CLIENT Inventions at CLIENT’s expense. LHI will cooperate with CLIENT to file, prosecute and maintain patent applications and patents claiming CLIENT Inventions, and will have the right to
review and provide comments to CLIENT relating to such patent applications and patents. 
  

	12.	REPRESENTATIONS AND WARRANTIES 

 12.1 By
CLIENT. CLIENT hereby represents and warrants to LHI that, to the best of its knowledge, (i) it has the requisite intellectual property and legal rights related to the CLIENT Deliverables and the Product to authorize the performance of
LHI’s obligations under this Agreement, and (ii) the performance of the Statement of Work and the production by LHI of the Product as contemplated in this Agreement will not give rise to a potential cause of action by a Third Party against
LHI for infringement or another violation of intellectual property rights. Such representation and warranty will not apply to any production equipment supplied by LHI, method used by LHI or any other material or data used by LHI in the provision of
the Services and which were not received from the CLIENT or agreed by CLIENT to be used in the provision of the Services. 
 12.2 By
LHI. LHI hereby represents and warrants to CLIENT that, to the best of its knowledge, (i) it has the requisite intellectual property rights to be able to perform its obligations under this Agreement, and (ii) that LHI Intellectual
Property, including LHI Inventions and LHI New IP as contemplated in this Agreement will not give rise to a potential cause of action by a Third Party against CLIENT for infringement or another violation of intellectual property rights. 

 

	13.	DISCLAIMER; LIMITATION OF LIABILITY 

13.1 DISCLAIMER. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, INCLUDING WITHOUT LIMITATION THE EXPRESS PRODUCT WARRANTIES
SET FORTH IN SECTION 5.1, LHI MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, WITH RESPECT TO THE PRODUCTS, MATERIALS, AND SERVICES PROVIDED

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
UNDER THIS AGREEMENT, AND LHI SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR USE OR PURPOSE WITH RESPECT TO SUCH PRODUCTS, MATERIALS, OR SERVICES. 
 13.2 Disclaimer of Consequential Damages. IN NO
EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY
SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 13.3
Limitation of Liability. BOTH PARTIES HEREBY AGREE THAT TO THE FULLEST EXTENT PERMITTED BY LAW, LHI’S LIABILITY TO CLIENT, FOR ANY AND ALL INJURIES, CLAIMS, LOSSES, EXPENSES, OR DAMAGES, WHATSOEVER, ARISING OUT OF OR IN ANY WAY RELATED TO THIS
AGREEMENT FROM ANY CAUSE OR CAUSES, INCLUDING, BUT NOT LIMITED TO, NEGLIGENCE, ERRORS, OMISSIONS OR STRICT LIABILITY, SHALL BE LIMITED SOLELY TO LHI REPEATING ONE TIME, AT LHI’S EXPENSE, SERVICES WHICH WERE MUTUALLY DEEMED TO BE NON-CONFORMING.
HOWEVER THIS SECTION SHALL NOT APPLY IN THE EVENT BUT ONLY TO THE EXTENT OF GROSS NEGLIGENCE OR WILLFULL MISCONDUCT UNDER THIS AGREEMENT. TO THE EXTENT THAT THIS CLAUSE CONFLICTS WITH ANY OTHER CLAUSE, THIS CLAUSE SHALL TAKE PRECEDENCE OVER SUCH
CONFLICTING CLAUSE. IF APPLICABLE LAW PREVENTS ENFORCEMENT OF THIS CLAUSE, THEN THIS CLAUSE SHALL BE DEEMED MODIFIED TO PROVIDE THE MAXIMUM PROTECTION FOR LHI AS IS ALLOWABLE UNDER APPLICABLE LAW. 

 

	14.	TERM AND TERMINATION 

 14.1 Term. The
term of this Agreement will commence on the Effective Date and will continue until the fifth anniversary of the Effective Date unless terminated prior to that time or extended by the Parties. 

14.2 Termination for Material Breach. Either Party may terminate this Agreement, by written notice to the other Party, for any material
breach of this Agreement by the other Party, if such breach is not cured within thirty (30) days after the breaching Party receives written notice of such breach from the non-breaching Party; provided, however, that if such breach is not
capable of being cured within such thirty-day period and the breaching Party has commenced and diligently continued actions to cure such breach within such thirty-day period, except in the case of a payment default, the cure period shall be extended
to 60 days, so long as the breaching Party is making diligent efforts to do so. Such termination shall be effective upon expiration of such cure period.  

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

	 	14.3	Termination by Notice.  

 14.4 14.3.1 Without Cause. During the term of the
Agreement, the CLIENT may terminate the Agreement upon 60 days notice. After the first anniversary of the Effective Date, either Party may terminate this Agreement by providing written notice of termination no less than two months in advance of the
date of termination. For the avoidance of doubt, in the event of termination by CLIENT under this Section 14.3.1, CLIENT shall, at minimum, remain liable for all charges for materials that have already been purchased, all fees owed pursuant to
actual services rendered, including all work in process, and un-cancellable costs, including un-cancellable labor commitments, related to any outstanding Statement of Work. In addition to the foregoing, in connection with any termination under this
Section 14.3.1, CLIENT shall also pay to LHI a suite fee of Fifty Thousand Dollars ($50,000.00) per month for each of the three months prior to termination. Notwithstanding the foregoing, LHI will use commercially reasonable efforts to secure
new projects (but excluding any project then under contract with LHI) for the suite space reserved for all cancelled CLIENT SOWs, for the same dates and duration that would have been occupied by CLIENT. If such new projects are secured by LHI, the
suite fee due from CLIENT upon cancellation shall be reduced by an amount equal to one hundred percent (100%) of the production fees associated with such new projects; provided, however, in no event shall any such reduction result in a refund
or credit to CLIENT.  
 14.3.2 Termination of Clinical Trials. Either Party may terminate this Agreement if such Party
receives notice that the production of Product hereunder or the clinical trials for which Product is being produced hereunder have been or will be suspended or terminated by the FDA (or other regulatory authority) by providing written notice of
termination not less than 2 months in advance of the date of termination. For the avoidance of doubt, in the event of termination by CLIENT under this Section 14.3.2, CLIENT shall, at minimum, remain liable for all charges for materials that
have already been purchased, all fees owed pursuant to actual services rendered, including all work in process, and un cancellable costs, including un-cancellable labor commitments, related to any outstanding Statement of Work during such two-month
period. 
 14.5 Termination by Insolvency. Either Party may terminate this Agreement upon notice to the other Party, upon
(a) the dissolution, termination of existence, liquidation or business failure of the other Party; (b) the appointment of a custodian or receiver for the other Party who has not been terminated or dismissed within ninety (90) days of
such appointment; (c) the institution by the other Party of any proceeding under national, federal or state bankruptcy, reorganization, receivership or other similar laws affecting the rights of creditors generally or the making by such Party
of a composition or any assignment for the benefit of creditors under any national, federal or state bankruptcy, reorganization, receivership or other similar law affecting the rights of creditors generally, which proceeding is not dismissed within
ninety (90) days of filing. All rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code, licenses of rights of “intellectual
property” as defined therein. 
 14.6 Effects of Termination. 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 14.6.1 Accrued Rights. Termination of this Agreement for any reason will be without
prejudice to any rights that will have accrued to the benefit of a Party prior to such termination. Such termination will not relieve a Party of obligations that are expressly indicated to survive the termination of this Agreement. 

14.6.2 Disposition of Remaining CLIENT Property and Confidential Information. Upon termination or expiration of this Agreement, LHI will
store any Remaining CLIENT Property as set forth in Section 7.2 and, at CLIENT’s option, return or destroy any CLIENT Confidential Information in the possession or control of LHI. Likewise, CLIENT will, at LHI’s option, return or
destroy any LHI Confidential Information in the possession or control of CLIENT. Notwithstanding the foregoing provisions: (i) LHI may retain and preserve, at its sole cost and expense, samples and standards of each Product following
termination or expiration of this Agreement solely for use in determining LHI’s rights and obligations hereunder; and (ii) each Party may retain a single copy of the other Party’s Confidential Information for documentation purposes
only and which shall remain subject to the obligations of nonuse and confidentiality set forth in this Agreement. 
 14.6.3 Survival.
Sections 1, 3.4, 4.8, 7.2, 10, 11, 13, 14.4, 15, 16 and 17 of this Agreement, together with any appendices referenced therein, will survive any expiration or termination of this Agreement. 

 

	15.	INDEMNIFICATION 

 15.1 Indemnification of Client. LHI will
indemnify CLIENT, its Affiliates, and their respective directors, officers, employees and agents, and defend and hold each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys’ fees and expenses) in connection with any and all liability suits, investigations, claims or demands (collectively, “Losses”) to the extent such Losses arise out of or result from any claim, lawsuit or other action
or threat by a Third Party arising out of: (a) any material breach by LHI of this Agreement, or (b) the gross negligence or willful misconduct on the part of one or more of the LHI Parties in performing any activity contemplated by this
Agreement, except for those Losses for which CLIENT has an obligation to indemnify the LHI Parties pursuant to Section 15.2, as to which Losses each Party will indemnify the other to the extent of their respective liability for the Losses.

 15.2 Indemnification of LHI. CLIENT will indemnify LHI and its Affiliates, and their respective directors, officers, employees
and agents (the “LHI Parties”), and defend and hold each of them harmless, from and against any and all Losses to the extent such Losses arise out of or result from any claim, lawsuit or other action or threat by a Third Party
arising out of: (a) any material breach by CLIENT of this Agreement, (b) the use or sale of Products, except to the extent such Losses arise out of or result from a breach by LHI of the Product Warranties, (c) the gross negligence or
willful misconduct on the part of CLIENT or its Affiliates in performing any activity contemplated by this Agreement, or (d) the use or practice by LHI of any process, invention or other intellectual property supplied by CLIENT to LHI under
this Agreement, except for those Losses for which LHI has an obligation to indemnify CLIENT pursuant to Section 15.1, as to which Losses each Party will indemnify the other to the extent of their respective liability for the Losses. 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 15.3 Indemnification Procedure. 

15.3.1 An “Indemnitor” means the indemnifying Party. An “Indemnitee” means the indemnified Party, its
Affiliates, and their respective directors, officers, employees and agents.  
 15.3.2 An Indemnitee which intends to claim
indemnification under Section 15.1 or Section 15.2 hereof shall promptly notify the Indemnitor in writing of any claim, lawsuit or other action in respect of which the Indemnitee, its Affiliates, or any of their respective directors,
officers, employees and agents intend to claim such indemnification. The Indemnitee shall permit, and shall cause its Affiliates and their respective directors, officers, employees and agents to permit, the Indemnitor, at its discretion, to settle
any such claim, lawsuit or other action and agrees to the complete control of such defense or settlement by the Indemnitor; provided, however, that in order for the Indemnitor to exercise such rights, such settlement shall not adversely affect the
Indemnitee’s rights under this Agreement or impose any obligations on the Indemnitee in addition to those set forth herein. No such claim, lawsuit or other action shall be settled without the prior written consent of the Indemnitor and the
Indemnitor shall not be responsible for any legal fees or other costs incurred other than as provided herein. The Indemnitee, its Affiliates and their respective directors, officers, employees and agents shall cooperate fully with the Indemnitor and
its legal representatives in the investigation and defense of any claim, lawsuit or other action covered by this indemnification, all at the reasonable expense of the Indemnitor. The Indemnitee shall have the right, but not the obligation, to be
represented by counsel of its own selection and expense.  
 15.4 Insurance. LHI will maintain, at all times during the term of
this Agreement and for five years thereafter, a sufficient insurance policy, including a products liability policy, to assure its obligations under this Agreement (the “Insurance Policy”), with a per occurrence limit of at least
five million dollars ($5,000,000) and an aggregate limit of at least five million dollars ($5,000,000), and will provide a Certificate of Insurance to the CLIENT that the Insurance Policy has been endorsed to designate the CLIENT as an additional
insured. LHI shall maintain the Insurance Policy with an insurance company having a minimum AM Best rating of A. CLIENT will maintain, during the term of its clinical trials and to the extent required by law thereafter, a Clinical trials insurance
policy, with a per occurrence limit of at five million dollars ($5,000,000) and an aggregate limit of five million dollars ($5,000,000), and will provide a Certificate of Insurance evidencing that the CLIENTS Insurance Policy has been endorsed to
include LHI as an additional insured. Should any of the above described policies be cancelled before the expiration date thereof, notice will be delivered in accordance with the policy provisions. 

 

	16.	ADDITIONAL COVENANTS 

 16.1 Non-Solicitation. During
the term of this Agreement and for two (2) years thereafter, each of the Parties agrees not to seek to induce or solicit any employee of the other Party or its Affiliates to discontinue his or her employment with the other Party or its
Affiliate in order to become an employee or an independent contractor of the soliciting Party or its Affiliate; provided, however, that neither Party shall be in violation of this Section 16.1 as a result of 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
making a general solicitation for employees or independent contractors. For the avoidance of doubt, the publication of an advertisement shall not constitute solicitation or inducement.

 16.2 Commercial Scale Manufacture. In the event that CLIENT desires to commence commercial scale manufacture of Product, and
following manufacture of the Product in accordance with the Process, the Parties agree to negotiate for the provision of such manufacturing services to CLIENT by LHI. 
  

	17.	MISCELLANEOUS 

 17.1 Independent Contractors. Each of the Parties
is an independent contractor and nothing herein contained shall be deemed to constitute the relationship of partners, joint venturers, nor of principal and agent between the Parties. Neither Party shall at any time enter into, incur, or hold itself
out to Third Parties as having authority to enter into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever. 

17.2 Force Majeure. Neither Party shall be in breach of this Agreement if there is any failure of performance under this Agreement
(except for payment of any amounts due under this Agreement) occasioned by any reason beyond the control and without the fault or negligence of the Party affected thereby, including, without limitation, an act of God, fire, flood, act of government
or state, war, civil commotion, insurrection, acts of terrorism, embargo, sabotage, a viral, bacterial or mycoplasmal contamination which causes a shutdown of the Facility, prevention from or hindrance in obtaining energy or other utilities, a
shortage of raw materials or other necessary components, labor disputes of whatever nature, or any other reason beyond the control and without the fault or negligence of the Party affected thereby (a “Force Majeure Event”). Such
excuse shall continue as long as the Force Majeure Event continues. Upon cessation of such Force Majeure Event, the affected Party shall promptly resume performance under this Agreement as soon as it is commercially reasonable for the Party to do
so. Each Party agrees to give the other Party prompt written notice of the occurrence of any Force Majeure Event, the nature thereof, and the extent to which the affected Party will be unable to fully perform its obligations under this Agreement.
Each Party further agrees to use commercially reasonable efforts to correct the Force Majeure Event as quickly as practicable (provided that in no event shall a Party be required to settle any labor dispute) and to give the other Party prompt
written notice when it is again fully able to perform such obligations. 
 17.3 Condemnation. If the Facility is condemned or
taken as a result of the exercise of the power of eminent domain or will be conveyed to a governmental agency having power of eminent domain under the threat of the exercise of such power (any of the foregoing, a “Condemnation”),
then this Agreement will terminate as of the date on which title to the Facility vests in the authority so exercising or threatening to exercise such power and CLIENT will not have any right to the Condemnation proceeds. 

17.4 Notices. Any notice required or permitted to be given under this Agreement by any Party shall be in writing and shall be
(a) delivered personally, (b) sent by registered mail, return receipt requested, postage prepaid, (c) sent by a nationally-recognized courier service guaranteeing next-day or second day delivery, charges prepaid, or (d) delivered
by facsimile (with documented evidence of transmission), to the addresses or facsimile numbers of the other  

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
Party set forth below, or at such other addresses as may from time to time be furnished by similar notice by any Party. The effective date of any notice under this Agreement shall be the date
of receipt by the receiving Party. 
 If to LHI: 

Lonza Houston, Inc. 
 Attn:
Business Head 
 8066 El Rio St. Houston, TX 77056 

With a copy to: 
 Assistant
General Counsel 
 Lonza America, Inc. 

90 Boroline Road 
 Allendale, NJ
07401 
 Fax: (201) 378-5630 

If to Client: 
 Vascular
Biogenics Ltd. Attn: Eyal Breitbart 
 6 Yonni Netanyahu St. 

Or –Yehuda Israel 
 Fax:
+972-3-6346449 
 Either Party may change its address for notice by giving notice thereof in the manner set forth in this Section 17.4. 

17.5 Entire Agreement; Amendments. This Agreement, including the Appendices attached hereto and referenced herein, constitutes the full
understanding of the Parties and a complete and exclusive statement of the terms of their agreement with respect to the specific subject matter hereof and supersedes all prior agreements and understandings, oral and written, among the Parties with
respect to the subject matter hereof. No terms, conditions, understandings or agreements purporting to amend, modify or vary the terms of this Agreement (including any Appendix hereto) shall be binding unless hereafter made in a written instrument
referencing this Agreement and signed by each of the Parties. 
 17.6 . Governing Law. This Agreement will be governed by and
construed in accordance with the internal laws of the Kingdom of England and Wales, without giving effect to its conflicts of laws provisions. Any dispute under this Agreement which cannot be resolved amicably shall be settled by the, shall be
finally settled under the Rules of Arbitration of the International Chamber of Commerce (“ICC”) by one arbitrator appointed in accordance with the said rules. The award shall be final and binding and enforceable in any court of competent
jurisdiction. The arbitration shall be held in London, United Kingdom, in English language. 
 17.7 Counterparts. This Agreement and
any amendment hereto may be executed in any number of counterparts, each of which shall for all purposes be deemed an original and all of which shall constitute the same instrument. This Agreement shall be effective upon full 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 
execution by facsimile or original, and a facsimile signature shall be deemed to be and shall be as effective as an original signature. 

17.8 Severability. If any part of this Agreement shall be found to be invalid or unenforceable under applicable law in any jurisdiction,
such part shall be ineffective only to the extent of such invalidity or unenforceability in such jurisdiction, without in any way affecting the remaining parts of this Agreement in that jurisdiction or the validity or enforceability of the Agreement
as a whole in any other jurisdiction. In addition, the part that is ineffective shall be reformed in a mutually agreeable manner so as to as nearly approximate the intent of the Parties as possible. 

17.9 Titles and Subtitles. All headings, titles and subtitles used in this Agreement (including any Appendix hereto) are for convenience
only and are not to be considered in construing or interpreting any term or provision of this Agreement (or any Appendix hereto). 
 17.10
Exhibits. All “RECITALS”, “DEFINITIONS”, exhibits and appendices referred to herein form an integral part of this Agreement and are incorporated into this Agreement by such reference. 

17.11 Pronouns. Where the context requires, (i) all pronouns used herein will be deemed to refer to the masculine, feminine or
neuter gender as the context requires, and (ii) the singular context will include the plural and vice versa. 
 17.12 Assignment.
This Agreement shall be binding upon the successors and assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns. Neither Party may assign its interest under this Agreement
without the prior written consent of the other Party, such consent not to be unreasonably withheld. Any permitted assignment of this Agreement by either Party will be conditioned upon that Party’s permitted assignee agreeing in writing to
comply with all the terms and conditions contained in this Agreement. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party of responsibility for the performance of any obligation that accrued prior
to the effective date of such assignment.  
 17.13 Waiver. The failure of any Party at any time or times to require
performance of any provision of this Agreement (including any Appendix hereto) will in no manner affect its rights at a later time to enforce the same. No waiver by any Party of any term, provision or condition contained in this Agreement (including
any Appendix hereto), whether by conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or condition of this
Agreement (including any Appendix hereto). 
 17.14 Dispute Resolution. If the Parties are unable to resolve a dispute, despite its
good faith efforts, either Party may refer the dispute to the President of each Party’s respective business unit (or other designee). In the event that no agreement is reached by the Presidents (or other designees) with respect to such dispute
within thirty (30) days after its referral to them, either Party may pursue any and all remedies available at law or in equity according to section 17.6 above.  

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 17.15 No Presumption Against Drafter. For purposes of this Agreement, CLIENT hereby
waives any rule of construction that requires that ambiguities in this Agreement (including any Appendix hereto) be construed against the drafter. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date last
signed by the parties hereto. 
  

							
		 		 	VASCULAR BIOLOGICS, LTD.
				
	1/05/2012	 		 	By:	 	 /s/ Dror Harats

	Date	 		 		 	Name: Dror Harats
		 		 		 	Title: CEO
			
		 		 	LONZA HOUSTON, INC.
				
	1/05/2012	 		 	By:	 	 /s/ J. David Enloe Jr.

	Date	 		 		 	Name: J. David Enloe Jr.
		 		 		 	Title: Head of Viral-based Therapeutics

  
 Portions of this exhibit
have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

  
 

 
 APPENDIX A-1 

Statement of Work VBLT-001 

Formulation Buffer Evaluations for VB-111 Final Product 

January 31, 2012 
  

	I.	Introduction and Background 

 This Statement of Work (SOW) between Vascular Biologics,
Ltd. and Lonza Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biogenics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is
incorporated therein and made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 

This SOW outlines the performance of a [***] designed to evaluate [***] as potential alternatives to the [***] currently utilized for VBL
Therapeutics’ (“VBL”) VB-111 [***] final product. The study will be performed by Lonza Process Development and/or Quality Control personnel, except for the execution of the [***] assays performed by VBL; assays will be performed under
GLP conditions and documented in laboratory notebooks. In addition, a study to evaluate the [***] at [***] will be performed by VBL using samples generated by Lonza and transferred to VBL. 

The [***] consist of the following components: 
  

	 	1.	[***] 

  

	 	2.	[***] 

  

	 	3.	[***] 

 Samples of VB-111 formulated in VBL’s standard final product buffer consisting of
[***] and [***] at [***] will be analyzed alongside [***], for comparison and as a control. 
 II. Project Assumptions 

In the development of this SOW, the following assumptions were made: 
  

	 	1.	The two batches of research and development-grade VB-111 provided by VBL will have been documented to be Mycoplasma-free and bioburden-free and/or sterile, prior to their arrival at Lonza; 

 

	 	2.	The VB-111 material provided for the study will be purified and formulated in [***] at a [***] and be of a [***] of approximately [***]; and 

 

	 	3.	For each instance of physical virus particle titer determination, Lonza’s standard [***] method will be utilized. In addition, it is assumed that Lonza’s standard [***] standard curve generation procedure will
be followed and will utilize VB-111 Reference Standard in the performance of this activity. 

 III. Scope of Work 

The scope of the project includes the following tasks: 
  

	 	a.	Sample Preparation 

  

					
	Lonza Job Code VBLT-001	  		  	Page 1 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 Using [***] of [***] of VB-111 [***] formulated with [***] in [***] provided by VBL, [***] will
be stored at [***] upon sample arrival to be used as controls for the [***] and [***], described below. The remaining [***] of [***] will be [***] and the material from both batches will be [***] Of the [***] will be [***] into each of [***] as
described above [***]. Following [***], the material will be [***] at [***] into approximately [***] for each [***] before [***] 
 [***]

 One VB-111 [***] will be subjected to [***] and tested after the final cycle. Testing that is to be performed both before and after [***]
includes [***], total, are required to perform this study; the total number of samples to be analyzed during this study is [***] of approximately [***] will be made from each [***] on the date of testing and used for analysis. [***] will be stored
at [***] for future analysis usage. 
  

	 	c.	Temperature Storage Condition Stability Study 

 Following preparation, samples will be
transferred to storage at [***] at Lonza and provided to VBL for transfer to proper storage temperature and analysis at each time point by VBL as desired by VBL, according to the following analysis plan: 

 

							
	 Testing Time point

(month)
	  	 Storage Condition

	  	
4oC
	  	
-20oC
	  	
-80oC

	[***]	  	[***]	  	[***]	  	[***]

  

	 	d.	Deliverables 

 In addition to sample preparation and study performance, Lonza will
compose a Process Development Protocol (PDP) in standard Lonza format prior to study commencement, and upon completion of the [***], a summary report for the [***] in standard Lonza format which will describe the materials and procedures used in,
and the results of, the study. Lonza will provide the report to VBL via electronic mail for review prior to report finalization. VBL will be provided with a signed copy of the report for its records. 

 

	IV.	Fees and Terms 

 The fees and payment terms for the activities described above total
[***], payable as follows: 
  

	 	1.	[***] 

  

					
	Lonza Job Code VBLT-001	  		  	Page 2 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

	 	2.	[***] 

 Shipments from Lonza to VBL will be made via World Courier and utilize VBL’s World
Courier account. In the event that shipments from Lonza to VBL utilize Lonza’s World Courier courier account, such shipment(s) will be invoiced for as pass-through costs and supporting documentation of associated fees will be provided along
with the invoice. 
 Invoices will be provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via
wire transfer using the Lonza account information set forth in the Agreement. 
 In the event of a termination of this SOW or the Agreement
for any reason, VBL shall pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all
uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 
  

	V.	Acceptance 

  

											
		 	Lonza Houston, Inc.	  		  	Vascular Biologics, Ltd.
						
		 	By:	  	 /s/ J. David Enloe, Jr.
	  		  	By:	  	 /s/ Amos Ron

		 	J. David Enloe, Jr.	  		  	Name:	  	Amos Ron
		 	Head, Viral-based Therapeutics	  		  	Title:	  	Chief Financial Officer
						
		 	Date:	  	  
	  		  	Date:	  	  

  

					
	Lonza Job Code VBLT-001	  		  	Page 3 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-2 

Statement of Work VBLT-002 

Small-scale [***] Process Development & 

Downstream Process Technology Transfer for VB-111 

February 14, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biogenics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
  

	II.	Scope of Work 

 Lonza will provide the following services surrounding the process
development activities for the VB-111 product: 
 Phase 1, [***] 

At the [***] Lonza will perform two studies simultaneously to determine parameters for [***] as well as [***] The cell densities to be
evaluated are [***] will be used for VB-111 infection. [***] An extra sample per time point will be taken and stored for possible future analysis by VBL. 

Phase 2, [***] 
 Lonza
Process Development personnel will evaluate the feasibility of a [***] as an alternative to [***] in the manufacture of the VB-111 product at volumes of [***] Three studies will be performed during Phase 1, as listed below: 

[***] 
 [***] 

[***] 
 Study 1, above, will be
performed in parallel with the [***]. The goal for Study 1, above, is to evaluate the [***] and to demonstrate that [***] Observations from and data generated during this activity 

  

					
	Lonza Job Code VBLT-002	  		  	Page 1 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 
will be drawn upon during the performance of Studies 2 and 3 to achieve [***] 

Studies 2 and 3 may be overlapped as reasonably possible to shorten overall project timeline. Transferred standard operating parameter
set-points from VBL’s existing VB-111 manufacturing procedure ([***]) will be used [***] 
 Cells from [***] provided by VBL, and
standard [***] added by Lonza at [***] provided by VBL, will be used throughout the studies. 
 [***] using previously determined and
transferred [***] for the product [***] will be determined by analyzing the [***] will be compared to historical VB-111 [***] to determine whether [***] In addition, samples will be provided to VBL [***]. 

Phase 3, [***] 
 Using
technical documentation and SOPs provided by VBL as basis for experiment planning and [***], Lonza will perform a technology transfer of the existing VB-111 downstream production process at the appropriate scale. Two executions of VBL’s
downstream production process will be performed. The first execution will utilize [***]; the second execution will utilize [***] will be processed first, followed by [***] The major processing steps for each [***] are as follows: [***] The [***]
will be analyzed for [***] Samples will be taken throughout the downstream process for each [***] as follows: [***] These samples will be analyzed for [***] by both Lonza and VBL and the data from both parties compared for consistency. 

[***] 
 Deliverable 

Upon completion of the above activities, Lonza will compose a Technology Transfer Report in standard Lonza format, which will describe the
materials and procedures used in, and the results of, the activities associated with this Project Component. Lonza will provide the report to VBL via 

  

					
	Lonza Job Code VBLT-002	  		  	Page 2 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***] .

 electronic mail for review prior to report finalization. VBL will be provided with a signed copy
of the report for its records. 
  

	III.	Fees and Terms 

 The fees for the activities described above total [***], payable as
follows: 
  

	 	1.	Phase 1, [***], due upon Statement of Work acceptance; 

  

	 	2.	Phase 2, [***] 

  

	 	a.	[***], due upon Statement of Work acceptance; 

  

	 	b.	[***], due upon Phase 1 completion. 

  

	 	3.	Phase 3, [***] 

  

	 	a.	[***], due upon Phase 2 activity commencement; 

  

	 	b.	[***], due upon issuance of the Summary Report. 

 Courier fees for shipments from Lonza to VBL
which utilize Lonza’s courier account will be invoiced for as pass-through costs and supporting documentation of associated fees will be provided along with the invoice. 

Invoices will be provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the
Lonza account information set forth in the Agreement. 
 In the event of a termination of this SOW or the Agreement for any reason, VBL shall
pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all uncancellable labor commitments
and all work in process (including all professional services rendered) through the effective date of termination. 
 IV. Acceptance 

 

											
	 	 	Lonza Houston, Inc.	  	 	  	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe Jr.
	  		  	By:	  	 /s/ Amos Ron

		 	J. David Enloe, Jr.	  		  	Name:	  	Amos Ron
		 	Head, Viral-based Therapeutics	  		  	Title:	  	 Chief Financial Officer

						
		 	Date:	 	  
	  		  	Date:	  	  

  

					
	Lonza Job Code VBLT-002	  		  	Page 3 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***] .

  
 

 
 APPENDIX A-2 

Change Order 1 to Statement of Work VBLT-002 

Resin Capacity Study for IEX Chromatography Resin 

June 12, 2012 
  

	I.	Introduction and Background 

 This Change Order (CO) to Statement of Work (SOW) VBLT-002
between Vascular Biologics, Ltd. and Lonza Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the
“Agreement”) and is incorporated therein and made a part of such Agreement. In the event of an inconsistency between the Agreement and this CO, the Agreement shall control. 

VBL has requested that Lonza perform analysis on samples taken during the performance of the activities as described in SOW VBLT-002, Section
II., “Phase 2, [***]” which are incremental to the analyses included in the SOW. The analyses to be performed per this Change Order are listed in Section II.A., below. 

In addition, VBL has requested that Lonza evaluate the capacity of the ion exchange (IEX) chromatography resin that is used for the
purification of VBL’s VB-111 product, in consideration of the potential need for increasing the size of the column and/or the quantity of resin utilized to purify VB-111 when produced at larger (i.e., 500L) working volumes. VB-111 material
produced by Lonza in the performance of the work described in SOW VBLT-002, Section II., “Phase 2, Small Scale Stirred-tank Bioreactor (STB) Process Development,” will be used as test article for the activities described in Section II.B.,
below. 
  

	II.	Scope of Work 

 A., Incremental Analysis on VB-111 Material 

Lonza will perform or coordinate the performance of the following assays, which are incremental to the work scope described in SOW VBLT-002, on
two samples of VB-111 material [***] generated in the performance of the work scope described in SOW VBLT-002: 
 [***] 

B., [***] 
 [***] 

Following verification of the [***], the maximum quantity [***] per milliliter of [***] will be determined. This activity will be performed
utilizing approximately [***] in each of [***]. VB-111 column load material produced as per [***], will be added to each of the [***] and [***], followed by [***] from each tube will be collected and stored for future titer analysis, which, if
necessary, will be performed under a separate CO. The [***] will be [***] with [***] and the [***]. Following this, the material will be [***] with [***]; each of the [***] will be tested for [***] by [***] Should either [***] than what was analyzed
be detected, this study may be repeated one time. 

  

					
	Lonza Job Code VBLT-002	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***] .

 Operational Capacity 

Based on the outcome of the [***] the operational capacity of an [***] will be determined. VB-111 will be [***] using [***] of the maximum
column load capacity as determined in the [***] will be tested for [***] by [***] and for purity, [***] using [***] Based on the assay results when compared to the historical [***] recoveries and product purity using this process [***] will be
tested and analyzed, if appropriate. This process may be repeated up to three times at [***] until the [***] s reached which delivers comparable data to the [***] 

Column Height Evaluation 

Based on the outcome of the [***] the height of the [***] will be increased from [***] to match the [***] The [***] will be used to perform
[***] and the [***] will be analyzed for [***] and [***] 
 Deliverable 

Upon completion of the above activities, Lonza will compose a Technology Transfer Report in standard Lonza format, which will describe the
materials and procedures used in, and the results of, the activities described above, as well as the activities described in SOW VBLT-002. Lonza will provide the report to VBL via electronic mail for review prior to report finalization. VBL will be
provided with a signed copy of the report for its records. 
  

	III.	Fees and Terms 

 The fees for the activities described above total [***], payable as
follows: 
  

	 	1.	[***]; 

  

	 	2.	[***]. 

 Invoices will be provided via e-mail and associated payments are due upon invoice
receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 
 In the event of a
termination of this CO or the Agreement for any reason, VBL shall pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become
unusable by reason of termination), all uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 

IV. Acceptance 
  

											
		 	Lonza Houston, Inc.	  		  	Vascular Biologics, Ltd.
						
		 	By:	  	 /s/ J. David Enloe, Jr.
	  		  	By:	  	 /s/ Amos Ron

		 	J. David Enloe, Jr.	  		  	Name:	  	Amos Ron
		 	Head, Viral-based Therapeutics	  		  	Title:	  	Chief Financial Officer
						
		 	Date:	  	  
	  		  	Date:	  	  

  

					
	Lonza Job Code VBLT-002	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***] .

  
 

 
 APPENDIX A-3 

Statement of Work VBLT-003 

[***] Demonstration Run in 

Process Development Laboratory Environment 

May 7, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd.
(“Client”) and Lonza Houston, Inc. (“Lonza”) is subject to the Manufacturing Services Agreement dated January 5, 2012 (2012-01-05 VBL-Lonza MSA_fully executed.pdf), between Client, and Lonza (the “Agreement”) and
is incorporated therein and made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
  

	II.	Scope of Work 

 Lonza will provide the following services surrounding the process
development activities for the VB-111 product: 
 Upon successful completion of the deliverables described in SOW-002, Lonza will perform
[***] using a [***] provided by Client and [***] will be used throughout the production process; the batch will be [***] will be used in the performance of this batch. 

It is assumed that the [***] of the upstream process used in the [***] will be identical to that of the [***] In addition, it is assumed that
[***] is not necessary for [***] 
 The existing VB-111 downstream process that has been transferred to Lonza under SOW-002 will be used in
the performance of the [***] as reasonably requested by Client; [***] as reasonably requested by Client. [***] will be analyzed for the presence of [***] 

Deliverable 
 Upon
completion of the above activities, Lonza will compose a Report in standard Lonza format, which will describe the materials and procedures used in, and the results of, the activities associated with this Project Component. Lonza will provide the
report to Client via electronic mail for review prior to report finalization. Client will be provided with a signed copy of the report for its records. 
  

	III.	Fees and Terms 

  

					
	Lonza Job Code VBLT-003	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***] .

 The fees for the activities described above total [***], payable as follows: 

 

	 	1.	[***] due upon execution of this Statement of Work; 

  

	 	2.	[***] due upon Lonza’s completion of the upstream work 

  

	 	3.	[***] due upon Lonza’s issuance of the initial draft Summary Report 

 Courier fees for
shipments from Lonza to Client which utilize Lonza’s courier account will be invoiced for as pass-through costs and supporting documentation of associated fees will be provided along with the invoice. 

Invoices will be provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the
Lonza account information set forth in the Agreement. 
 In the event of a termination of this SOW or the Agreement for any reason, Client
shall pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all uncancellable labor
commitments and all work in process (including all professional services rendered) through the effective date of termination. 
 IV. Acceptance 

 

											
		 	Lonza Houston, Inc.	  		  	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.
	  		  	By:	 	 /s/ Amos Ron

		 	J. David Enloe, Jr.	  		  	Name:	 	Amos Ron
		 	Head, Viral-based Therapeutics	  		  	Title:	 	Chief Financial Officer
						
		 	Date:	 	  
	  		  	Date:	 	  

  

					
	Lonza Job Code VBLT-003	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***] .

  
 

 
 APPENDIX A4 -Statement of Work VBLT-004 Purchase of Cell Culture 

Medium for VB-111 Production at the [***] Scale 

June 12, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologies, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologies, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 Lonza and
VBL are currently planning for Lonza to perform a [***] scale production batch of VBL’s VB-111 product during Quarter 4 2012. To provide a sufficient quantity of medium to produce the [***] and to have [***] VBL has requested that Lonza order a
total of [***] The standard approximate lead time from the time the [***] In consideration of the duration of the lead time and shelf life, VBL has requested that Lonza order [***] to be produced as soon as possible and [***] to be produced two to
three months later. 
  

	II.	Scope of Work 

 Lonza will order [***]. The [***] is to be produced as soon as possible;
the second [***] is to be produced two to three months after the first batch. 
  

	III.	Fees and Terms 

 The cost of each [***], supplied in [***], is [***] USD. 

The Lonza fee for medium procurement and receiving is [***], in addition to the batch cost. 

The total fee for the activities described above is [***], payable as follows: 

 

	 	1.	[***], due upon SOW execution; 

  

	 	2.	[***], due upon notification of VBL by Lonza that the [***] has been fully received. 

 Any
shipping and handling fees and sales tax charged by [***] and/or FedEx to Lonza will be passed through to VBL at no mark-up. 
 Invoices will
be provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 

In the event of a termination of this SOW or the Agreement for any reason, VBL shall pay reasonable costs incurred by Lonza up to the effective
date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all uncancellable labor commitments and all work in process (including all professional
services rendered) through the effective date of termination. 

  

					
	Lonza Job Code VBLT-004	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 IV. Acceptance 
  

											
		 	Lonza Houston, Inc.	  		  	Vascular Biologies, Ltd.
						
		 	By	  	 /s/ J. David Enloe, Jr.
	  		  	By:	  	 /s/ Amos Ron

		 	J. David Enloe, Jr.	  		  	Name:	  	Amos Ron
		 	Head, Viral-based Therapeutics	  		  	Title:	  	Chief Financial Officer
						
		 	Date:	  	  
	  		  	Date:	  	  

  

					
	Lonza Job Code VBLT-004	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-4 Statement of 

Work VBLT-005 VB-111 

Sample Analysis July 5, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologies, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologies, Ltd. (“VBL”), and Lonza Houston, Inc. (‘Lonza’) (the “Agreement”) and is incorporated therein and
made a part of such Agreement, in the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 

VBL has requested that Lonza analyze five samples of its VB-111 Drug Product using Lonza’s [***] The samples and documentation of each
sample’s Mycoplasma-free and sterile or bioburden-free status will be provided to Lonza by VBL, at VBL’s sole expense. The VB-111 samples to be analyzed are one sample from each of the following lots: 

 

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	II.	Scope of Work 

 Lonza Quality Control (QC) personnel will perform two executions of
assay [***], analyzing three of the VB-111 samples on one assay and the other two VB-111 samples on one separate assay. Upon assay completion, the assay documentation will be audited by Lonza QC and Quality Assurance personnel. 

VBL will be provided with QA-reviewed and -approved assay documentation for its records. 

 

	III.	Pees and Terms 

 The fee for each [***] assay is [***] USD for the first sample [***]
for each additional sample submitted and analyzed simultaneously on the same Test Record Form, up to three total samples per assay. To analyze [***] samples, [***] separate assays are required. Thus, the total fee for the activities as described
above is [***] USD, 100% payable upon Lonza’s issuance of the assay documentation to VBL. 
 Invoices will be provided via e-mail
and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 

In the event of a termination of this SOW or the Agreement for any reason, VBL shall pay reasonable costs incurred by Lonza up to the
effective date of term !nation (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all uncancellable labor commitments and aN work in process (including all
professional services rendered) through the effective date of termination. 
  

	IV.	Acceptance 

  

			
	Lonza Houston, Inc	  	Vascular Biologies, Ltd.
		
	By [Illegible]	  	By: /s/ Amos Ron
	Name: [Illegible]	  	Name: Amos Ron
	Title:	  	Title: Chief Financial Officer
		
	Date:	  	Date:

  

					
	Lonza Job Code VBLT-005	  		  	Page 1 of 1
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-6 

Statement of Work VBLT-006 

50L GMP Production & Analysis of VB-111 

September 6, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 VBL has
requested that Lonza produce VBL’s VB-111 product under cGMP conditions at the [***] in a [***], as well as perform in-process and release testing on the VB-111 material as outlined in Section III., below. 

 

	II.	Project Assumptions 

 In the development of this SOW, the following assumptions were
made: 
  

	 	1.	United States Pharmacopoeia (USP) and FDA, as well as European Pharmacopoeia (EP) and European Medicines Agency (EMA), guidelines will be followed in the manufacture and analysis of VB-111; 

 

	 	2.	PER.C6 cell and VB-111 materials provided by VBL will have been certified to be bioburden-free and/or sterile and Mycoplasma-free, prior to their arrival at Lonza; 

 

	 	3.	[***] is not required for the [***] of the [***] at the [***]; 

  

	 	4.	For [***] a [***] and [***] is required. Note: [***] no longer requires [***]; 

  

	 	5.	For [***] a [***] and [***] is required; 

  

	 	6.	A concentration of [***] is required for the [***] and the [***] for this [***] is [***]; 

  

	 	7.	The [***] for the [***] and [***] consists of [***] In addition, it is assumed that it is necessary to verify the identity of each component of the [***]; 

 

	 	8.	[***] and [***] will be utilized throughout the project; 

  

					
	Lonza Job Code VBLT-006	  		  	Page 1 of 8
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

	 	9.	VB-111 Drug Product will be filled using a [***] in accordance with EMA guidelines into [***]; 

  

	 	10.	Based on previous discussions with VBL, it is estimated that [***] thus, it is assumed that approximately [***] could be produced at the [***] it is estimated that approximately [***] could be achieved at the [***] It
is therefore assumed that the quantity of [***] under this SOW is [***]; 

  

	 	11.	Product release testing will be performed and/or coordinated by Lonza, with the exception of the assays designated in Section III., below, to be performed by VBL. Lonza will, at the written direction of VBL, sample the
VB-111 material as needed for these assays and provide the samples to VBL for analysis by VBL or a VBL-designated third-party testing laboratory; 

  

	 	12.	[***] will have previously been performed, and a report for this activity is available to Lonza for reference. 

  

	 	13.	As the product is a [***] Lonza has assumed that its [***] which have been shown to [***]. 

  

	 	14.	The quality agreement signed between Lonza and VBL will be an addendum to this agreement. 

  

	III.	Scope of Work 

  

									
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	 Estimated
Duration
	  	 Fee
(USD)

	a.	  	Materials Transfer from VBL to Lonza	  	[***]	  	[***]	  	N/A
	b.	  	 Manufacturing Preparation:

Project-Specific GMP

Documentation
	  	 Lonza will create documents specific to the project, including but not limited to: Specifications and Part Numbers for VB-111 product
intermediates, raw materials such as resins, filters, columns, buffers, etc.; Master Label for DP; Certificates of Analysis for BDS and DP; Sample Transfer Forms for BDS and DP; In-process Testing and Yield Form; Product-specific Master Flow Record;
Formulation Records for the Final Formulation Buffer and various buffers for downstream processing; product-specific Manufacturing Batch Records, Component Assembly Records.
  

Information presented within summary reports developed by Lonza Process Development personnel, as well as information contained within the technical
documentation provided by VBL, will be utilized and referenced in the development of the VB-111 project GMP documentation. Draft Manufacturing Batch Records and other draft GMP documentation, as appropriate and reasonably desired by VBL, will be
provided to VBL for review and approval prior to implementation and use by Lonza.
	  	[***]	  	[***]

  

					
	Lonza Job Code VBLT-006	  		  	Page 2 of 8
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

									
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	 Estimated
Duration
	  	 Fee
(USD)

	c.	  	 Manufacturing Preparation:

Product-Dedicated Equipment Procurement
	  	 Lonza will purchase, install, and qualify (as appropriate) product-dedicated equipment, including but not limited to:

 
 [***]

[***]
 [***]

[***]
 [***]

 
 Product-dedicated equipment will be designated property of VBL and may be used for future
GMP batches of VB-111.
  
 Lonza shall have the right of possession and control of the
equipment. Title to the equipment shall at all times remain with Client and the equipment shall be owned by Client. All costs for maintenance, service, repairs and replacements shall be borne by Client. Client shall bear all risk of loss of
equipment in Lonza’s possession, except for losses due to the gross negligence or willful misconduct of Lonza.
	  	[***]	  	[***]
					
	d.	  	 cGMP Manufacturing of VB-111

Clinical Lot
 [***]
	  	 Upon successful completion of the [***] Process Development run currently underway at Lonza per SOW VBLT-005, and utilizing official GMP
documentation and VB-111-dedicated equipment obtained and qualified during Project Components b. and c., Lonza Manufacturing personnel will produce VB-111 clinical trial material in one GMP production run at the [***] scale utilizing [***].

 
 Cells from the [***] provided by VBL will be utilized in the production of the batch.
VB-111 infection and harvest parameters as previously identified by VBL and by Lonza Process Development personnel in the performance of SOWs A-2 and A-3 will be utilized throughout the production process. Standard Lonza SOP’s will be used
where possible, except those project-specific documents created during Project Component b.
  

As stated in Section II., Project Assumptions, above, it is estimated that approximately [***] could be produced at the [***] it is estimated that
approximately [***] could be achieved at the [***] It is therefore assumed that the [***]; however, [***]
  

Production will occur in Lonza’s multi-product GMP manufacturing facility at 8076 El Rio Street in Houston, Texas USA. Copies of all controlled documents
executed during batch preparation will be uploaded to the VBL Projects site on the Lonza Extranet following Lonza Quality Assurance review for compliance.
	  	[***]	  	[***]

  

					
	Lonza Job Code VBLT-006	  		  	Page 3 of 8
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

									
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	 Estimated
Duration
	  	 Fee
(USD)

	e.	  	 Cleaning Verification

Study
	  	Post-production, Lonza will perform [***] testing [***].	  	[***]	  	[***]

  

					
	Lonza Job Code VBLT-006	  		  	Page 4 of 8
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project

Component
	  	 Description
	  	 Detailed Description
	  	 Estimated

Duration
	  	 Fee (USD)

	f.	  	In-Process and Release Testing, VB-111 Bulk Drug Substance	  	Lonza will coordinate the performance of required contract and in-house testing as required by the agreed-upon Bulk Certificate of Analysis. A list of recommended analyses is below; the price estimate assumes that the
BDS will be analyzed using the methods listed. Should VBL desire to add to or remove tests from the list, or to use a version of a test that is different than the method listed, the price will be adjusted accordingly. Assay quantities are considered
to be “1,” unless otherwise noted. In addition and as desired by VBL, Lonza will take VB-111 samples throughout the production process in addition to those listed herein, to be analyzed under separate SOW(s), as appropriate and as desired
by VBL.	  	[***]	  	[***]
	  	  	  

Assay
	  	 Vendor / Protocol
	  	  
	  	  	  
 HARVEST
	  	  
	  	  	  
 [***]
	  	[***]	  	  
	  	  	  
 IN-PROCESS
	  	  
	  	  	  
 [***]
	  	[***]	  	  
	  	  	  
 FINAL FORMULATED BULK
	  	  
	  	  	  
 [***]
	  	[***]	  	  

  

	*	Assay will be performed/coordinated by VBL and will not be reported on the Lonza-issued Certificate of Analysis. 

	y	Assay will be performed/coordinated by Lonza and the results reported to VBL for information only. Results will not be included on the Lonza-issued Certificate of Analysis. 

	

  

					
	Lonza Job Code VBLT-006	  		  	Page 5 of 8
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project

Component
	  	 Description
	  	 Detailed Description
	  	 Estimated
Duration
	  	 Fee (USD)

	g.	  	Release Testing, VB-111 Drug Product	  	Lonza will coordinate the performance of required contract and in-house testing as required by the agreed-upon DP Certificate of Analysis. A list of recommended analyses is below; the price estimate assumes that the DP
will be analyzed using the methods listed. Should VBL desire to add to or remove tests from the list, or to use a version of a test that is different than the method listed, the price will be adjusted accordingly.	  	[***]	  	[***]
	  	  	  

Assay
	  	 Vendor / Protocol
	  	  
	  	  	  
 [***]

(Continued below)
	  	[***]	  	  

  

					
	Lonza Job Code VBLT-006	  		  	Page 6 of 8
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project

Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
	 g.
(Cont’d)
	  	Release Testing,
VB-111
Drug Product
(Cont’d)	  	 Assay
	  	Vendor / Protocol	  	 	  	 
	  	  	[***]	  	[***]	  	See above	  	See above
	  	  	 *Assay will be performed/coordinated by VBL and will not be reported on the Lonza-issued Certificate of Analysis.

 
 **Assay will be performed by both Lonza and VBL
and the results compared. Only the Lonza result will be reported on the Lonza-issued Certificate of Analysis.
	  		  	
				
	 Deliverable for Project Components

f. and g.
	  	Lonza Quality Assurance representatives will review all testing records/reports and will issue Certificates of Analysis for VB-111 DS and DP for review by VBL or a VBL-designated Qualified Person (QP). VBL personnel or a
delegate will be responsible for release of the DS and DP for use.	  	2 weeks	  	Included
	  
 TOTAL, VB-111: PROCESS DEVELOPMENT, GMP
MANUFACTURE, AND ANALYSIS
	  	[***]	  	[***]
	  
 OTHER SERVICES

	Regulatory Support	  	  
 Lonza Viral has extensive Regulatory experience both with
FDA and EMA, and if desired, will perform consulting services on VBL’s behalf. Examples of such activities include the assembly of documents or data-mining of information for inclusion in a Product Master File; writing, reviewing, or editing of
Chemistry, Manufacturing, and Controls (CMC) sections of regulatory filings; participation in teleconferences with regulatory agencies, etc.
	  	As
needed	  	[***]
	Product Storage	  	  
 Lonza will store vialed product in fully monitored, GMP
conditions free of charge for a period of up to thirty (30) days after issuance of the product’s Certificate of Analysis.
 [***]

[***]
 [***]

[***]
	  	Monthly	  	To be
Determined

  

					
	Lonza Job Code VBLT-006	  		  	Page 7 of 8
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

	IV.	Fees and Terms 

 The total fee for the activities described above, not inclusive of
Regulatory Support and Product Storage services, is [***] , payable as follows: 
 [***] 

[***], due upon SOW execution 

[***], due upon [***] 
 [***]

 [***], due upon SOW execution 

[***], due upon [***] 
 [***],
due upon [***] 
 [***], due upon [***] 

[***] 
 [***], due upon [***]

 [***], due upon [***] 
 c.
[***], due upon completion of testing 
 Fees for Regulatory Support services will be invoiced for on a monthly basis, as applicable. Fees
for Product Storage, if applicable, will be invoiced for on a semi-annual basis, in advance. 
 Invoices will be provided via e-mail and
associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 

In the event of a termination of this SOW or the Agreement for any reason, VBL shall be responsible for any charges for all labor, testing and
materials, including raw materials, that have already been purchased to perform the services detailed in this SOW and VBL shall pay all other reasonable costs incurred by Lonza up to the effective date of termination, including completed but
unbilled services, all uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 
  

	V.	Acceptance 

  

									
	Lonza Houston, Inc.	 		 	Vascular Biologics, Ltd.
					
	By:	 	 /s/ J. David Enloe, Jr.
	 		 	By:	 	 /s/ Amos Ron

	J. David Enloe, Jr.	 		 	Name:	 	Amos Ron
	Head, Viral-based Therapeutics	 		 	Title:	 	Chief Financial Officer
					
	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-006	  		  	Page 8 of 8
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-7 Statement of Work VBLT-007 Stability 

Study [***] November 5, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologies, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologies, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 

VBL has requested that Lonza, via [***], perform a stability study on the [***], which is used in the manufacture of VBL’s VB-111 product.
The lot of [***] to be analyzed is currently being produced by [***] for Lonza on behalf of VBL under SOW VBLT-004, “Purchase of [***] for VB-111 Production at the [***],” dated June 12, 2012. 

 

	II.	Scope of Work 

 Lonza will coordinate the performance of a stability study on one lot of
[***] as described in the attached study protocol, “Product Chemical Stability Study” on GMP product number [***] to evaluate product stability over one year when stored at [***]. Client hereby agrees to the terms of such attached study
protocol. 
 Lonza Quality Control and Quality Assurance personnel will review each report provided to Lonza by [***], and will provide an
electronic copy of each report to VBL for its records upon completion of Lonza’s review of each report. The reports will be issued by [***] according to the following time schedule: 

 

	 	a.	An Interim Report will be provided within four weeks of completion of the tests at each of the 3-6-, , and 10-month time points; 

  

	 	b.	A Final Report will be provided within four weeks of completion of the tests at the 13-month time point. 

Lonza shall not be responsible for any act or omission of [***], including any delay by [***] in releasing any report. 

 

	III.	Fees and Terms 

 The fee for the activities described herein is [***], payable as
follows: 
  

	 	a.	[***], payable upon SOW execution; 

  

	 	b.	[***], payable upon Lonza providing VBL with an electronic copy of the final study report issued by [***]. 

  

					
	Lonza Job Code VBLT-007	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 Invoices will be provided via e-mail and associated payments are due upon invoice receipt.
Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 
 In the event of a termination of
this SOW or the Agreement for any reason, VBL shall pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of (i) unmarketable materials which have become unusable by
reason of termination and (ii) services from a third party), all uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 

 

	IV.	Acceptance 

  

									
	Lonza Houston, Inc.	 		 	Vascular Biologies, Ltd.
					
	By:	 	 /s/ J. David Enloe, Jr.
	 		 	By:	 	 /s/ Amos Ron

	J. David Enloe, Jr.	 		 	Name:	 	Amos Ron
	Head, Viral-based Therapeutics	 		 	Title:	 	Chief Financial Officer
					
	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-007	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-8 

Statement of Work VBLT-008 

Procurement of Dedicated Equipment for Large-Scale VB-111 GMP Production 

September 21, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 

Production of VBL’s VB-111 product at the [***] at Lonza is planned to occur in the late 2012 to early 2013 timeframe under a separate
SOW. The [***] are known to exist in limited quantities and to have relatively long lead times from order placement to material receipt, which could possibly jeopardize the timing of the planned [***]. To address the availability of the [***] VBL
has requested that Lonza order these items on VBL’s behalf under this SOW. 
  

	II.	Scope of Work 

 The following items will be purchased by Lonza from [***] on VBL’s
behalf, in support of VB-111 production: 
  

									
	 Item / Description
	  	 Qty
	  	GEHC
Catalog No.	  	Cost, ea
(USD)	  	Total Cost
(USD)
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	TOTAL	  	[***]

  

	III.	Fees and Terms 

 Should shipping and handling fees for the items listed above be assessed
by [***], Lonza will invoice VBL for the charges as a pass-through cost. 
 The total fee for the items listed above, not inclusive of any
shipping and handling charges, is [***], payable as follows: 
  

	 	a.	[***], payable upon SOW execution; 

  

	 	b.	[***], payable upon Lonza’s receipt of all the items listed above from [***]. 

 These items
will be designated property of VBL and may be used for future GMP batches of VB-111. 

  

					
	Lonza Job Code VBLT-008	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 Lonza shall have the right of possession and control of the equipment. Title to the equipment
shall at all times remain with Client and the equipment shall be owned by Client. All costs for maintenance, service, repairs and replacements shall be borne by Client. Client shall bear all risk of loss of equipment in Lonza’s possession,
except for losses due to the gross negligence or willful misconduct of Lonza. 
 Invoices will be provided via e-mail and associated payments
are due upon invoice receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 
 In
the event of a termination of this SOW or the Agreement for any reason, VBL shall be responsible for any charges for all labor, testing and materials, including raw materials and equipment, that have already been purchased to perform the services
detailed in this SOW and VBL shall pay all other reasonable costs incurred by Lonza up to the effective date of termination, including completed but unbilled services, all uncancellable labor commitments and all work in process (including all
professional services rendered) through the effective date of termination. 
  

	IV.	Acceptance 

  

									
	Lonza Houston, Inc.	 		 	Vascular Biologics, Ltd.
					
	By:	 	 /s/ J. David Enloe, Jr.
	 		 	By:	 	 /s/ Amos Ron

	J. David Enloe, Jr.	 		 	Name:	 	Amos Ron
	Head, Viral-based Therapeutics	 		 	Title:	 	Chief Financial Officer
					
	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-008	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-9 

Statement of Work VBLT-009 

Evaluation of [***] 

December 22, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 VBL has
requested that Lonza evaluate the use of a [***] for performance of [***] in the formulation of VBL’s VB-111 product instead of performing [***] in an effort to increase product recovery at the [***] in the VB-111 production process. Lonza has
drafted and VBL has reviewed and approved the plan for this study, entitled, “[***] (attached). 
  

	II.	Scope of Work 

 Lonza Process Development (PD) personnel will perform the study as
described in the attached study plan. The study includes the [***] followed by up to [***]. The below table outlines the samples to be taken and the analyses to be performed on the sampled material: 

 

					
	 Sample Material
	  	 Quantity
Samples
	  	 Assay

	[***]	  	[***]	  	[***]

  

	*	[***] will be performed by PD; R&D-grade 

	**	Retained samples will be stored at [***] in Lonza PD in anticipation of future analysis if VBL so requests in writing, in which case a Change Order to this SOW will be drafted to document the incremental work scope and
associated fees. 

 Upon the completion of the study, Lonza will draft a brief Summary Report in standard Lonza format which
will describe the materials, equipment, and procedures which were utilized throughout the study, as well as the study results and conclusions. An electronic copy of the report will be provided to VBL for review and approval prior to finalization.
Upon its finalization VBL will be provided with a signed electronic copy of the report for its records. 
  

	III.	Fees and Terms 

 The fee for the activities described herein is [***], payable as
follows: 

  

					
	Lonza Job Code VBLT-009	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

	 	a.	[***], payable upon SOW execution; 

  

	 	b.	[***], payable upon Lonza providing VBL with an electronic copy of the draft study report for its records. 

Invoices will be provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the
Lonza account information set forth in the Agreement. 
 In the event of a termination of this SOW or the Agreement for any reason, VBL shall
pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all uncancellable labor commitments
and all work in process (including all professional services rendered) through the effective date of termination. 
  

	IV.	Acceptance 

  

									
	Lonza Houston, Inc.	 		 	Vascular Biologics, Ltd.
					
	By:	 	 /s/ J. David Enloe, Jr.
	 		 	By:	 	 /s/ Amos Ron

	J. David Enloe, Jr.	 		 	Name:	 	Amos Ron
	Head, Viral-based Therapeutics	 		 	Title:	 	Chief Financial Officer
					
	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-009	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-10 

Statement of Work VBLT-010 

VB-111 Drug Product Room Temperature Stability Study and Sample Analysis 

November 9, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
  

	II.	Scope of Work 

 The work scope includes the execution of two activities, as described
below: 
 A. Drug Product Stability Study at Room Temperature 

During [***] filling [***] at Lonza [***] are routinely maintained at [***] throughout [***] before being transferred to [***] The purpose of
this study is to evaluate the [***] 
 Lonza Process Development (PD) and Quality Control (QC) personnel will execute the study outlined in
the attached file, [***] In addition to study planning, set-up, sampling, and documentation, four samples will be tested using [***]. The assays will be performed on official Quality Assurance-issued Test Record Forms. Upon assay completion, the
assay documentation will be audited by Lonza QC and Quality Assurance personnel. 
 Upon study completion, a Summary Report will be created
by Lonza in standard Lonza format, which will be provided to VBL for review prior to finalization. 
 Should additional testing be desired by
VBL, this testing would be captured under a separate SOW or via a Change Order to this SOW. 
 B. Analysis of VB-111 for [***] 

Lonza QC will analyze five samples of the VB-111 Drug Product using [***] The VB-111 samples to be analyzed are one sample from each of the
following lots: 
 [***] 
 [***]
Upon assay completion, the assay documentation will be audited by Lonza QC and Quality Assurance personnel. 

  

					
	Lonza Job Code VBLT-010	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 VBL will be provided with QA-reviewed and –approved assay documentation for its records.

  

	III.	Fees and Terms 

 The fee for the activities described above is as follows: 

 

	 	A.	[***] 

  

	 	B.	[***] 

 The total fee, [***], is payable as follows: 

 

	 	A.	[***], due upon SOW execution; 

  

	 	B.	[***], due upon Lonza providing the [***] and [***] 

 Invoices will be provided via e-mail and
associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 

In the event of a termination of this SOW or the Agreement for any reason, VBL shall pay reasonable costs incurred by Lonza up to the effective
date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all uncancellable labor commitments and all work in process (including all professional
services rendered) through the effective date of termination. 
  

	IV.	Acceptance 

  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.
	 		 	By:	 	 /s/ Amos Ron

		 	J. David Enloe, Jr.	 	Name:	 	Amos Ron
		 	Head, Viral-based Therapeutics	 	Title:	 	Chief Financial Officer
						
		 	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-010	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-11 

Statement of Work VBLT-011 

Evaluation of [***] 

December 5, 2012 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 In
consideration of the high cost of the [***] that are required for [***] produced at the [***] that is planned to be performed at Lonza under a separate SOW, VBL has requested that Lonza perform a study to evaluate the [***] rather than [***], which
is VBL’s current practice. Lonza has drafted and VBL has approved the plan for this study, entitled, [***]; attached). 
  

	II.	Scope of Work 

 [***] personnel will perform the study as described in [***] The study
includes the performance of up to [***] and up to [***] Following completion of the [***] will be analyzed by analytical [***] For both [***] will be performed to [***] 

Upon the completion of the study as described in [***], Lonza will draft a Summary Report in standard Lonza format which will describe the
materials, equipment, and procedures which were utilized throughout the study, as well as the study results and conclusions. An electronic copy of the report will be provided to VBL for review and approval prior to finalization. Upon its
finalization VBL will be provided with a signed electronic copy of the report for its records. 
  

	III.	Fees and Terms 

 The fee for the activities described herein is [***], payable as
follows: 
  

	 	a.	[***], payable upon SOW execution; 

  

	 	b.	[***], payable upon Lonza providing VBL with an electronic copy of the draft study report for its records. 

  

					
	Lonza Job Code VBLT-011	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 Invoices will be provided via e-mail and associated payments are due upon invoice receipt.
Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 
 In the event of a termination of
this SOW or the Agreement for any reason, VBL shall pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason
of termination), all uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 

IV. Acceptance 
  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.
	 		 	By:	 	 /s/ Amos Ron

		 	J. David Enloe, Jr.	 	Name:	 	Amos Ron
		 	Head, Viral-based Therapeutics	 	Title:	 	Chief Financial Officer
						
		 	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-011	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-12 

Statement of Work VBLT-012 

[***] 
 February 26,
2013 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 The
volume of [***] that will be generated during the performance of the [***] by Lonza on behalf of VBL is estimated to be approximately [***] This material is planned to be [***] and is to be [***] VBL has requested that Lonza perform a study to
determine [***] Lonza has drafted and VBL has reviewed and approved the plan for this study, entitled, [***]; attached). 
  

	II.	Scope of Work 

 Lonza Validation personnel will perform the study as described in the
attached study plan. 
 Upon the completion of the study, Lonza will draft a brief Summary Report in standard Lonza format which will
describe the materials, equipment, and procedures which were utilized throughout the study, as well as the study results and conclusions. An electronic copy of the report will be provided to VBL for review and approval prior to finalization. Upon
its finalization VBL will be provided with a signed electronic copy of the report for its records. 
  

	III.	Fees and Terms 

 The fee for the activities described herein is [***], payable as
follows: 
  

	 	a.	[***], payable upon SOW execution; 

  

	 	b.	[***], payable upon Lonza providing VBL with an electronic copy of the draft study report for its records. 

Invoices will be provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the
Lonza account information set forth in the Agreement. 
 In the event of a termination of this SOW or the Agreement for any reason, VBL shall
pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all uncancellable labor commitments
and all work in process (including all professional services rendered) through the effective date of termination. 

  

					
	Lonza Job Code VBLT-012	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***] .

	IV.	Acceptance 

  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.
	 		 	By:	 	 /s/ Amos Ron

		 	J. David Enloe, Jr.	 	Name:	 	Amos Ron
		 	Head, Viral-based Therapeutics	 	Title:	 	Chief Financial Officer
					
		 	 Date:
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-012	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 Amended and Restated APPENDIX A-13 

Statement of Work VBLT-013 

[***] GMP Production & Analysis of VB-111 

May 23, 2013 
  

	I.	Introduction 

 This Amended and Restated Statement of Work (SOW) between Vascular
Biologics, Ltd. and Lonza Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is
incorporated therein and made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 

VBL has requested that Lonza produce VBL’s VB-111 product under cGMP conditions at the [***], as well as perform in-process and release
testing on the VB-111 material as outlined in Section II., below. 
 This Amended and Restated Appendix A-13, Statement of Work VBLT-013,
[***] replaces in its entirety the original Appendix A-13, Statement of Work VBLT-013, [***] entered by the parties, dated December 20, 2012 (the “Original SOW”). 

 

	II.	Scope of Work 

  

									
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
	a.	  	 Manufacturing Preparation:
  

Project-Specific GMP

Documentation
	  	 Lonza will create documents specific to the project, including but not limited to: Specifications and Part Numbers for VB-111 product
intermediates, raw materials such [***]; In-process Testing and Yield Form; Product-specific Master Flow Record; Formulation Records for the Final Formulation Buffer and various buffers for downstream processing; product-specific Manufacturing Batch
Records, Component Assembly Records.
  
 Information presented within summary reports
developed by Lonza Process Development personnel, as well as information contained within the technical documentation provided by VBL, will be utilized and referenced in the development of the VB-111 project GMP documentation. Draft Manufacturing
Batch Records and other draft GMP documentation, as appropriate and reasonably requested by VBL, will be provided to VBL for prompt review and approval prior to implementation and use by Lonza.
	  	[***]	  	[***]

  

					
	Lonza Job Code VBLT-0013	  		  	Page 1 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

									
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
	b.	  	 Manufacturing Preparation:
  

Product-dedicated Equipment Installation & Qualification
	  	 The following items which were purchased by VBL for this project per SOW A-8 will be utilized in the production of VB-111 at the [***]

 
 [***]

 
 This product-dedicated equipment will be designated property of VBL and may be used for
future GMP batches of VB-111.
  
 Lonza shall have the right of possession and control of
the equipment. Title to the equipment shall at all times remain with Client and the equipment shall be owned by Client. All costs for maintenance, service, repairs and replacements shall be borne by Client. Client shall bear all risk of loss of
equipment in Lonza’s possession, except for losses due to the gross negligence or willful misconduct of Lonza.
  

The fee at right represents the fee for installing and qualifying the [***]
	  	[***]	  	[***]
					
	c.	  	Refrigerated Storage Container Preparation & Rental	  	As the large quantity of refrigerated buffers and cell culture media that will be used throughout this project exceeds the quantity that Lonza’s cold room can accommodate at one time, a portable refrigerated storage container
will be leased by Lonza from an equipment supply vendor for use throughout the duration of this project to supplement the cold room storage space. The container (20’ long x 8’ wide x 8.5’ high) is designed to maintain temperatures
[***] and will be transported and delivered to Lonza, where it will remain on-site until the project is complete. The fee at right represents the fee for container transport to Lonza; the monthly rental fee for up to 4 months; and for supplying
electricity to the container. If the project extends beyond 4 months, VBL shall be charged an additional [***] per month. Temperature data will be electronically monitored regularly.	  	[***]	  	[***]

  

					
	Lonza Job Code VBLT-013	  		  	Page 2 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

									
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
	d.	  	 cGMP Manufacturing of VB-111

Clinical Lot
 [***]
	  	 Utilizing official GMP documentation created under Project Component a. and VB-111-dedicated equipment obtained and qualified during in the
performance of SOW A-8 and Project Component b., Lonza Manufacturing personnel will produce VB-111 clinical trial material in one GMP production run at the [***] as the production reactor. [***] to be used in the performance of the [***] include
[***]
  
 [***] as previously identified by VBL and by Lonza Process Development and
Manufacturing personnel in the performance of SOWs A-2, A-3, and A-6 will be utilized throughout the production process. Standard Lonza SOP’s will be used where possible, except those project-specific documents created during Project Component
a.
  
 It is understood that the [***] will be operated at the [***] and that the entire
[***] material produced will be [***] A portion of this [***] will be [***] Following this, a [***] will be [***] to produce a [***]
  

It is assumed that two full [***] However [***] be necessary or desired by [***], a Change Order to this SOW will be drafted to accommodate the incremental
work scope.
  
 Production will occur in Lonza’s multi-product GMP2 manufacturing
facility at 8076 El Rio Street in Houston, Texas USA. Copies of all controlled documents executed during batch preparation will be uploaded to the VBL Projects site on the Lonza Extranet following Lonza Quality Assurance review for
compliance.
	  	[***]	  	[***]

  

					
	Lonza Job Code VBLT-013	  		  	Page 3 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

															
	 Project

Component
	  	 Description
	  	 Detailed Description
	  	 Estimated
Duration
	  	 Fee (USD)

					
		  		  	Changes in quantities and types of some production raw materials from those originally contemplated have resulted in the need for Lonza to purchase additional materials in support of this [***] These items are as
follows:	  		  	
								
	 	  	 	  	 Item
	  	 Purpose
	  	 Manufacturer
/Vendor
	  	 Qty
	  	 	  	 
		  		  	[***]	  	[***]	  	[***]	  	[***]	  		  	
		  	Additional	  		  		  		  		  	[***]	  	[***]
		  	Harvest and	  		  		  		  		  		  	
	 e.
	  	Downstream Processing	  		  		  		  		  		  	
		  	Materials	  		  		  		  		  		  	

  

	*	[***] are required for the performance of the [***] However, should any of them require replacement [***] 

	**	A total of five filters are planned to be required for the [***] However, should any of them require replacement due to [***] or for other reasons as deemed necessary, VBL will be charged [***] used over these five.

  

					
	Lonza Job Code VBLT-013	  		  	Page 4 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

									
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
	f.	  	Satellite Cultures in Process Development	  	 At the time the GMP culture is transferred from the [***] In parallel with the [***]

 
 The process and monitoring described above will be repeated when the culture is
transferred from the [***]. This satellite culture will be discontinued after four days post-infection and will not be harvested or purified. Results of tests performed throughout the culture will be provided to VBL in summary table format.
	  	[***]	  	[***]
					
	g.	  	 Cleaning Verification

Study
	  	Post-production, Lonza will perform [***].	  	3 weeks	  	[***]

  

					
	Lonza Job Code VBLT-013	  		  	Page 5 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

													
	 Project
Component
	  	 Description
	  	 Detailed Description
	 	  	Estimated
Duration	  	Fee (USD)
		  		  	Lonza will coordinate the performance of required contract and in-house testing on the VB-111 Harvest material as required by the agreed-upon Bulk Drug Substance Certificate of Analysis. A list of recommended analyses is
below; the price estimate assumes that the Harvest will be analyzed using the methods listed. Should VBL desire to add to or remove tests from the list, or to use a version of a test that is different than the method listed, the price will be
adjusted accordingly. Assay quantities are considered to be “1,” unless otherwise noted. In addition and as reasonably requested in writing by VBL, Lonza will take VB-111 samples throughout the production process in addition to those
listed herein, to be analyzed under separate SOW(s), as appropriate and as reasonably requested in writing by VBL.	             	  		  	
						
	 	  	 	  	 Assay
	  	Vendor /
Protocol	 	  	 	  	 
		  		  	HARVEST	  				  		  	
		  		  	[***]	  	 	[***]	  	  	[***]	  	[***]
		  	In-Process and	  		  				  		  	
	 h.
	  	Release Testing,	  		  				  		  	
		  	VB-111 Harvest	  		  				  		  	
						
		  		  	IN-PROCESS	  				  		  	
		  		  	[***]	  	 	[***]	  	  		  	

  

	*	Assay will be performed/coordinated by VBL, at VBL’s sole expense and responsibility, and will not be reported on the Lonza-issued Certificate of Analysis. 

	y	Assay will be performed/coordinated by Lonza and the results reported to VBL for information only. Results will not be included on the Lonza-issued Certificate of Analysis. 

  

					
	Lonza Job Code VBLT-013	  		  	Page 6 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

													
	 Project
Component
	  	 Description
	  	 Detailed Description
	 	  	Estimated
Duration	  	Fee (USD)
		  		  	Lonza will coordinate the performance of required contract and in-house testing as required by the agreed-upon Bulk Certificates of Analysis. A list of recommended analyses is below; the price estimate assumes that the
BDS will be analyzed using the methods listed. Should VBL desire to add to or remove tests from the list, or to use a version of a test that is different than the method listed, the price will be adjusted accordingly. Assay quantities are considered
to be “1,” unless otherwise noted. In addition and as reasonably requested in writing by VBL, Lonza will take VB-111 samples throughout the production process in addition to those listed herein, to be analyzed under separate SOW(s), as
appropriate and as reasonably requested in writing by VBL. Results of assays performed on the VB-111 material as described below will be included in the Certificate of Analysis for each Bulk Drug Substance.	               	  		  	
						
	 	  	 	  	 Assay
	  	Vendor /
Protocol	 	  	 	  	 
		  		  	IN-PROCESS	  				  		  	
		  		  	[***]	  	 	[***]	  	  		  	
		  	In-Process and	  		  				  		  	
	 i.
	  	Release Testing,	  		  				  		  	
		  	VB-111 Bulk	  		  				  	[***]	  	[***]
		  	Drug Substance	  		  				  		  	
						
		  		  	FINAL FORMULATED BULK	  				  		  	
		  		  	[***]	  	 	[***]	  	  		  	
		  		  		  				  		  	

  

	*	Assay will be performed/coordinated by VBL, at VBL’s sole expense and responsibility, and will not be reported on the Lonza-issued Certificate of Analysis. 

	y	Assay will be performed/coordinated by Lonza and the results reported to VBL for information only. Results will not be included on the Lonza-issued Certificate of Analysis. 

  

					
	Lonza Job Code VBLT-013	  		  	Page 7 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

													
	 Project
Component
	  	 Description
	  	 Detailed Description
	 	  	Estimated
Duration	  	Fee (USD)
		  		  	Lonza will coordinate the performance of required contract and in-house testing as required by the agreed-upon DP Certificate of Analysis. A list of recommended analyses is below; the price estimate assumes that the
DP will be analyzed using the methods listed. Should VBL desire to add to or remove tests from the list, or to use a version of a test that is different than the method listed, the price will be adjusted accordingly.	        	  		  	
						
	 	  	 	  	 Assay
	  	Vendor /
Protocol	 	  	 	  	 
		  		  	[***]	  	 	[***]	  	  		  	
		  		  		  				  	[***]	  	[***]
		  		  		  				  		  	
	 j.
	  	Release Testing,	  		  				  		  	
		  	VB-111	  		  				  		  	
		  	Drug Product	  		  				  		  	
		  		  	(Continued below)	  				  		  	

  

					
	Lonza Job Code VBLT-013	  		  	Page 8 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
						
	 	  	 	  	 Assay
	  	Vendor /
Protocol	  	 	  	 
		  		  	[***]	  	[***]	  		  	
		  	Release Testing,	  		  		  		  	
	j.	  	VB-111	  		  		  	See above	  	See above
	(Cont’d)	  	Drug Product (Cont’d)	  	 *       Assay will be performed/coordinated by VBL, at VBL’s sole expense and
responsibility, and will not be reported on the Lonza-issued Certificate of Analysis.
	  		  	
		  		  	 **     Assay will be performed by both Lonza and VBL and the results compared. Only the Lonza
result will be reported on the Lonza-issued Certificate of Analysis.
	  		  	
				
	 Deliverable for Project Components

h., i., and j.
	  	Lonza Quality Assurance representatives will review testing records/reports and will issue Certificates of Analysis for VB-111 Harvest, DS and DP for review by VBL or a
VBL-designated Qualified Person (QP). VBL personnel or a delegate will be responsible for release of the Harvest, DS and DP for use.	  	[***]	  	[***]
					
		  		  	The following analyses will be performed by Lonza Process Development personnel on VB-111 samples taken throughout the GMP production process:	  		  	
						
	 	  	 	  	 Assay
	  	Quantity	  	 	  	 
		  	R&D-grade	  	[***]	  	[***]	  		  	
	k.	  	VB-111 In-	  		  		  		  	
		  	Process	  		  		  	[***]	  	[***]
		  	Testing	  		  		  		  	
					
		  		  	Analysis activities will be documented in laboratory notebooks and the results reported to VBL in an electronic Excel file.	  		  	
			
	TOTAL, VB-111 GMP MANUFACTURE AND ANALYSIS	  	[***]	  	[***]
	
	OTHER SERVICES
				
	Regulatory Support	  	Lonza Viral has extensive Regulatory experience both with FDA and EMA, and if desired, will perform consulting services on VBL’s behalf. Examples of such activities include the assembly of documents or data-mining
of information for inclusion in a Product Master File; writing, reviewing, or editing of Chemistry, Manufacturing, and Controls (CMC) sections of regulatory filings; participation in teleconferences with regulatory agencies, etc.	  	As needed	  	[***]

  

					
	Lonza Job Code VBLT-013	  		  	Page 9 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
	 Product Storage
	  	 Lonza will store vialed product in fully monitored, GMP conditions free of charge for a period of up to thirty (30) days after
issuance of the product’s Certificate of Analysis.
  
 After the 30-day complimentary
storage period, Lonza will provide ongoing GMP product storage at <-60oC, as follows:
  

1.      [***]—Waived if Lonza-produced material

 
 2.      [***]

 

3.      [***]
	  	Monthly	  	To be
 Determined

  

	III.	Fees and Terms 

 The total fee for the activities described above, not inclusive of
Regulatory Support and Product Storage services, is [***], payable as follows: 
  

	 	  	[***] 

	 	a.	[***], due upon SOW execution 

  

	 	  	[***], due upon [***] 

  

	 	  	[***] 

  

	 	  	[***], due upon SOW execution 

  

	 	  	[***], due upon [***] 

  

	 	  	[***], due upon [***] 

  

	 	  	[***], due upon [***] 

  

	 	  	[***] 

  

	 	  	[***], due upon [***] 

  

	 	  	[***], due upon [***] 

  

	 	  	[***] 

 Fees for Regulatory Support services will be invoiced for on a monthly basis, as
applicable. Fees for Product Storage, if applicable, will be invoiced for on a semi-annual basis, in advance. 
 For each shipment of final
product or other VB-111 materials samples to VBL, BioReliance or other parties at VBL’s written request, Lonza will charge a fee of [***] for handling and shipment preparation. Courier fees will be charged in addition to the shipping and
handling fee should Lonza’s World Courier account be used instead of VBL’s World Courier account. Courier fees will not be charged should VBL’s World Courier account be used instead of Lonza’s. Fees for shipping services will be
invoiced for on a monthly basis, as applicable. 
 Fees for additional materials as outlined in Project Component e., “Additional
Harvest and Downstream Processing Materials,” if applicable, will be invoiced for after completion of the downstream processing activities. 

  

					
	Lonza Job Code VBLT-013	  		  	Page 10 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 Invoices will be provided via e-mail and associated payments are due upon invoice receipt.
Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 
 In the event of a termination of
this SOW or the Agreement for any reason, VBL shall be responsible for any charges for all labor, testing and materials, including raw materials, that have already been purchased to perform the services detailed in this SOW and VBL shall pay all
other reasonable costs incurred by Lonza up to the effective date of termination, including completed but unbilled services, all uncancellable labor commitments and all work in process (including all professional services rendered) through the
effective date of termination. 
  

	IV.	Acceptance 

  

									
	Lonza Houston, Inc.	 		 	Vascular Biologics, Ltd.
					
	By:	 	 /s/ J. David Enloe, Jr.        
	 		 	By:	 	 /s/ Amos Ron         

	J. David Enloe, Jr.	 		 	Name:	 	Amos Ron
	Head, Viral-based Therapeutics	 		 	Title:	 	Chief Financial Officer
	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-013	  		  	Page 11 of 11
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-14 

Statement of Work VBLT-014 

VB-111 Sample Analysis 

January 31, 2013 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 VBL has
requested that Lonza coordinate the performance of integrity testing on the container/closure that will be used for vialing VBL’s VB-111 Drug Product. The container/closure unit consists of a [***] 

 

	II.	Scope of Work 

 Lonza Quality Control (QC) personnel will coordinate the performance of
[***] on VBL’s behalf, using [***] were previously filled by Lonza with [***]. Lonza QC and Quality Assurance personnel will review and audit the [***] upon its receipt by Lonza. 

VBL will be provided with a scanned electronic copy of the Lonza QA-reviewed and –approved assay final report documentation from [***] for
its records. 
  

	III.	Fees and Terms 

 The fee for this activity is [***], 100% payable upon Lonza’s
issuance of the [***] to VBL. 
 Invoices will be provided via e-mail and associated payments are due upon invoice receipt. Payments are to
be made via wire transfer using the Lonza account information set forth in the Agreement. 
 In the event of a termination of this SOW or the
Agreement for any reason, VBL shall pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination),
all uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 
  

	IV.	Acceptance 

  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.        
	 		 	By:	 	 /s/ Amos Ron         

		 	J. David Enloe, Jr.	 	Name:	 	Amos Ron
		 	Head, Viral-based Therapeutics	 	Title:	 	Chief Financial Officer
						
		 	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-014	  		  	Page 1 of 1
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-15 

Statement of Work VBLT-015 

[***] 
 February 26,
2013 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 The
volume of [***] that will be generated during the performance of the [***] by Lonza on behalf of VBL is estimated to be approximately [***]. VBL has requested that Lonza evaluate [***] held in [***]) for up to [***], as a potential alternative to
[***] Lonza has drafted and VBL has reviewed and approved the plan for this study, entitled, [***] (attached). 
  

	II.	Scope of Work 

 Lonza Process Development and Quality Control personnel will perform the
study as described in the attached study plan. Sample analysis will be performed by Lonza QC personnel; testing documentation will be audited by Lonza QC and Quality Assurance personnel. The following analyses will be performed on the samples
collected during the study: 
  

	 	•	 	Lonza method [***] (one assay execution to analyze 4 samples) 

  

	 	•	 	Lonza method [***] (one assay execution to analyze 4 samples) 

 Upon the completion of the
study, Lonza will draft a brief Summary Report in standard Lonza format which will describe the materials, equipment, and procedures which were utilized throughout the study, as well as the study results and conclusions. An electronic copy of the
report will be provided to VBL for review and approval prior to finalization. Upon its finalization VBL will be provided with a signed electronic copy of the report for its records. 

 

	III.	Fees and Terms 

 The fee for the activities described herein is [***], payable as
follows: 
  

	 	a.	[***], payable upon SOW execution; 

  

	 	b.	[***], payable upon Lonza providing VBL with an electronic copy of the draft study report for its records. 

Invoices will be provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the
Lonza account information set forth in the Agreement. 
 In the event of a termination of this SOW or the Agreement for any reason, VBL shall
pay reasonable costs incurred by Lonza up to the effective date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason 

  

					
	Lonza Job Code VBLT-015	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 
of termination), all uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 

 

	IV.	Acceptance 

  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.        
	 		 	By:	 	 /s/ Amos Ron         

		 	J. David Enloe, Jr.	 	Name:	 	Amos Ron
		 	Head, Viral-based Therapeutics	 	Title:	 	Chief Financial Officer
						
		 	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-015	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 Amended and Restated APPENDIX A-16 

Statement of Work VBLT-016 

Analysis of VB-111 

May 23, 2013 
  

	I.	Introduction and Background 

 This Statement of Work (SOW) between Vascular Biologics,
Ltd. and Lonza Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is
incorporated therein and made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 

VBL has requested that VB-111 [***] not be filled as [***] and subsequently tested, as planned per SOW [***] However, [***] stage has been
performed by Lonza as outlined in SOW [***] The purpose of this Amended and Restated Appendix A-16, Statement of Work VBLT-016, is to remove the cGMP Production of VB-111 Drug Product and GMP-grade Release Testing for VB-111 Drug Product from the
Scope of Work of SOW VBLT-016. This Amended and Restated Appendix A-16, Statement of Work VBLT-016, “Analysis of VB-111,” replaces in its entirety the original Appendix A-16, Statement of Work VBLT-016, “GMP Filling &
Analysis of VB-111,” entered by the parties, dated March 14, 2013 (the “Original SOW”). 
  

	II.	Scope of Work 

  

													
	 Project

Component
	  	 Description
	  	 Detailed Description
	 	  	Estimated
Duration	  	Fee (USD)
	 a. 
	  	 GMP-grade In-Process and Release Testing, VB-111 Bulk Drug Substance
	  	Lonza will coordinate the performance of required contract and in-house testing as required by the agreed-upon Bulk Certificate of Analysis. A list of recommended analyses is below; the price
estimate assumes that the BDS will be analyzed using the methods listed. Should VBL desire to add to or remove tests from the list, or to use a version of a test that is different than the method listed, the price will be adjusted accordingly. Assay
quantities are considered to be “1,” unless otherwise noted. In addition and as requested by VBL, Lonza will take VB-111 samples throughout the production process in addition to those listed herein, to be analyzed under separate SOW(s), as
appropriate and as desired by VBL.	            	  		  	
	  	  	  

Assay
	  	Vendor / Protocol	 	  	[***]	  	[***]
	  	  	 HARVEST
	   
	  		  	
	  	  	  
 [***]
	  	 	[***]	  	  		  	
	  	  	  
 (Continued below)
	  				  		  	

  

					
	Lonza Job Code VBLT-006b	  		  	Page 1 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***] .

											
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	 Estimated

Duration
	  	 Fee (USD)

	 	  	 	  	 Assay
	  	Vendor / Protocol	  	 	  	 
					
		  		  	IN-PROCESS	  		  	
						
		  		  	[***]	  	[***]	  		  	
	  
 a.,

Cont’d
	  	  
 GMP-grade In-Process and Release Testing,
VB-111 Bulk Drug Substance, Cont’d
	  	  
 FINAL FORMULATED BULK
	  	  
 See above
	  	  
 See above

	  	  	  
 [***]
	  	[***]	  		  	
	  	  	  

*       Assay will be performed/coordinated by VBL and will not be reported on the
Lonza-issued Certificate of Analysis. Cost is not included in fee at right.
	  		  	
	  	  	  
 y      Assay will be performed/coordinated by Lonza and the results reported to VBL for information only. Results will not be included on the Lonza-issued Certificate of
Analysis.
	  		  	
	  
 Deliverable for Project Component a.
	  	  
 Lonza Quality Assurance representatives will review all
Lonza-performed or –coordinated testing records/reports and will issue a Certificate of Analysis for VB-111 BDS for review by VBL or a VBL-designated Qualified Person (QP).
	  	[***]	  	Included
					
		  		  	The following analyses will be performed by Lonza Process Development personnel on VB-111 samples taken throughout the GMP production process:	  		  	
	 	  	R&D-grade
VB-111 In-
Process
Testing	  	  

Assay
	  	  

Quantity
	  	 	  	 
	b.	  	  	[***]	  	[***]	  	[***]	  	[***]
		  	  	  
 Analysis activities will be documented in laboratory
notebooks and the results reported to VBL in an electronic Excel file comparing the process step-yields for the production of lots S820002 and S820001.
	  		  	
		  		  	  
 TOTAL, VB-111 ANALYSIS
	  	[***]	  	[***]

  

					
	Lonza Job Code VBLT-006b	  		  	Page 2 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

	III.	Fees and Terms 

 The total fee for the activities described above is [***], payable as
follows: 
  

	 	1.	[***], due upon SOW execution 

  

	 	2.	[***], due upon Lonza’s issuance of [***] 

 Invoices will be provided via e-mail and
associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 

For each shipment of final product or other VB-111 materials samples to VBL, BioReliance or other parties at VBL’s written request, as of
the date of this Amended and Restated SOW VBLT-016, Lonza will charge a fee of [***] USD for handling and shipment preparation. Courier fees will be charged in addition to the shipping and handling fee should Lonza’s World Courier account be
used instead of VBL’s World Courier account. Courier fees will not be charged should VBL’s World Courier account be used instead of Lonza’s. Fees for shipping services will be invoiced for on a monthly basis, as applicable. 

In the event of a termination of this SOW or the Agreement for any reason, VBL shall be responsible for any charges for all labor, testing and
materials, including raw materials, that have already been purchased to perform the services detailed in this SOW and VBL shall pay all other reasonable costs incurred by Lonza up to the effective date of termination, including completed but
unbilled services, all uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 
  

	IV.	Acceptance 

  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.
	  		 	By:	 	 /s/ Amos Ron

		 	J. David Enloe, Jr.	 	Name:	 	Amos Ron
		 	Head, Viral-based Therapeutics	 	Title:	 	Chief Financial Officer
						
		 	Date:	 	  
	  		 	Date:	 	  

  

					
	Lonza Job Code VBLT-006b	  		  	Page 3 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 

 
 APPENDIX A-17 

Statement of Work VBLT-017 

GMP Filling & Analysis of VB-111 

May 23, 2013 
  

	I.	Introduction and Background 

 This Statement of Work (SOW) between Vascular Biologics,
Ltd. and Lonza Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is
incorporated therein and made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
  

	II.	Scope of Work 

  

									
	 Project
Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
	a.	  	cGMP Production of VB-111 Drug Product	  	 VB-111 will be [***] It is assumed that:
  

[***]
  

[***]; however, this number may vary;
  

[***]
  

[***]
  

GMP documentation such as the DP Quality Control Sample Transfer Form, Master Label for DP, and BDS and DP Certificates of Analysis for VB-111, which were
created during the performance of SOW 6, will be used throughout the performance of this SOW. Draft GMP documentation, as appropriate and reasonably requested by VBL, will be provided to VBL for review and approval prior to implementation and use by
Lonza.
  
 Production of DP will occur in Lonza’s multi-product GMP manufacturing
facility at 8066 El Rio Street in Houston, Texas USA. Copies of all controlled documents executed during batch preparation will be sent by air mail to VBL at VBL’s expense following Lonza Quality Assurance review for compliance.
	  	[***]	  	[***]

  

					
	Lonza Job Code VBLT-006c	  		  	Page 1 of 5
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project

Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
		  		  	Lonza will coordinate the performance of required contract and in-house testing as required by the agreed-upon Bulk Certificate of Analysis. A list of recommended analyses is below; the price estimate assumes that the
BDS will be analyzed using the methods listed. Should VBL desire to add to or remove tests from the list, or to use a version of a test that is different than the method listed, the price will be adjusted accordingly. Assay quantities are considered
to be “1,” unless otherwise noted. In addition and as requested by VBL, Lonza will take VB-111 samples throughout the production process in addition to those listed herein, to be analyzed under separate SOW(s), as appropriate and as
desired by VBL.	  		  	
						
	 	  	 	  	 Assay
	 	 Vendor / Protocol
	  	 	  	 
		  		  	HARVEST	  		  	
		  		  	  
 [***]
	 	  
 [***]
	  		  	
		  	GMP-grade	  		 		  		  	
		  	In-Process and	  		 		  		  	
		  	Release	  	IN-PROCESS	  	[***]	  	[***]
	b.	  	Testing, VB-111	  		 		  		  	
		  	Bulk Drug	  		 		  		  	
		  	Substance	  	[***]	 	[***]	  		  	
					
		  		  	FINAL FORMULATED BULK	  		  	
		  		  	[***]	 	[***]	  		  	
					
		  		  	 *       [***] will be performed/coordinated by VBL
and will not be reported on the Lonza-issued Certificate of Analysis. Cost is not included in fee at right.
  

y      [***] will be performed/coordinated
by Lonza and the results reported to VBL for information only. Results will not be included on the Lonza-issued Certificate of Analysis.
	  		  	

  

					
	Lonza Job Code VBLT-006c	  		  	Page 2 of 5
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project

Component
	  	 Description
	  	 Detailed Description
	  	Estimated
Duration	  	Fee (USD)
		  		  	Lonza will coordinate the performance of required contract and in-house testing as required by the agreed-upon DP Certificate of Analysis. A list of recommended analyses is below; the price estimate assumes that the DP
will be analyzed using the methods listed. Should VBL desire to add to or remove tests from the list, or to use a version of a test that is different than the method listed, the price will be adjusted accordingly.	  		  	
						
	 	  	 	  	 Assay
	  	Vendor / Protocol	  	 	  	 
	c.	  	 GMP-grade

Release Testing, VB-111

Drug Product
	  	[***]	  	[***]	  	[***]	  	[***]
						
		  		  	 (Continued below)
	  		  		  	

  

					
	Lonza Job Code VBLT-006c	  		  	Page 3 of 5
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project

Component
	 	 Description
	  	 Detailed Description
	 	Estimated
Duration	 	Fee (USD)
						
	 	 	 	  	 Assay
	 	Vendor / Protocol	 	 	 	 
		 		  	[***]	 	[***]	 		 	
	 c.
 (Cont’d)
	 	Release Testing, VB-111 Drug Product (Cont’d)	  		 		 		 	
		 		  	 *       Assay will be performed/coordinated by VBL and will not be reported on the
Lonza-issued Certificate of Analysis.
	 	See above	 	See above
					
		 		  	 **     Assay will be performed by both Lonza and VBL and the results compared. Only the
Lonzaresult will be reported on the Lonza-issued Certificate of Analysis.
	 		 	
				
	 Deliverable for Project

Components b. and c.
	  	Lonza Quality Assurance representatives will review all Lonza-performed or –coordinated testing records/reports and will issue Certificates of Analysis for VB-111 DS and DP for review by VBL or a VBL-designated
Qualified Person (QP). VBL personnel or a delegate will be responsible for release of the DP for use in the clinic.	 	2 weeks	 	Included
					
		 		  	The following analyses will be performed by Lonza Process Development personnel on VB-111samples taken throughout the GMP production process:	 		 	
						
	 	 	 	  	 Assay
	 	Quantity	 	 	 	 
		 	R&D-grade VB-	  	[***]	 	[***]	 	[***]	 	[***]
	d.	 	111 In-Process	  		 		 		 	
		 	Testing	  		 		 		 	
					
		 		  	Analysis activities will be documented in laboratory notebooks and the results reported to VBL in an electronic Excel file comparing the process step-yields for the production of [***]	 		 	
		 		  		 		 		 	
					
		 		  	TOTAL, VB-111: DRUG PRODUCT GMP MANUFACTURE AND ANALYSIS	 	[***]	 	[***]
						
		 		  	OTHER SERVICES	 		 		 	
				
	Regulatory Support	  	Lonza Viral has extensive Regulatory experience both with FDA and EMA, and if desired, will perform consulting services on VBL’s behalf. Examples of such activities include the assembly of documents or data-mining
of information for inclusion in a Product Master File; writing, reviewing, or editing of Chemistry, Manufacturing, and Controls (CMC) sections of regulatory filings; participation in teleconferences with regulatory agencies, etc.	 	As needed	 	[***]

  

					
	Lonza Job Code VBLT-006c	  		  	Page 4 of 5
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

											
	 Project

Component
	 	 Description
	  	 Detailed Description
	 	Estimated
Duration	 	Fee (USD)
	Product Storage	  	 [***]
  

[***]
  

         [***]

 

         [***]

 

3.      [***]
	 		 	Monthly	 	To be
 Determined

  

	III.	Fees and Terms 

 The total fee for the activities described above, not inclusive of
Regulatory Support and Product Storage services, is [***], payable as follows: 
  

	 	1.	[***], due upon SOW execution 

  

	 	2.	[***], due upon Lonza’s issuance of [***] 

 Fees for Regulatory Support services will be
invoiced for on a monthly basis, as applicable. Fees for Product Storage, if applicable, will be invoiced for on a semi-annual basis, in advance. 

For each shipment of final product or other VB-111 materials samples to VBL, BioReliance or other parties at VBL’s written request, Lonza
will charge a fee of [***] for handling and shipment preparation. Courier fees will be charged in addition to the shipping and handling fee should Lonza’s World Courier account be used instead of VBL’s World Courier account. Courier fees
will not be charged should VBL’s World Courier account be used instead of Lonza’s. Fees for shipping services will be invoiced for on a monthly basis, as applicable. 

Invoices will be provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the
Lonza account information set forth in the Agreement. 
 In the event of a termination of this SOW or the Agreement for any reason, VBL shall
be responsible for any charges for all labor, testing and materials, including raw materials, that have already been purchased to perform the services detailed in this SOW and VBL shall pay all other reasonable costs incurred by Lonza up to the
effective date of termination, including completed but unbilled services, all uncancellable labor commitments and all work in process (including all professional services rendered) through the effective date of termination. 

 

	IV.	Acceptance 

  

											
		 	Lonza Houston, Inc.	  	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.
	  		  	By:	 	 /s/ Amos Ron

		 	J. David Enloe, Jr.	  	Name:	 	Amos Ron
		 	Head, Viral-based Therapeutics	  	Title:	 	Chief Financial Officer
						
		 	Date:	 	  
	  		  	Date:	 	  

  

					
	Lonza Job Code VBLT-006c	  		  	Page 5 of 5
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-18 

Statement of Work VBLT-018 

VB-111 Sample Analysis for [***] 

August 22, 2013 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 VBL has
requested that Lonza coordinate the performance of VB-111 in-process sample analysis for determination of [***] 
  

	II.	Scope of Work 

 Lonza Quality Control (QC) personnel will coordinate the performance of
“for information only” [***] for determination of [***] Lonza will provide the following samples of VB-111 material to [***] for analysis: 
  

					
	 Lonza Part
No.
	  	 Description
	  	 Qty

	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

 The samples will be analyzed by [***]. 

Deliverable: Lonza will provide VBL with an electronic copy of the report provided to Lonza by Dow, which will consist of a summary of
results including a general description of test method, [***]. Follow-up consultation of up to 0.5 hours to clarify report content with [***]s included in the testing fee; consultation beyond [***] and any changes to the result reporting format
and/or report will be charged at a rate of [***]. 
  

	III.	Fees and Terms 

 The fee for this activity, exclusive of any additional fees for
consultation or report or result reporting format revision, is [***] 100% payable upon Lonza providing a copy of the analysis report to VBL. Should consultation with [***] hours or should Lonza be charged by [***] for report or result reporting
format revisions, a separate invoice will be issued by Lonza to VBL for the applicable charges at [***] USD/hour. 
 Invoices will be
provided via e-mail and associated payments are due upon invoice receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 

In the event of a termination of this SOW or the Agreement for any reason, VBL shall pay reasonable costs incurred by Lonza up to the effective
date of termination (including out-of-pocket losses to Lonza for purchase of unmarketable materials which have become unusable by reason of termination), all uncancellable labor commitments and all work in process (including all professional
services rendered) through the effective date of termination. 

  

					
	Lonza Job Code VBLT-018	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

	IV.	Acceptance 

  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ J. David Enloe, Jr.        
	 		 	By:	 	 /s/ Eyal Breitbart

		 	J. David Enloe, Jr.	 	Name:	 	Eyal Breitbart
		 	Head, Viral-based Therapeutics	 	Title:	 	Vice President, Research and Operations
						
		 	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-005	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 

 
 APPENDIX A-19 

Statement of Work VBLT-019 

Regulatory Support Services 

January 15, 2014 (“SOW Date”) 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologies, Ltd.
(“VBL”) and Lonza Houston, Inc. (“Lonza”) is subject to the Manufacturing Services Agreement dated January 5, 2012, between VBL., and Lonza (the “Agreement”) and is incorporated therein and made a part of such
Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
  

	II.	Scope of Work 

 Lonza personnel will act as consultant(s) to VBL with respect to
developing [***]. Lonza will perform these activities as directed by the Client in writing. It is estimated that these activities will take approximately 50 hours. Other activities can be performed under this SOW as mutually agreed by the parties in
writing. 
  

	III.	Fees and Terms 

 Fees will be charged on a monthly or less frequent basis. Lonza will
charge a labor fee [***]. All invoices are due upon receipt. Labor fees may be adjusted by Lonza upon written notice in accordance with Section 9.6 of the Agreement. 

Either party may terminate this SOW upon sixty (60) days’ written notice to the other party. If this SOW is terminated for any
reason, Client shall be responsible for any labor charges that have already been performed as detailed in this SOW, including completed but unbilled labor charges through the effective date of termination. 

The pricing and terms offered in this SOW shall be valid until April 15, 2014. If this SOW is not accepted by both parties by this date, a
revision of the SOW may be necessary prior to execution. 
  

	IV.	Acceptance 

 IN WITNESS WHEREOF, the parties have caused their duly-authorized
representatives to execute this SOW as of the dates below, effective as of the SOW Date. 
  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ Ryan Scanlon
	 		 	By:	 	 /s/ Eyal Breitbart

		 	Ryan Scanlon	 	Name:	 	Eyal Breitbart
		 	 Global Head of Business Development

Viral Therapeutics, Custom Manufacturing
 Lonza Pharma &
Biotech
	 	Title:	 	Vice President, Research and Operations
						
		 	Date:	 	  
	 		 	Date:	 	  

  

					
	Lonza SOW VLBT-019	  		  	Page 1 of 1
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-21 

Statement of Work VBLT-021 

Final Product Container/Closure Procurement & Media Fills 

February 04, 2014 (“SOW Date”) 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd.
(“VBL”) and Lonza Houston, Inc. (“Lonza”) is subject to the Manufacturing Services Agreement dated January 5, 2012, between VBL, and Lonza (the “Agreement”) and is incorporated therein and made a part of such
Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
  

	II.	Scope of Work 

 Lonza personnel will procure the final product container/closures and
perform media fills as described below: 
  

																	
	 Item
	  	 	  	 Detailed Description
	 	  	Fee (USD)
		  		  	Lonza will purchase, release for GMP use on arrival, and store, on VBL’s behalf, the following materials:	   	  	
							
	 	  	 	  	 Item
	  	 Lonza Part
Number
	  	Qty	 	  	Unit	 	  	 
		  		  	[***]	  	[***]	  	 	[***]	  	  	 	[***]	  	  	
				
	1	  	Procurement of Final Product Vials	  	 The quantity of [***] as listed above is assumed to be [***], in consideration and assuming the following:

 
 •   [***]

 
 •   [***]

 
 •   [***]

 
 These materials will be designated property of VBL and used by Lonza in the performance of
projects for VBL as directed by VBL. Lonza shall have the right of possession and control of the materials. VBL shall bear all risk of loss of materials in Lonza’s possession, except for losses due to the gross negligence or willful misconduct
of Lonza. All costs for maintenance, service, repairs and replacements shall be borne by VBL. VBL shall bear any expenses associated with transferring this equipment from Lonza to VBL or to a third party.

 
 Fees for these items, until this stock is depleted, will not be included in fees for
activities such as final product filling operations or fill line qualifications that are performed by Lonza related to VBL projects, as VBL will have already purchased these items under a separate Statement of Work (SOW).
	    
 

     
 

     
 

     
 

       
 

     
	  	[***]

  

					
	Lonza SOW VLBT-021	  		  	Page 1 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

													
	 Item
	  	 	  	 Detailed Description
	  	Fee (USD)
	2	  	Fill Line Qualification using [***]	  	 Lonza has previously performed [***] [***] to qualify the product filling process for VB-111. [***]

 
 Accordingly, Lonza will execute [***] The following assumptions are made:

 
 •   [***] vial[***]

 
 •   [***]

 
 •   [***]
	  	[***]
				
	3	  	Shipment of caps to VBL	  	VBL has requested Lonza to ship 1000 [***] to their site. The fee includes the materials and shipment but excludes courier costs. Courier costs will be applied as a pass thru cost or applied to the clients designated
courier account.	  	[***]
	Total	  	[***]

  

	III.	Fees and Terms 

 The total fee for the activities described above is [***], payable as
follows: 
  

	 	1.	[***], due upon SOW execution 

  

	 	2.	[***], due upon initiation of [***] 

  

	 	3.	[***], due upon completion of [***] 

 Any additional media fills beyond the [***] identified
above in early 2014, will be billed once initiated. 
 Invoices will be provided via e-mail and associated payments are due upon invoice
receipt. Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 
 In the event of a
termination of this SOW or the Agreement for any reason, VBL shall be responsible for any charges for all labor, testing and materials, including raw materials, that have already been purchased to perform the services detailed in this SOW and VBL
shall pay all other reasonable costs incurred by Lonza up to the effective date of termination, including completed but unbilled services, all uncancellable labor commitments and all work in process (including all professional services rendered)
through the effective date of termination. 

  

					
	Lonza SOW VLBT-021	  		  	Page 2 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 The pricing and terms offered in this SOW shall be valid until May 04, 2014. If this SOW is
not accepted by both parties by this date, a revision of the SOW may be necessary prior to execution. 
  

	IV.	Acceptance 

 IN WITNESS WHEREOF, the parties have caused their duly-authorized
representatives to execute this SOW as of the dates below, effective as of the SOW Date. 
  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ Ryan Scanlon        
	 		 	By:	 	 /s/ Dror Harats         

		 	Ryan Scanlon	 	Name:	 	Dror Harats
		 	 Global Head of Business Development

Viral Therapeutics, Custom Manufacturing
 Lonza Pharma &
Biotech
	 	Title:	 	Chief Executive Officer
						
		 	 Date:
	 	  
	 		 	Date:	 	  

  

					
	Lonza SOW VLBT-021	  		  	Page 3 of 3
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

  
 

 
 APPENDIX A-23 

Statement of Work VBLT-023 

Purchase of Cell Culture Medium for VB-111 Production at the [***] 

April 14, 2014 
  

	I.	Introduction 

 This Statement of Work (SOW) between Vascular Biologics, Ltd. and Lonza
Houston, Inc. is subject to the Manufacturing Services Agreement dated January 5, 2012, between Vascular Biologics, Ltd. (“VBL”), and Lonza Houston, Inc. (“Lonza”) (the “Agreement”) and is incorporated therein and
made a part of such Agreement. In the event of an inconsistency between the Agreement and this SOW, the Agreement shall control. 
 Lonza and
VBL are currently planning for Lonza to perform [***] production batches of VBL’s VB-111 product [***]. To provide a sufficient quantity of [***] to produce each batch and maintain a back-up supply for each batch, Lonza will order a total of
[***]. The standard approximate lead time from the time the [***] order is placed with the vendor is [***]. In consideration of the duration of the lead time, Lonza will order [***] to be produced as soon as possible, with [***] to ship as soon as
possible to Lonza and the other [***] to be held in storage at the vendor for two to three months and then shipped to Lonza, and another [***] to be produced four to six months later in anticipation of the [***] VB-111 batch being performed Q1 2015.

  

	II.	Scope of Work 

 Lonza will order [***] and [***] to be supplied in [***] Lonza will order
the [***]o be produced as soon as possible with half of it shipped to Lonza as soon as possible and the other half to be held in storage at the vendor for two to three months and then shipped to Lonza, and a [***] to be produced four to six months
after the [***] 
  

	III.	Fees and Terms 

 The fee for the activities described herein is [***], payable as
follows: 
  

	 	1.	[***], due upon SOW execution; 

  

	 	2.	[***], due upon notification of VBL by Lonza that the [***] has been fully received; 

  

	 	3.	[***], due upon notification of VBL by Lonza that the [***] has been fully received. 

 Any
shipping and handling fees, storage fees, and/or sales tax charged by [***] and/or courier to Lonza will be billed to VBL as pass-through costs. 

  

					
	Lonza Job Code VBLT-023	  		  	Page 1 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

 Invoices will be provided via e-mail and associated payments are due upon invoice receipt.
Payments are to be made via wire transfer using the Lonza account information set forth in the Agreement. 
 In the event of a termination of
this SOW or the Agreement for any reason, VBL shall be responsible for any charges for all labor, testing and materials, including raw materials, that have already been purchased to perform the services detailed in this SOW and VBL shall pay all
other reasonable costs incurred by Lonza up to the effective date of termination, including completed but unbilled services, all uncancellable labor commitments and all work in process (including all professional services rendered) through the
effective date of termination. 
 The pricing and terms offered in this SOW shall be valid until July 4, 2014. If this SOW is not
accepted by both parties by this date, a revision of the SOW may be necessary prior to execution. 
  

	IV.	Acceptance 

  

											
		 	Lonza Houston, Inc.	 	Vascular Biologics, Ltd.
						
		 	By:	 	 /s/ Ryan Scanlon        
	 		 	By:	 	 /s/ Dror Harats         

		 	Ryan Scanlon	 	Name:	 	Dror Harats
		 	 Global Head of Business Development

Viral Therapeutics, Custom Manufacturing
 Lonza Pharma &
Biotech
	 	Title:	 	Chief Executive Officer
						
		 	 Date:
	 	  
	 		 	Date:	 	  

  

					
	Lonza Job Code VBLT-023	  		  	Page 2 of 2
	 CONFIDENTIAL

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]